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ABSTRACT 
Familial lipoprotein lipase (LPL) deficiency is a rare disorder of lipid metabolism associated 
with massive chylomicronaemia. Patients often present early in life with abdominal pain, 
pancreatitis, hepatosplenomegaly, eruptive xanthomata and zero to near zero levels of LPL 
activity in post-heparin plasma. The genetic heterogeneity underlying this disease is well-
characterised and over 40 mutations have been described at the LPL gene loci. In this report 
three mutations are described at the LPL locus in two unrelated probands, namely , JJ (Kindred 
I) and LB (Kindred II). 
JJ presented early in childhood with signs and symptoms suggestive of LPL-deficiency. 
These were abdominal pain , hepatosplenomegaly and a markedly reduced LPL activity (38% of 
normal) in post-heparin plasma. DNA studies showed JJ to be a compound heterozygote for two 
point mutations in the LPL gene, these being, the 1194T and C418Y substitutions, which occur 
in exons 5 and 9, respectively. Several mutation detection systems were set up as part of the 
characterisation and screening workup for these mutations; these were, allele-specific 
oligonucleotide (ASO) hybridisation, "ARMS" PCR, PCR-SSCP, RT-PCR and DNA sequence 
analysis. In an earlier separate study, in vitro transfection results showed that the I194T mutant 
was catalytically inactive. Our findings of zero LPL activity in JJ's post-heparin plasma, implies 
that the C418Y mutation is also likely to produce an inactive protein product. The differences in 
LPL activity observed during the pre- and post-pubertal stages, if not artefactual, may be due to 
differential processing of LPL during human development with loss o f activity post puberty. 
LB was first diagnosed with pancreatitis during the third trimester of her pregnancy. 
Although her child, BB, was successfully delivered by caesarian section, LB died of haemorrhagic 
pancreatitis with the marked hyperlipidaemia being suggestive of an underlying deficiency in LPL 
activity. Genomic DNA from her parents was first subjected to mutation analysis, since only slide 
specimens of post-mortem material were available from LB. Maternal DNA revealed a 0-A 
transition at nucleotide position 1516 which results in the substitution of lysine for glutamic acid 
at codon 421 in exon 9 (E421K), while paternal DNA show a single polymorphism at codon 108 
in exon 3 of the LPL gene. Analysis of archival DNA obtained from histopathological slides of 
spleen tissue from LB also showed the E421K mutation. This mutation was also detected in her 
offspring, BB indicating maternal inheritance in three generations. While, this mutation may 
produce a catalytically defective product, the evidence is insufficient to propose a role for LPL 
deficiency as the primary cause of death in this patient, hence the search for a second mutation 
in the LPL gene of LB is imperative to establish this association. 
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CHAPTER 1 
INTRODUCTION 
1.1 The Role of LPL in Lipoprotein Metabolism. 
1.1.1 Triglyceride Transport. 
Lipoprotein Lipase (LPL) plays a pivotal role in lipid metabolism and triglyceride transport 
through the hydrolysis of triglyceride present in circulating chylomicrons and very low density 
lipoproteins (YLDL)(Fig. 1). LPL is synthesised predominantly in the parenchymal cell and is found 
in a variety of organ ti ssues with muscle , adipose tissue, Kupffer cells, and monocyte-derived 
. 
macrophages being the major sites of synthesis (Table l ). The enzyme is transported from it's site . 
of synthesis via an unknown mechanism to the luminal surface of the capillary endothelium where it 
is bound through ionic interactions to heparan sulfated proteoglycan (HSPG) moieties. This is the 
primary site of hydrolysis of the triglyceride core of circulating chylomicrons and very low density 
lipoproteins (YLDL). 
Fig. I: 
LPL 
I MUSCLE ANO ADIPOSE TJSSL'E I 
Role of LPL in Lipoprotein Metabolism. 
IDL 
'--LDL 
VLDL - very low density lipoprotcins , IDL - intermediate density 
Iipoproteins , LDL - low density lipoprnteins, FFA - free fatty acids. 
Table 1 Tissue distribution of LPL. 
ORGAN CELL TYPE FUNCTION REFERENCES 
Aorta (a) (b) Semenkovich et.al., 1989 
Brain Purkiaje cells of the Glycolipid synthesis Vilaro et. al. , 1990 
cerebellum, substantia Goldberg et. al., 1989 
nigra Eckel and Robbins, 1984 
Heart Mesencbymal cells, FFA provides Rodrigrues et. al., 1992, 
cardiac myocytes oxidative energy Liu and Olivecrona, 1991 
Stein et. al., 1991 
Pederson et. al., 1983 
Intestine (a) (b) La Rosa et. al., 1972 
Kidney Renal medulla (b) Camps et. al., 1990 
Cryer, 1987 
Lungs Macrophages Synthesis of Camps et. al., 1991 
pulmonary surfactant 
Lactating Mammary adipocyte Milk synthesis Jensen et. al., 1991 
mammary Camps et. al., 1990 
gland Rebuffe-Scrive et. al., 1986 
Ramirez, 1983 
Neonatal liver Hepatocyte Organ development, Vilaro et. al., 1988 
catabolism of LPL 
Ovaries (a) (b) Camps et. al., 1990 
Skeletal muscle (a) (b) Boreu:rstayn, 1987 
Spleen Macrophages (b) Camps et. al. , 1991 
Uterus Parametrial adipose tissue Contraction and Gray and Greenwood, 1983 
prostaglan din 
synthesis 
The cell type indicates the proposed site of synthesis of LPL within these specific organ tissues. 
(a) - undetermined, (b) - unknown 
Chylomicrons are assembled in the endoplasmic recticulum of enterocytes in the intestine after 
a fat-containing meal (Brunzell, 1989; Glueck, 1977). These particles are then transported via the 
thoracic duct into the circulation where they acquire apoC-Il, the physiological activator of LPL. 
LPL is principally responsible for the conversion of chylomicrons into remnant particles which are 
rapidly removed from the circulation. This action of LPL results in the clearance of all chylomicrons 
by 9 hours after a fatty meal. The process of chylomicron conversion to remnant particles involves 
a depletion of triglyceride and a loss of cholesterol, phospholipid and surface proteins. Most of these 
surface components are either transferred to or converted into high density lipoproteins 
(HDL)(Lewis, 1988). The liberated fatty acids are either used as fuel by the various tissues or are 
taken up by adipose tissue for storage. 
2 
3 
VLDL are synthesised mainly in the sinusoidal cells of the liver from where they are secreted 
into the space of the Disse. These lipoproteins serve as a means of transport for liver derived 
triglyceride which originates from remnant uptake, lipogenesis and reesterification of fatty acids. 
VLDL are metabolised to the remnant particles, namely, intermediate density (IDL) and low density 
(LDL) lipoproteins. IDL are avidly taken up via the hepatic apoB/E receptor, with 50% being 
removed in this manner. The rest are converted to LDL by further remodelling of the surfaces and 
core lipids, probably under the action of hepatic lipase. LDL are catabolised in various peripheral 
tissues with the liver being their major site of uptake and degradation. 
1.1.2 The Role of LPL as a Ligand in the Uptake of Lipoproteins. 
In addition to it's role in the hydrolysis of triglyceride, LPL also appears to mediate the uptake 
of lipoproteins. The evidence for this comes mainly from in vitro studies which suggest that this 
process occurs via two independent receptor-mediated endocytotic pathways, involving the low 
density lipoprotein receptor (LDLR, also known as the apoB ,E receptor) and the low density 
lipoprotein receptor-related protein/a2-macroglobulin receptor (LRP)(Fig. 2). 
LPL has been shown to facilitate uptake of LDL and VLDL via the LDL receptor pathway in 
normal fibroblasts (Gianturco et. al., 1983) and HepG2 cells (Mulder et. al., 1993). This process 
occurs as a direct result of LPL-mediated bridging between the lipoprotein and HSPG's. Transfer of 
VLDL and LDL from the complex to the LDL receptor is followed by rapid internalisation and 
degradation. Likewise, Choi et. al. (1990) demonstrated that 25-35% of chylomicron remnant uptake 
also occurs via the LDL receptor. The remainder appears to be taken up by a 600kd LRP receptor 
which has been shown to bind to LPL-lipoprotein complexes with high affinity (Beisegel et. al. 1991). 
LPL appears to act as a ligand in enhancing the binding of lipoproteins to LRP. Chappell et. al. 
(1992, 1993, 1994) demonstrated that this process was mediated by the specific binding of the C-
terminal domain of LPL to LRP and was independent of LPL activity. In addition, they showed that 
apoE and HSPG's were essential requirements for the binding of these large triglyceride-rich 
lipoproteins to LRP. A third mechanism of LPL-mediated uptake is the endocytosis of the entire 
LPL-HSPG-lipoprotein complex, a process which occurs at a much slower rate. Likewise, 
chylomicron remnants have also been shown to be catabolised via similar pathways (Mahley and 
Hussain, 1991; Brown et. al. , 1991; Nagata et. al., 1988). 
=LDLR 
(FAST) 
VLDL 
LDL 
RIM 
VLDL LDL REMNANT 
'\. l / 
LPL 
VLDL.LPL 
LDL.LPL 
RIM.LPL 
HSPG 
(SLOW) 
VLDL.LPL.HSPG 
LDL.LPL.BIPG 
I.IM.LPL.HSPG 
LYSOSOME 
RIM.LPL (1p1I-DIPIHDINT) 
TLDL.LPL 
LRP 
(FAST) 
I 
Fig 2 : LPL-mediated lipoprotein uptake via LDLR and LRP. 
SINUSOID 
MEMBRANE 
HIPATOCYTE 
VLDL - very low density lipoprotein, LDL - low density lipoprotein, REM -
lipoprotein remnant particles, LDLR - low density lipoprotein receptor, 
LRP - low density lipoprotein receptor-related protein, HSPG - heparnn 
sulfated proteoglycan. 
4 
j 
·1 
I 
I 
,I 
5 
1.2 Molecular Genetics. 
1.2.1 Gene Structure. 
The human LPLcDNA was cloned and sequenced in 1987 (Wion et. al.)(Fig. 3). The gene 
was subsequently localL<;ed to chromosome 8 (p22 region) (Sparkes et. al., 1987) and determined to 
be 30kb in length, with the coding sequence comprising 10 exons (Deeb el. al., 1989; Oka et. al., 
1990)(Fig. 4). Exon 1 comprises 188 bp of the 5'-untranslated sequence, and the coding sequence 
of the signal peptide and the first two amino acid residues of the mature protein (Kirchgessner et. al., 
1987). Several cis-acting regulatory motifs have been identified in the 5'-untranslated region of the 
LPL gene (Table 2). Exons 2 to 9 code for the rest of the protein sequence while exon 10 codes for 
the last base of the termination codon and the entire 1948 bp 3' untranslated region which contains 
two poly-adenylation signals (Wion et. al., 1987)(Fig. 3). These signals generate two mRNA species, 
approximately 3350 and 3750 nucleotides in length, and of roughly equal frequencies. 
Table 2: Location of' potential ds-acting regulatory motirs in the promoter region of 
the human LPL gene. 
REGULATORY MOTIFS LOCATION (hp) REFERENCES 
CAAT -64, -506 Deeb et. al., 1989 
Dorn et. al., 1987 
TATA -26 Hua et. al., 1991 
tsp (ATG) +189 Hua et. al., 1991 
last nt of'exonl +276 Hua et. al., 1991 
Oct l (5'-ATTTGCAT-3') -581, -186, -46 Currie et. al., 1992 
Singh et. al., 1986 
GRE (5'-AGATCA-J') -1534, -1272, -777, -645 Schcidereit et. al., 1984 
TRE (5'-GGAGGAGG-3') +22 Umek et. al., 1991 
FSE 1 -362 Scheidereit et. al., 1984 
FSE 2 (5'-GAGAGGAG-3') -630 
CRE (5'-ACGTCA-3') -306 Rupp et. al., 1990 
C/EBP -68, -509 Umek et. al., 1991 
CAAT • potential binding sites for the nuclear factor, NF-1; Oct l • octamer 
transcdptinn factor recognition sct111c11ccs; G RE - glucucorticoid response clement; 
TRE • thyroid response clement; FSE 1/FSE 2 • fat specific elements; CRE • cAMP 
response clc111e11l ; C/EBP - liver and adipocyte clilTcrenlialion transcriptional factor or 
CCAAT/enhanccr hinding protein; tsp· transcriptional start site. 
Fig. 3: 
1 CCCCTCTTCCTCCTCCTCAACCCAAACCTCCCCACTTCTAGCTCCCCTCCC ATCCCCTTTAAACGGCCACTTGCTC ACCCCC.V.ACCCCCCCTCCACCCC 
101 TCTCC AGCC TCCGGCTCAGCCGGCTCATC AGTCGGTCCCCGCCTTCCACCTCCTCC ACAGGCACCCCCCCCCAC ATC GAG A.CC AM CCC CTC 
- 21 H•t Clu Se r Lya Al• Leu 
19 I CTC GTG ere ACT CTC CCC CTC TCC CTC CAC A.GT CTC ACC CCC TCC CCC CCA CCC CTC CCC CCC rccc, CAC C:.A AGA 
- Jt l. • u Val l,eu Thr Leu Ala Va l Trp Le u Cl n Ser Leu Thr Ah Set Ar9 Cly Cly Va l Ah Ah ~A•p Cln Ar9 
168 A. 1:A r. AT TTT ATC CAC ATC CAA ACT A.AA TTT CCC CTA ACC ACC CCT CAA CAC ACA CCT GAG CAC ACl TCC CAC CTC ~ Af'q Aap Ph• lle Aap Ile Glu Ser Ly • Ph • Al• lAu Arc, Thr Pro Glu Aap Thr Ala Clu Asp Th r Cy1 H11 Leu 
H) ATT CCC GGA GT A t.;CA GAG TCC CTC CCT A.CC TCT CAT TTC MT CAC A.CC ACC AAA ACC TTC ATC CTC ATC CAT CCC )0 J le t'r o Gly Val Ala Glu Ser Val Ah Thr Cya Hla Pbe A•n Ht• Ser Ser Ly • Thr Phe Met. Val Ile Hh Cly 
4 JI TCC ACC CTA ACA CC A ATC TAT CAC ACT TCC CTC CCA AM CTT CTC GCC GCC CTC TAC .V.C AGA C.V. CCA CAC TCC ) ) Trp Thr Val Thr C ly Met. Tyr Clu Se r Trp Val Pro Lye Le u Yal Ah Ah Leu Tyr Lye Ar9 Clu Pro Aap Ser 
4 t J AAT CTC A.TT CTC CTC CAC TCC CTC TCA CCC GCT CAC CAC CAT TAC CCA CTC TCC GCC GGC TAC ACC AAA CTC CT C 110 Aan Val I 1• Val Val Aap Trp Leu Ser Ar9 Ala Cln Clu Hla Tyr Pro Val Ser Al• Cly Tyr Tbr Ly • Leu Va l 
~68 CC A CAG CAT CTG CCC CCC TTT ATC A.AC TCC ATC GAG CA.G CAC TTT .UC TAC CCT CTC CAC A.AT CTC CAT ( TC TTG 105, Cly Cln Asp Va l Ah Ar9 Phe lle Aan 1' r p Het Clu Clu Clu Pb• Aa o Tyr Pro Leu Asp ":" v :1 H~a Leu Leu 
6 4 J CCA TAC ACC CTT CCA CCC CAT GCT CCT CCC ATT CCA CCA ACT CTG ACC AJ.T AJ.C AAA CTC MC ACA ATT ACT cc~ lJO C~y Tyr s :r L:u C!y Ala H~• A!e A!• C!y Ile A!• G!y Ser Leu Tbr Aan Lye Ly e Va l Aan Ar9 Ile Thr Cly 
718 CTC CAT CCA CCT GG A CCT .V.C TTT C.AC TAT CCA GA.A CCC CCC AGT CCT en TCT CCT CAT CAT CCA CAT TTT GTA 155 Leu Asp Pro Ala Cly Pro Aao Ph• Clu Tyr Ala Clu Al a Pro Ser A.rCJ Leu Ser Pro Asp Asp Ala Asp Ph• Val 
79) CAC CTC nA CAC ACA TTC ACC ACA CGC TCC CC'T CGT CCA ACC Aff CCA ATC CAC AAA CCA CTT CCC CAT CTT CAC 180 Asp ·1a1 Le u His Thr Pb• Tbr Ar9 Cly Ser Pro Cly Ar9 Ser Ile cay 11• Cl n Ly• Pro Val Cly Hu Val Asp 
868 ATT TAC CCC A.AT CCA CC1' ACT 1"M' CAC CCA CCA TC'? .V.C A.TT CCA CAA CCT ATC CCC CTC ATT CC A CAC ACA CCA 205 lle Tyr Pro Aso Cly Cly Tbr Pbe Cln Pro Cly Cya Aan Ile Cly Glu Ala Ile Ar9 Val Ila Ah Ch, Ar9 Cly 
94) CTT GCA CAT GTC GAC CAC Cl'A CTC AAC tCC TCC CAC GAG CCC TCC ATT CAT CTC TTC ATC CAC lCT ere TTC A.AT 2)0 Leu Cly Asp Val Asp Cln Lau Val Lye Cy• Ser Hi • Clu A.rCJ Se.r 11• His Leu Ph• Ila Asp Se r Leu Leu Aan 
1018 CAA CAA A.AT CCA ACT A.AG CCC TAC ACC TCC ACT TCC A.AC CAA CCC TTT CAC A.A.A CCC CTC TCC TTC ACT TCT .:.CA 255 Clu Clu As n Pro Ser Lya Al• Tyr Ar9 Cy• Ser Ser Lye Clu Al• Ph• Clu Ly• Cly Lau Cys Leu Ser Cy s Ar9 
1093 A.AC A.AC CCC TCC AAC AAT CTC CCC TAT GAG ATC A.AT AAA CTC AC.A CCC AAA ACA ACC ACC AAA ATC TAC CTC AAC 280 Ly e As n Ar9 Cys Asn Asn L•u Cly Tyr Clu Ile A•o Ly• Val Ar9 Ala Ly• Ar9 Ser Ser Ly• Xet Tyr Leu Lys 
1168 ACT CCT TCT CAC ATC CCC TAC AAA CTC TTC CAT TAC CAA CTA A.AC An CAT TTT TCT CCC ACT CAG ACT C.V. AC C 305 Thr A.r9 Ser Cln Met Pro Tyr Lya Val Pbe Hi• Tyr Cln Val Ly• Ile Hh Ph• Ser Cly Thr Cl u Se r Clu Thr 
124 l CAT ACC A.AT CAC CCC TTT CAG ATT TCT CTG TAT CGC ACC CTC CCC GAG ACT GAG A.AC ATC CCA TTC ACT CTG CCT ]JO Hu Thr Aan Cln Ala Ph• Clu Ile Ser Leu Tyr Cly Tbr V• l Al• Glu Sar Clu Aa n Ile Pro Phe Thr Leu Pr o 
1)18 CAA GTT TCC ACA A.AT AAC ACC TAC TCC TTC CTA An TAC A.CA GAG CTA CAT An CCA GA.A CTA CTC ATC l"TG AAC )5\ Clu Val Ser Thr Aan Ll• Thr Tyr Ser Pb• Leu Ile Tyr Tbr Clu Val Asp Il e Cly Clu Leu Leu :-tat Lau Ly• 
1)9) CTC AAA TCC AAC AGT CAT TCA TAC TTT ACC TCC TCA CAC TCC TCC ACC ACT CCC CCC TTC CCC ATT CAC A.AG AT C )80 Lou Ly• Trp Ly• Ser As p Ser Tyr Ph• Sar Trp Ser A•p Trp Trp Ser Ser Pro Cly Ph• Ala Ila Gln Lys I le 
1468 ACA CTA AAA CCA CCA GAG ACT CAC A.A.A A.AC CTC ATC rrc TCT TC1' ACG CAC AAA CTC TCT CAT TTC CAC AAA CC A 4 05 ArcJ Val Lys Ala Cly Clu Thr Cln Lys Lys Yal Il• Pb• Cy• Sar AI9 Clu Ly• Va l Sar Hie Leu Cln Lys C ly 
1541 .UC GCA CCT CCC GTA TTT CTC AAA TCC CAT CAC AAC TC"l' CTC A.AT A.AC A.AC TCA CGC ?CA A.ACTCCCCCAATCTACACA 4 lO Lys Ala Pro Ah Va l Ph• Val Ly• Cy• Hh Asp Lya Ser Leu Aan Lys Lys Sar Cly tnd 
1622 ACAAACAACCCCATCTCAATTC'TCTCAACAATCAAGTGCACG.U.CTAACTm'ACAAAACATACCCACTCTTTCGGCTCTTTCAAAACTGGATTTTCC":'G 
l 7 2 2 AA T ATT AA TCCC ACCCCT ACCCTTGT'l' ACTT A rrrr ACCACACACTCTCAACCACTAAAAACTCGCT AA TT CAA TTT ATCCCCT AT AGTCGCC A.AA T AGC 
1 8 2 2 ACATCCTCCAACGTT A.MAGltCACTCC.A TCA TCAAMCTCCTGTTTTCTCC'TTTCACA.AACAAATAA TTGTTTCAGCCCACAC1' A.AAA T AAGCCTCCTTC 
1922 ATCTCCCCTATTCCCCC ATACCCTATAATTCCTTA<;A.ACCTCC'?ATTTTAATTGCAATTCTGGATCTTTCCCACTCAGGCCTTCTCA.MC'TTTACTCTAA 
2 0 2 2 CTCTCCAACAA T ACAC>.AAA TGCTTTTCCCCCGCACCAA TCACACTCATCTACACAGCACT ATC.UTCATCTTTT AGAA TCATTCCCTCTTCC1 ATTGCA 
2122 ATCTCCTCCACACCTCAACC-'GCAACATCTAACTTGCACAGGCACCA.AGAAAGGGTCTCATAMCACACACCTTTTAAACACTCCCTA.CCATTCCCCTCC 
2222 ATCATGACAAAGTTACAAATTCAACCACATATAAMTC'TACATCAATTAATTCTTAATACccrnATCCTTTAT TGCTTAATCCC TCTCTCCCCCTTCT!' 
2 l 2 l TTTTCTCTCAAGA TT AT A TT AT AA T AATGT'l'CTCTCCCTACCTCTTCAAM TCACCCTCT AA TCCTCACCTCAC A.CAT AA TTTCAA TGGTCCAC1'.A>J,,.J,.A 
2422 AAAACATACCCTAATTTTATTATTACATTCTCCAAATCATTM'CATCAATTrAAA>.TCAffCAA.TATCTCACAGTTA.CTCTTCACTTTTACCCTTACCTT 
2522 GCTCATGCTTCAGTTGTACTTCCACTCCGTCTCTTTTCTTCCTCCCTTTC.ACATCAAAACATAGCTTTCACTTCAAATTTTCCATTGTGTCACCTTCTAC 
2 6 2 2 ACA TTTT ACAC AACCACCCTTTTT ACT AACT AAAACCCTCCACACCTTCCTCCCCTCCA TTCCT AJ.CCACTCCTTCT AAJ.CCA TCCCCTCCM TCAuCC A 
.l 1 2 2 CATCCACT ACCATCAGCCTTCTT A TTTCTTCTTTTT A>.CAACTAA TCAACACTCAGTCAACAACT ATTT AT AAA CT ACATCTCCT A TTTTTC AGAA TCC T 
2 8 2 2 CTTCT ACCT AT AAAT ATCAAATCA.T AAACATCTCAAAT ATCTCACACCCT AT ACCTCCCAACCCCACTCTCAAACT ATGTG AT ATCTCAACACA TACT AC 
l 9 2 l AAACCTCTGCATGTGTCTTGTCCTTCACCAT AA TTCCCAACGGA.U.ACACTCCATCAACCCATCT A TTCCAAC ATCTCCCAGT AGAA>. TTGTTCCTCA. TC 
)022 TCCCACAJ.CTTCCACCCTTTCTCTCACACACATC ATCCTCCCTATAMTACTACCACCMTCTTCTCATTAJ.CATCATCACCCTTCCAJ.TCAJ.TTCTCTC 
)122 T~ATCATCTATCATTTCTTCTTCCC,TCCCCTTrATTAATTCATTAMTTTCTCCATTTCCCTTCTCACCCACCCTCCATTAACTTAJ.AACA 
1222 TTCACTAAACCACCACAT ACCACTCGCAACTCTCCCTCCCAA.AAACTTTCTTATATATATCAACCATCTTCTCCCTTTACATTTTATTT ATTACCTCTAA 
llll ATACATCTCTCCATCTCTAJJ.TCCACCTTCTACATATTCCAAACC'ICATTCTCCC'TATCTGCATTTATAAATCTCTCCTCCTAACTCTATCTGTCTTTAT 
1 4 2 l CACTCATCCTC'TCACACAGCCAACTCACTCTT ATCAA.ATCCCCTTJ' AACAAAACAAGAA>.CAAACCT ACTT AACTCTCTGAAGAAA TCGAA. TCAGCTTTT 
)~22 AATAAAATTGACAACATTTTATTACCACA••••u . .a••••• 
-==== • 
The cDNA sequence of Lipoprotein Lipase (Reprinted from Wion et. al., 
1987). The complete predicted amino acid sequence of LPL is shown below 
the cDNA sequence. Negative amino acid numbers refer to the predicted 
signal peptide sequence. Also included is 174 nucleotides of the 5'-
untrnnslated region and the entire 1948 nucleotides of the 3'- untrnnslated 
region. The first amino acid of the mature protein is boxed . Amino acids 
predicted as part of the intcrfacial recognition site in porcine pancreatic 
lipase are inclicatcd hclow with an asterisk. The three potential N-
glycosy lation sites arc underlined. The two polyadenylation signals 
(AATAAA) at positions 3126 and 3522 are double underlined and precede 
the two alternative sites of polyaclcnylation at positions 3155 ancl 3550 
indicated hy asterisks. 
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Fig. 4: LPL gene varialions and stnu:turc. 
/\11 misscnsc ( e ), framcshirt (A) and nonsense (D •) mutations descrihcd 
in litcrahll"c (up to 1994) including the two novel misscnsc mutations 
dcsuihcd in this manuscript arc shown (Reprinted from Hayden and 
llcnclcrson, 1995). Exon numbers (I - 10) and sizes [eg: (276)] in base pairs 
arc indicated. Exon-intron hounda.-ics .u-c indicated. The catalytic triad 
residues (cg: 132 S) arc shown. The disulliclc bridge (217-------238) at the 
hase of the loop domain(.) are indicated. The proposed heparin hinding 
regions (I~~) arc shown. The N-tcrminal and C-tenninal domains rd"cr to 
the distinct stmctural domains of the monomeric subunit of LPL as dcdm:cd 
from the homologous 31> molecular model of human pancreatic lipase 
(Winkler et. al., 1990). The amino acids arc indicated hy the single letter 
code with gene variations inclicatccl. 
1.2.2 Gene Variants. 
8 
A large number of patients with familial LPL deficiency have now been examined for coding 
sequence variations at the LPL locus (Bruin et. al, 1994; Lalouel et. al., 1992). These sequence 
variants include, insertional, deletional and point mutations (utlouel et. al., 1992; Devlin et. al., 1990; 
Langlois et. al., 1989). The majority of mutations described to date are missense mutations which 
cluster in the central exons 4, 5 and 6 (Fig. 4). Fig 4 is a schematic diagram of the LPL gene 
showing the location of some the mutations described in this section. Also included in the diagram 
are the two novel exon 9 mutations which are the subject of this dissertation. 
The population frequency of primary LPL deficiency has been estimated at 1 in 106 worldwide. 
This gives a carrier frequency of 1 in 500 in the general population (Nikkila, 1978). Higher 
frequencies have been reported and these occur within the French Canadian population, in areas 
surrounding Quebec City, Canada, where founder genes have increased the carrier rate to 1:40 
(Gagne et. al., 1989). Genealogies constructed from several restriction fragment length 
polymorphisms (RFLP haplotypes) indicated that these founder mutations were introduced into 
Quebec by French settlers who had migrated mainly from Brittany, Normandy in the 17th century. 
9 
They settled mainly in and around Quebec City where they remained socially and linguistically 
isolated, with little expansion of their gene pool. Two founder mutations, the Pro207'-+Leu (P207L) 
(Ma et. al., 1991) and Gly188'-+Glu (G188E) (Monsalve et. al., 1990) predominate in this French 
Canadian population. For instance, the P207L mutation occurs in 54 (73%) out of 74 mutant alleles 
in 37 patients with LPL deficiency, while the G188E mutation accounted for 15 (21.6%) of the LPL 
deficient alleles. The G 188E mutation is not only found in the French Canadians but has been 
reported in persons of different ancestries, including people of Polish, English, German, Dutch, 
Austrian (Miesenoock et. al., 1993) and East Indian (Henderson et. al., 1992) descent. In the South 
African population this mutation was detected in 9 probands from 4 families of Indian extraction. The 
higher than expected frequency of LPL deficiency in this population group can be attributed to a few 
carriers who arrived in South Africa in the early part of this century. Haplotype analysis has shown 
that the G188E mutation associates predominantly with a single haplotype in all the population 
groups, suggesting an ancient origin possibly pre-dating the spread of Caucasoid populations. 
Another missense mutation which occurs at codon 194 in exon 5 of the LPL gene (Ile194'-+Thr or 
1194T mutation) was reported in 5 unrelated kindreds of different ancestries (Dichek et. al., 1991; 
Henderson et. al., 1991). It has been reported in four South African (S.A.) patients, one of Dutch, 
one of French and one of mixed ancestry with the fourth patient being of unknown ancestry. This 
mutation was demonstrated to be associated with two divergent RFLP haplotypes in the S.A patients 
and most likely is indicative of recurrent mutations occurring on different chromosomal backgrounds, 
giving a multicentric origin for this mutation. 
1.3 Structural and Functional Properties of LPL 
Technological advances in molecular biology have greatly facilitated the characterisation of 
pro- and eucaryotic lipases and their corresponding gene sequences. The complete structure and 
organisation of LPL genes from a variety of species is now known, for exam pie, human (Deeb et. al., 
1989; Wion et. al., 1987; Kirchgessner et. al., 1989; Oka et. al., 1990), guinea pig (Enerback and 
Bjursell, 1989), rat (Brault et. al., 1992; Wicker-Planquart and Puigserver, 1992), cow (Senda et. al., 
1987), mouse (Kirchgessner et. al., 1987) and chicken (Cooper et. al., 1992). Sequence comparisons 
of all known lipases reveal the existence of several lipase gene families. Human pancreatic lipase 
(hPL)(Lowe et. al., 1989), human hepatic lipase (hHL)(Martin et. al., 1988; Ameis et. al., 1990) and 
human LPL (as shown) show a high degree of homology, indicative of a common ancestral gene, and 
10 
represent one of these families (Kirchgessner et. al., 1989). A striking feature in this family is the 
extensive homology observed for a region located between residues 120 and 260 (Fig. 
S)(Kin.:hgessner et. al., 1989). This region contains the cat.1lytic triad residues, Ser, Asp and His 
(Wang et. al., 1992) and the "nucleophilic elbow" motif, G-X-S-X-G, reminiscent of the serine 
protease family of enzymes (Oerewenda and Derewenda, 1991 )(Table 3). 
hLPL 153 V N R I T G L D P A G P N F E Y A E A P S R L S P 
h H L 164 I G R I T G L O 0 A G P L F E G S A P S N R L S P 
hPL 170 
hLPL 178 0 0 A D F V O V L II T F T R G S 
hllL 189 0 0 A S F V O E1 I II T F T R E H 
hPL 195 S O A K F V O V I 
I K 
L S V G I K 
hLPL 
hllL 
202 Q P V G II V D I Y P N G G T F Q P G C 
212 QPl]GIIYOFYPNGGS FQ PGC 
hPL 220 
Fig 5 : Central homology or the regions or human lipoprotein (hLPL), hepatic (hHL) 
and pancreatic (hPL) lipases. Portions or the protein sequences of hLPL, 
hHL and hPL are shown with the numhers indicating the amino acid 
nmnher in thesecreted protein. Maximal homology was obtained hy the 
introduction of" gaps (indicated by clots). Regions of homology are boxed. 
'fuble 3: 
11 
Mummuliun Lipun1 and Rdutrd Proldn1 
hLl'L ~ II I. L (; y s L G A IJ A ~ 
hLl'L ~ II 1 L G y s L G A II A ~ 
hllL V II ~ G y s L G A n V J 
hPL J II ~ I G II s L G A II A g 
hGL ::!: II }; V G II s Q G T T g 
hllAL :!: T 1 F G E s A G G A s ~ 
hLCAT ~ F 1 G II s L G C L II 1 
rLL :!: n }; V G II s Q G T T I g 
•·ungul Lipuses 
RML ~ A ~ T G n s L G G A T ~ 
GCL ~ M J •• G E s A G A M s ~ 
CCL ~ T 1 •• G E s A G s 
l'CL 1 V ~ V G II s L G A A V g 
lluckriul Lip1c«·• 
l'. fragi ~ N ::!: G II s Q G A L T g 
P. c1pacia ~ N 1 V G II s Q G Q 
S. aur1us ~ II 1 V G II s M G G Q T 
Othtr 
F. sol. culinuse 4! g G G y s Q G A A L ~ 
A. 1/ydrophila V II r; L G II s I, G A s It V 
h. prolyl oligopepliduse 1 T N G G s N G L L V g 
Compauison lo uline ntrrasts 
T. cal. AChE 
~TJ:•· GESAGAAS~ 
Amino Held sequence comparisons corresponding to the 1)-eSer-u structural motif. The acllve site Ser 
und conserved residues mnklng up the "nuclcophllllc elbow", GXSXG, are boxed. Acljaccnt residues 
Involved In the hellx-P~hcct packing or this motlr arc double-underlined. The sequences compared are 
human llpoprot.eln llpnse (hLl'L)(Wlon et. al., 1987), bovine lipoprot.eln lipase (bLPL)(Senda et. al., 
1987), humnn hepatic lipase (hHL)(Dntta et. al., 1988), human pancreatic lipase (hPL)(Lowe et. al., 
1989), human gastric lipase (hGL)(Hodmcr et. al., 1987), human bile-salt activated lipase (hBAL)(Wong 
and Hartsuck, 1993), human lcclthln-cholcst.erol acyltrnnsfcrase (hLCA T)(McLean el. al., 1986), rat 
llngunl lipase (rLL)(l)ochcrty et. al., 1985), Rhlzomucor Michel lipase (RML)(llocl et. al., 1988), 
Gcotrlchum candldum lipase (GCL)(Shlmnda et. al., 1990), Cadlda rugosa lipase (CRL)(Longhl et. al., 
1992), Pcnlcllllum camembcrtJI lipase (l'CL)(lsobe and Noklhara, 1993), Pscudomonas fragl lipase 
(Wohlforth and Winkler, 1991), l'scudomonns ccp11cl11 lipase (Cyglcr et. al., 1992), Staphylococcus 
nurcus lipase (Lee et. al., 1986), Fusnrium solunl cutinase (Soliday el. al., 1984), Acromonns Hydrophila 
extracellular lipit~c (Anguila et. al., 1993), human prolyl oligopcptidasc (l'olgar, 1992), Torpedo 
Californlcn ncctylcholincslcnt~c (I'. cul. AChE)(Sussman et. al., 1991). 
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Several approaches have been adopted to study structure-function relationships of lipases. 
While much data has been obtained from earlier protein and enzyme kinetic studies, the recent X-ray 
crystallographic data from the human pancreatic lipase (hPL)(Winkler et. al., 1990) and fungal 
lipases, Rhizmucor Miehei (RML)(Brady et. al. , 1990), Geotrichum candidum (GCL)(Shrag et. al., 
1991), Candida rugosa (CRL)(Grochulski et. al., 1993) and the bacterial lipase, Pseudomonas glumae 
(PGL)(Noble et. al., 1993) have provided structural models for lipase function. The PL model has 
been used as a general blueprint for LPL and HL function, even though each of these enzymes 
possess distinctive properties, which alludes to local domain-specific differences. 
1.3.1 Structural Properties. 
1.3.1.1 Molecular Size 
Molecular weight (MW) determination utilising radiation inactivation (Olivecrona et. al., 1982, 
1985) and gel filtration (Osborne et. al., 1985) techniques, revealed apparent molecular weights for 
the non-covalent LPL homodimer of between 83 OOOd and 110 000d. While monomeric LPL was 
shown to have apparent MWs ranging from 34 OOOd to 96 900d (Quinn et. al., 1982), determination 
of the human LPLcDNA sequence (Wion et. al., 1987)(Fig. 3) revealed a mature protein of 448 
amino acids preceded by a 27 amino acid signal peptide with a calculated molecular weight of 50 
394d. With an estimated carbohydrate content of 8%, the predicted apparent MW may be around 
60 000d. A similar apparent MW (60 OOOd) was obtained upon SDS-PAGE of human milk LPL 
(Zechner, 1990). 
1.3.1.2 Monomer and Dimer Forms. 
Sedimentation equilibrium dialysis and gel filtration performed on bLPL shows that lipase 
activity is essentially associated with the protein dimer species (Osborne et. al, 1985). Mild treatment 
of intact bLPL with guanidinium chloride, leads to an irreversible loss of activity, due to dimer to 
monomer dissociation, as evidenced by the loss in secondary structure based on circular dichroic 
(CD) measurements (Osborne et. al, 1985). These findings provide evidence that the intact LPL 
dimer is an absolute requirement for full catalytic activity. Earlier studies have shown that heparin 
stabilises the LPL dimer against denaturation presumably by spanning the dimeric unit 
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following binding to specific binding sites on each individual subunit (Jackson et. al., 1980; Clarke 
et. al., I ')83). While this may represent an attractive vehicle for subunit stabilisation, direct protein-
protein interactions cannot he discounted . Hydrophobicity has been established as the major factor 
in stabilising protein-protein associations (Chothia and Jan in, 1975). Wong et. al. (1991) proposed 
two possible models for lipase dimt:r formation, (i) a head-to-head or (ii) a head-to-tail association 
(Fig. (l). In both structures a two-fold axis of symmetry exists with the head-to-head conformation 
having the two N-terminal c:1t,ilytic domains juxtaposed and the two C-terminal domains next to each 
other. The head-to-tai l conformation would bring the C-terminal domain in close proximity to the 
N-terminal active site. 
Fig. 6: 
(1) Head - to - Head (2) Head - to - Tail 
Schematic diagram of the proposed LPL dimer conformations (reprinted 
from Wong et. al., 1990). Monomeric LPL is represented with a larger N-
terminal domain linked via a spacer arm to the smaller C-terminal domain. 
The catalytic sites(-) are shown. 
B iochem ica I studies of monomeric LPL fol lowing proteolytic digestion had earlier suggested 
the existence of distinct functional domains (Bengtsson and Olivecrona, 1980; Bengtsson-Olivecrona 
et. al., 1986). This was confirmed hy the construction of a molecular model of the homologous 
human pancreatic lipase (PL)(Winkler et. al., 1990) which clearly shows a two domain structure for 
the members of thL5 lipase gene family (Fig. 7 and 8). The N-terminal domain is a globular a/P type 
structure whereas the C-terminal domain is of the P-sandwich type. The a/p-type scaffold of the N-
terminal domain appears to be a conserved topological feature of all Ii pases although their overall 
structures are different. The location of cysteine residues involved in the formation of five disulfide 
bridges in LPL (Ynng et. al., 1989), appenr to have been conserved in HL and PL indicating 
potentinlly similar tertiary conformation (Wang et. al., 1992; Persson et. al., 1989)(Fig. 9). The 
larger N-terminal domain of LPL (res 1-312) contains the cntalytic triad and the highly conserved 
consensus sequence, G-X-S-X-G (Derewenda and Derewenda, 1991). 
Lid 
SerU2 
Heparin 
Binding 
Siles 
Fig 7: 
Lipid 
Binding 
Site 
Disulfide Bridge 
C418-C438 
Ab5D2 
epitope 
C216 
~ 
Disulfide 
Bridge 
Ribbon diagram showing the a/P type structure of the human pancreatic 
lipase molecule. The proposed location of specific functional sites and 
residues of the homologous LPL molecule are superimposed. The active site 
residues (t{) forming the catalytic site are shown. The residues involved 
in the fonnation of the disulfide bridges at the base of the lid domain and at 
the C-terminus are shown. The heparin binding sites and lipid binding 
motifs are shown. 
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Fig 8: 
E421K 
Catalytic 
Triad 
1225T 
Ribbon diagram showing the a/P type structure of the human pancreatic 
lipase molecule. Location of LPL mutations discussed in the manuscript. 
The mutations are indicated by ( • ). The active site residues ~ involved 
in the formation of the catalytic triad are shown. The a-helix and P-sheet 
structures of the N-terminal domain are numbered lo facillitate the 
discussion. 
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Fig. 9: 
100 200 300 ~IO 
The location of disulfide bridges and conserved cysteine residues in the N-
and C- tenninal domains of human lipoprotein (hLPL), hepatic (hHL) and 
pancreatic lipase (hPL). Disulfide bridges are numbered 1 to 6 and free 
cysteine residues are marked (*). Also shown is the size of the individual 
proteins and the position of the catalytic tdad residues, Ser, Asp and His. 
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1.3.2 Fu11clio11:il Drn11:ii11s. 
The catalytic tri,1d, Scr ... l lis ... J\sp, of the serine prntcase and esterase family of enzymes 
(Roscnhcrry, 1975) is idcntical to that found in most lipases (Fig. 10), except for the Geotrichum 
rn11clic/11m lipase, where a Glu replaces an Asp in the triad. The putative catalytic Ser forms part of 
the conserved consensus se4ue11ce, G-X-S-X-G (Table 3) and seve· l lines of evidence show this 
residue to be tlw active site serim; in LPL. 
Fig. 10: 
\ 
. (7~~'"" 203 HI8 ._ - ) 
I j;' ~I ~ 
~ 
I \13 (jl. Y 
Stcreodiagram of the superimposed Asp-Ser-His catalytic triads of human 
pancreatic lipase (thick lines) and trypsin (Winkler, 1990). 
The catalytic triad in hPL (Serl 52, His263, A<;pl 76)(Winkler et. al., 1990) and RML (Serl 44, 
1-1 is 257, Asp203)(Brady et. al., 1990) was demonstrated to be situated in a cleft, buried under a 
surface loop, called the "lid", rendtring it inaccessible to the aqueous environment. Sequence 
alignment and structure homology predict ions suggest that Ser 1 32, Asp 156 and H is24 l would be the 
functionally equivalent cou11lerparls in LPL (Fig. 7) . Several investigall)rs have shown that 
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substitutions at all three active site residues lead to the expression of catalytically inactive LPL mutant 
products (Faustinella et. al. , 1991; Toshiro et. al., 1992; Emmerich et. al., 1992). The mutant LPL 
protein mass levels and heparin binding properties were similar to native LPL. These findings indicate 
that these substitutions disrupted only the hydrolytic activity of LPL, without affecting any of the 
other functional domains. Substitution of the homologous Ser147 in hepatic lipase (Davis et. al. , 
1990) caused a similar lack of activity against triolein emulsions and tributyrin substrates. 
Based on structural predictions for RML, the catalytic Ser144 was demonstrated to be 
part of a P-eSer-P conformation, unique to lipases (Derewenda and Derewenda, 1991). In identical 
fashion, Ser132 of LPL is located at the C-terminal end of P-strand 6 which is connected it to a-helix 
4 (Derewenda and Cambillau, 1991)(Fig. 8). In this position Ser132 is under considerable strain 
forming part ofa classical P-hairpin type II' turn or "nucleophilic elbow (Sibanda et. al., 1989) where 
it assumes the rare E conformation. The other triad residues, His241 and Asp156 are both located 
in tleXIble loops which vary markedly in size and structure between species. His241 is located at the 
end of helix 6 adjacent to a conserved disulfide bridge which forms the base of a loop structure called 
the "flap" or "lid" domain. Asp156 is located in the loop which connects strands, p7 to p8. This 
loop which is made up of eleven residues, partially obscures the catalytic Ser. 
Interestingly, an active site geometry similar to Iipases has been described in Dienelactone 
Hydrolase (DLH) from Pseudomonas sp. B13 (Pathak and Ollis, 1990). This enzyme which is also 
of the a/P type has an active site Cys123 in place of a Ser, which also assumes the identical P-eCys-p 
conformation. Evolutionary relationships based on codon interconversions confirmed a Cys residue 
as the precursor to all active site Ser residues (Brenner, 1988). 
1.3.2.2 " Lid " or Loop Domain. 
All the lipases crystallised to date have yielded molecular models showing an active site buried 
beneath surface loops which renders it inaccessible to solvent. In both RML (Cygler et. al., 1992; 
Dodson and Lawson, 1992) and hPL (vanTilbergh et. al. , 1993)(Fig. 8), this " lid" or loop domain is 
formed by a short coil which blocks the active site cleft and is linked to the main body by two short 
flanking a-helices. In hPL, however the lid is completed by disulfide-bridging at its base. 
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At the lipid-water interface this structure undergoes a conformational change which involves the 
unwinding of the one-turn a-helix causing the lid to role back exposing the active site to substrate 
(van Tilbergh et. al., 1993). This lid movement in turn causes a main chain movement of an adjacent 
active site loop resulting in the formation of the oxy-anion hole. This overall movement exposes the 
hydrophobic faces of the amphipathic lid helices which creates an extended hydrophobic surface with 
the non-polar surface of the cofactor, co lipase, facillitating interaction with the lipid substrate. 
Secondary structural predictions have also suggested a helix-tum-helix motif for the 22 amino 
acid LPL lid domain (res 217-238)(Dugi et. al., 1992; Faustinella et. al., 1992). This motif is 
disulfide-bridged (res Cys216-Cys239) at its base and contains helix A (8 amino acids in length), 
followed by a 3 amino acid P-turn or coil and a second helix B consisting of 7 amino acids (Fig. 11). 
Both helices are highly amphipathic in nature with hydrophobic moments 0.64 and 0.68, respectively, 
which are amongst the highest reported in the literature (Eisenberg et. al., 1990). The projected a-
helical character of the LPL lid domain is characteristic of proteins involved in lipid binding. Both 
helices in the LPL lid domain are of the A-helix type (high hydrophobic moments) which are 
characterised by the strong hydrophobicity of the non-polar faces and the charge distribution, with 
negatively charged residues in the centre and positively charged residues at the border between the 
hydrophobic and polar faces (Segrest et. al., 1990). 
Structural features of the lid domain such as amphilicity, length, periodicity and charge 
distribution are important for catalytic function. They may also be major determinants of substrate 
specificity, although this is yet to be explored. The secondary structural regions of the loop in hLPL, 
hHL and hPL are likely to be different as sequence conservation for this lid domain is poor (Fig. 11) 
and loops cannot be interchanged between enzymes. For example, replacement of the LPL lid with 
the HL lid generates a LPI)HL variant with 60% activity when compared to the normal LPL protein, 
while the LPL/PL loop mutant was totally inactive (Faustinella et. al., 1992; Dugi et. al., 1992). 
Alteration of the charge profile in the lid region of LPL (Henderson et. al., 1994; Dugi et. al., 1992) 
by the substitution of positively-charged residues with negatively-charged residues resulted in a 
markedly reduced or complete loss of activity against emulsified triolein, but activity against tributyrin 
was unaffected. This demonstrated that amphilicity and secondary structure in the lid domain was 
essential for activity (Dugi et. al., 1992). A naturally-occurring point mutation, namely, the 1225T, 
which occurs within the LPL lid domain caused a marked decrease in activity towards long-chain 
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Sequence alignment and topology of the lid domain of human lipoprntein lipase. 
A. The sequence and size of the lid domains of human lipoprotein (hLPL), 
hepatic (hllL) and pancreatic (hPL) lipase are shown by the single amino acid 
notation. Sequence homology is indicated hy hoxed residues. The cysteine 
residues involved in the formation of the disulfide bridge forming the hase of the 
lid domain are numbered. The size of the individual lid domains aa·e shown in 
brackets. 
B. The derived structure for the lid domain of human lipoprutein lipase is 
shown. This consist.; of helix A (1·es A221 - R228), helix B (res D232 - K237) and 
a 13-turn (res G229 - G23 l). Helix A contains an overall positve charge .ind helix 
B ,1 negative charge as indicated. llydrophohic residues aa·e indicated by an*. 
A naturally-occurring mutation at position 225 (1225T) is boxed. The disullide 
hridge at the base of the lid domain is shown (C216-----C238). 
lipid substrates (Fig. 8 and 11 )(Henderson el. al., 1993). The introduction of a hydroxyl (-OH) group 
from Thr in a highly hydrophobic region (flanked by Val and Ala residues) possibly disrupts 
interaction with lipid substrates or the main body of the enzyme. 
1.3.2.3 ApoC-11 Bindini,! Site. 
While the evidence for the specific sites of interaction between apoC-11 and LPL remains 
obscure, several studies suggest an N-terminal domain location. Characterisation of chimeric lipases, 
consisting of an N-terminal LPL domain and a rat (Davis el. al., 1991') or human (Dichek et. al., 
1992) HL C-terminal domain, demonstrated lipase activity only in the presence of apoC-11. Since HL 
is known to have no cofactor requirement for apoC-11, the interaction with the chimeric lipases are 
likely confined to the N-terminal domain. This is supported by the lack of an apoC-11 enhancing 
eflect on the activity of the reverse HULPL chimera. More recently, Bruin et. al. (1994) constructed 
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site-specific mutants of LPL to locate the exact apoC-11 binding site. Their approach was based on 
the hypothesis that the two C-terminal glutarnic acids of apoC-II mediate binding via ionic interaction 
with opposing positively-charged residues on LPL. Mutant constructs for the five dibasic sequences 
identified in LPL, revealed one mutant (K147A-K148A) with reduced LPL activity (35% of normal) 
in the presence of apoC-II, following expression in COS cells. Taken together, these findings are 
suggestive of an N-terminal domain location for the site of interaction of apoC-11. Lookene and 
Bengtsson-Olivecrona (1993) demonstrated effective binding of apoC-11 to an N-terminal 
chymotryptic fragment of LPL (cLPL). 
1.3.2.4 Heparin Binding Domain. 
Several heparin binding proteins, such as, the apolipoproteins, apoB-100 and apoE (Yang 
et. al., 1986; Innerarity et. al., 1983) have been shown to have regions rich in basic (B) amino acids, 
such as, lysine and arginine, conforming to consensus sequences, -X-B-B-X-B-X and -X-B-B-B-X-
X-B-X. Similar regions have been identified in LPL between residues 279-282 and 291-304 having 
the sequence CRKNRC and KVRAKRSSKMYLK, respectively (Enerback et. al., 1987; Yang et. al., 
1989). The other heparin-binding lipase, hHL, has 8 Lys or Arg residues (Martin et. al., 1988) while 
hPL has only 3 basic amino acid residues in the corresponding segments (Hata et. al., 1993). This 
is consistent with the differences in their heparin affinity, LPL> HL, with PL, devoid of any heparin 
binding affinity. 
Mutagenesis studies involving the substitution of charged residues in these regions support 
the contention that they form part of the heparin binding domain in hLPL (Hata et. al., 1993) and 
avian LPL (Berryman and Bensadoun, 1993). In the human PL model the residues homologous to 
the heparin binding domain in hLPL are located in a solvent exposed P-tum structure, positioned 
close to the junction of the N-and C-terminal domains, on the face, opposite the active site (Fig. 7). 
This places the heparin binding domain in an ideal position for interaction with the endothelial-bound 
HSPG's. While this may be so, the contribution to heparin binding from the other regions mentioned 
cannot be discounted. A further arginine-rich region in LPL, residues 146-151, was postulated to be 
involved in interaction with heparin, but abolition of charge by mutagenesis did not affect binding 
affinity (Hata et. al. , 1993). 
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A heparin binding site localised to the C-terminal domain was proposed by several 
investigators. For the chimera construct, LPL/HL (Dichek et. al., 1993; Wong et. al., 1991) heparin 
affinity was shown to be associated with the C-terminal domain. The hLPL/hHL chimera was eluted 
at a salt concentration of 0.9M from Heparin-Sepharose columns which represents an intermediate 
affinity for heparin between that for hLPL (l.lM) and hHL (0.75M)(Dichek et. al., 1993). This 
differs from the elution profile observed for a human LPL/rat HL chimera, which eluted at 0.75M 
NaCl similar to native human HL (Davis et. al., 1992). This may in part be explained by the sequence 
differences in the C-terminal domain between the human HL (residues 330-476) and rat HL (330-
472) consisting of 22 as opposed to 16 basic amino acids residues, respectively. Thus the greater 
basic residue content of the human HL domain may impart a higher affinity for heparin. 
1.3.2.5 Lipid Binding Site. 
An ideal lipid binding motif exists in the C-terminal domain and comprises residues proximal 
and distal to the Cys418-Cys438 disulfide bridge. The proximal six residues, APA VFV, are brought 
into close proximity with a three residue hydrophobic segment, juxtapositioned next to Cys418, 
following disulfide bridge formation (Fig. 7). Strong support for the localisation of a lipid binding 
domain in the region was provided by the expression in COS cells of C-terminal truncated LPL 
mutants (Kozaki et. al. , 1993). Interestingly in this study, LPL mutants, 435--+stop and 436--+stop 
exhibited respective lipase activities of 22 and 88% compared to native LPL, when using 
triacylglycerol emulsions as substrates. Notably, only four of the nine corresponding residues are 
conserved in HL with no such conservation observed in PL consistent with their variable substrate 
specificities. 
In addition, a mutant construct of a naturally occurring mutation, Trp382--+stop, produced a 
catalytically inactive protein establishing the importance of this hydrophobic domain in the expression 
of full activity towards emulsified lipid substrates. Further evidence for the involvement of the C-
terminal domain in lipid binding comes from the localisation of the epitope for the LPL monoclonal 
antibody, Ab5D2, to residue 400 (Lui et. al., 1992)(Fig. 7). This antibody inhibits activity to long-
chain triacylglycerols but does not affect activity towards tributyrin, implying a role for the C-terminal 
domain in lipid binding. 
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1.3.3 Function Properties. 
1.3.3.1 Jnterfacial activation. active site mechanism and physical properties 
Sch0nheyder and Volqvartz (1945) were the first to describe the phenomena of "lnterfacial 
Activation" for pancreatic lipase (PL). Chapus et. al. (1976) confirmed this mechanism of action for 
PL by demonstrating an increase in enzyme activity in the presence of substrates with hydrophobic 
interfaces e.g. inert silicon beads. The recent publication of the crystal structures of a fungal 
lipase-inlubitor complex (Brzozowski et. al., 1991) and the hPL-procolipase-phosphatidylcholine/bile 
salt complex (van Tilbergh et. al., 1993) provided a model for " interfacial kinetics". Since the long-
chain triacylglycerols embedded in large lipoproteins form emulsions in aqueous medium it would 
suggest that lipases work at the two dimensional (lipid-water) interface of an emulsion (Potts et. al., 
1991; Chapus et. al., 1976; McLean et. al., 1986; Shirai et. al., 1982, 1984; Quinn et. al., 1982). 
Subsequently, this phenomena was also confirmed for LPL following monomolecular lipid film studies 
(Macritchie, 1978; Vainio et. al., 1983; Burdette et. al., 1986). 
A classical acyl-enzyme pathway based on kinetic studies was demonstrated for the lipase 
reaction (Chapus et. al., 1976)(Fig. 12). This catalytic charge-relay reaction mechanism has been well 
documented, as the preferred mechanism in serine proteases (Warshel et. al., 1989) and esterases 
(Rosenberry et. al., 1975; Blow, 1976). The role of the Ser ... Asp ... His catalytic triad is now well 
established as the constellation of residues responsible for catalysis in the lipase family of proteins. 
The triglyceride substrate, upon binding to the interfacial binding site appears to migrate down a 
hydrophobic channel to the catalytic site by facilitated diffusion (Scot et. al., 1990). An ester bond 
between the carboxyl group of the fatty acid and serine hydroxyl of the enzyme characterises the 
acyl-enzyme intermediate that forms. Since the deacylation step is base-catalysed in both the lipase 
(Rojas et. al., 1989) and serine esterase (Rosenberry et. al., 1975) reaction, the histidine imidazole 
is implicated as the base catalyst in these reactions. The aspartic acid residue in turn stabilises the 
transition state complex by neutralising the positively-charged imidazole ring that forms during the 
reaction (Brady et. al., 1990)(Fig. 12). 
~ 
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Fig. 12: The catalytic charge-relay reaction mechanism of the serine esterase/ 
protease and lipase enzymes. The acyl-enzyme intermediate is shown. 
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LPL manifests maximal activity at an alkaline pH of 8.8 to 9.0 (Ehnholm et. al., 1975) and is 
inhibited by salt solutions of high ionic strength (Fielding and Fielding, 1976). This salt-mediated 
inhibition follows the Hofmeister series (I · > SCN· > N03· > c1· > F") and is fully reversible. Fielding 
and Fielding also showed that salt inhibition at lM NaCl could be reversed by lowering the ionic 
strength. LPL from a variety of sources, including adipose tissue and post-heparin plasma from the 
rat (Parkin et. al., 1982) and bovine milk (Kinnunen et. al., 1976) exhibit similar properties. Op Den 
Kamp et. al. (1974) demonstrated stability of the active LPL over a wide temperature range (l 7°C 
to 32°C) with maximal activity achieved at 37°C (Quinn et. al., 1982). 
1.3.3.2 Substrate Specificity. 
While long-chain triacylglycerides are the preferred substrates, LPL has also been shown to 
hydrolyse medium and short chain triglycerides, diglycerides and monoglycerides; long- and 
short-chain phosphatidylcholines and water-soluble p-nitrophenylesters (Cryer, 1985; Speake, 1985). 
While substrate specificity is low, positional specificity at the ester bonds in acylglycerols is strict, as 
the sn-1 and sn-3 positions are preferentially hydrolyzed, generating sn-2 monoglycerides and free 
futty acids. It has been shown that LPL is more effective in the catalysis of triglyceride-rich substrates 
containing the n-3 and n-6 class of fatty acids (Murphy et. al., 1993). 
1.3.3.3 lnten1ction with ApnC-11. 
ACTIVATES 
LIPOPROTEIN 
LIPASE 
/l - SHEET INTERACTION 
WITH 
LIPOPROTEIN 
LIPASE BINDING coo-TO 
LIPOPROTEIN LIPASE 
Fig. 13: ApoC-11 peptide sequence and slrndure. (Reprinted from Smith and 
Pownall, 1984). Specific active domains are indicated. 
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The exact mechanism for apoC-11 activation of LPL is still obscure, but a unifying hypothesis 
suggests that apoC-11 orientates LPL at the interface such that it's active site is readily accessible to 
substrate (Olivecrona et. al., 1987). Direct protein-protein interaction between the LPL and apoC-11 
was demonstrated by monitoring intrinsic flourescence upon interaction of dansylated apoC-11 with 
LPL (Clarke and Holbrook, 1985). They were able to show a 1 :1 stoichiometry for this interaction, 
with each subunit of the LPL homodimer binding a single apoC-11 molecule with a dissociation 
constant of 0.2µM (Olivecrona and Bengtsson-Olivecrona, 1987). This asssociation appears to 
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become tighter in the presence of lipid as evidenced by a 40 fold decrease in Kd (0.05µM)(McLean 
et. al., 1986). Varying the apoC-Il concentration had no effect on the apparent~ but the apparent 
V max was increased 20 fold for the LPL hydrolysis of emulsified triacylglycerol substrate (Posner et. 
al., 1983). The LPL-apoC-II complex formation is therefore not the rate-determining step. 
Furthermore, it has been shown that the apoC-II protein contains distinct regions involved in the 
activation of LPL (Fig. 13). A LPL binding domain spans residues 61 to 79, with the N-terminal 
residues 1-49 representing a lipid binding domain (Cetapano et. al., 1979). The C-terminal apoC-11 
tetrapeptide, KGEE appears to be involved in direct binding to LPL (Cheng et. al., 1990; Musliner 
et. al., 1977) and is therefore thought to represent an ionic binding site involved in electrostatic 
association with LPL. 
1.3.3.4 Interaction with Heparin. 
More than 50 years ago it was noted that intravenous heparin administration enhanced 
lipolysis by releasing a "clearing factor", later classified as "Lipoprotein Lipase", into the blood 
circulation of dogs (Hahn, 1943; Korn, 1955). This functional property of heparin was also 
demonstrated in humans (Ehnholm et. al., 1975 and 1985). Heparin appears to have a dual role, in 
that it was reported to stimulate the secretion of active LPL from guinea-pig adipocytes in a 
constitutive manner without affecting it's cellular activity (Semb and Olivecrona, 1987; Ashby et. al., 
1978). It is also known to stabilise the active LPL dimer against degradation (Cupp et. al., 1987). 
In support of these proposed roles, mast-cell deficient W/Wv mice (mast cells are heparin producing 
cells) were found to have markedly reduced levels of LPL and HL in post-heparin plasma, which 
correlated with their negligible heparin levels (Hatanaka et. al., 1986). Also, Yannier et. al. (1989) 
demonstrated a quantitative increase in LPL secretion from adipocytes in the presence of heparin 
While Cupp et. al (1991) showed that incubation of cultured adipocytes with heparin resulted in 
reduced degradation of LPL. Heparin may therefore play an integral role in the regulation of LPL 
secretion in vivo. 
1.3.3.5 Effect of ApoC-Ill. 
The role of apoC-III on LPL function is still unclear but the available evidence suggests an 
inhibitory role (McConathy et. al., 1992). Brown and Baginsky (1972) for instance, showed that the 
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hydrolysis of emulsified triglyceride by apoC-11-stimulated bovine LPL was inhibited by the addition 
of excess apoC-III. Earlier, Carlson and Ballantyne (1976) had demonstrated an inverse relationship 
between VLDI.rtriglyceride levels and the apoC-II/apoC-III 1 ratio, suggesting that alterations in the 
apoC-II and apoC-III, content in VLDL may cause decreases in LPL activity. In support of these 
findings, increased apoC-III2 levels in association with variant triglyceride-rich lipoproteins have been 
described in some patients with severe hypertriglyceridemia (Holdsworth et. al., 1982) and chronic 
renal failure (Staprans et. al. 1979). This variant lipoprotein was demonstrated to be a poor substrate 
for bovine LPL (Holdsworth et. al., 1982) which is attributed to elevated levels of the apoC-III2 
isoform of this lipoprotein, since normalisation of the apoC-II12/apoC-III 1 ratio following 
neuraminidase treatment, resulted in a normal lipoprotein species and interaction with LPL. In order 
to investigate the physiological role of apoC-111, a transgenic mouse model, containing an excess of 
human apoC-III gene copies, was shown to overexpress the apoC-lll product leading to severe 
hypertriglyceridemia (Ito et. al., 1990). VLDL was the predominant lipoprotein species which 
accumulated in the plasma of these hypertriglyceridemia transgenic mice. Less secure evidence for 
a regulatory role for apoC-III comes from association studies where a Sac I restriction fragment 
length polymorphism (RFLP) in the 31 untranslated region of the apoC-III gene was shown to 
segregate with severe hypertriglyceridemia in English Caucasians (Tas, 1989; Aalto-Selata et. al., 
1987) and the Arab population in Kuwait (Tas, 1989). Subjects with the Sac I allele also had 
decreased HDL consistent with a depressed LPL activity in these individuals. These findings do imply 
a possible regulatory role for apoC-III. 
1.3.3.6 Effect of Fatty Acids 
LPL hydrolysis of the triglyceride core of chylomicrons and VLDL liberates free fatty acids 
which are sequestered mainly by albumin. In the absence of albumin, the fatty acids become rate-
limiting due to their accumulation at the lipid-water interface. They may therefore act as competitive 
inhibitors with the enzyme forming complexes with the fatty acids, suggesting that a feedback 
inhibition mechanism may prevail (Peterson et. al., 1990). Saxena et. al. (1989) were able to 
demonstrate that the release of endothelial cell-bound LPL by its physiological substrates, 
chylomicrons and VLDL, was as a direct result of the increase in fatty acid production. Furthermore, 
incubation of cultured endothelial cells with fatty acids caused a dramatic release of LPL into the 
medium, due to dissociation of the LPL from it's binding sites, in accord with it's LPL inhibitory role 
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(Karpe et. al., 1992; Saxena et. al., 1990). This process occurred in a dose-dependent and specific 
manner, since fatty acids were unable to release antithrombin-111, another protein known to bind to 
endothelial cell-surface glycosaminoglycans (Shimada and Ozama, 1987; Stern et. al., 1985). 
Furthermore, free fatty acids also appear to destabilise the binding of LPL to heparin-sepharose 
columns (Olivecrona and Bengtsson-Olivecrona, 1985). 
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1.4 Type I Hyperlipoproteinemia. 
This rare disorder of lipid metabolism manifesting as the chylomicronemia syndrome is 
characterised by the presence in plasma of large triglyceride-rich chylomicrons, while in the fasted 
state. While the clinical phenotype presents a preliminary diagnosis for this condition, it is not 
sufficient to distinguish the heterogeneity underlying Type I hyperlipoproteinemia (Brunzell et. al., 
1980) which may be subdivided into four distinct inborn errors of lipid metabolism namely: 
1. Familial Lipoprotein Lipase Deficiency 
2. Apolipoprotein C-II Deficiency 
3. Transient expression and/or site-specific LPL deficiency 
4. Circulating Inhibitors of Lipoprotein Lipase 
1.4.1 Familial LPL Deficiency. 
The classical work by Havel and Gordon in 1960, established the role of LPL in the aetiology 
of Type I hyperlipoproteinemia. They reported on three siblings with fasting hyperchylomicronemia 
who demonstrated an inability to remove post-prandial fat from the circulation. The introduction of 
a fat-free diet failed to reduce the circulating triglyceride levels to within the normal range. Their 
finding of a decreased LPL activity in patient plasma led to the conclusion that a genetic deficiency 
of LPL was responsible for the defective lipolysis in these subjects. This condition is characterised 
by a marked reduction or complete absence of LPL activity in post-heparin plasma and has been 
shown to be due to mutations in the LPL gene. The genetic heterogeneity underlying this disease is 
well documented, with over 40 mutations being reported in literature to date (Fig. 4). 
1.4.1.1 Age of Onset. 
Clinical symptoms usually manifest in childhood, often in the first year of life (Sadan et. al., 
1977) but late diagnosis has been reported, with the oldest subject being a 75 year old man (Hoeg et. 
al. , 1983). This variable age of onset, again highlights the heterogeneity underlying this 
disorder. 
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1.4.1.2 Clinical and Biochemical Profile. 
A full clinical examination often reveals a history of recurrent abdominal pain, probably due 
to pancreatitis as the major complaint in association with one or two of the other clinical symptoms 
(Table 4)(Brown et. al., 1977). Serum amylase levels are often raised during the episodes of 
abdominal pain and pancreatitis. In early infancy, the disease is usually characterised by colicky pain, 
failure to thrive and eruptive xanthoma (Brunzell and Biermann, 1982). These patients present with 
creamy, milky plasma in the fasted state indicative of chylomicrons in the circulation. 
Chylomicronemia is usually indicative of triglyceride levels in excess of 15-20 mmol/1 (normal< 2 
mmol/1); fasting levels in excess of 80 mmol/1 have been reported in some patients. LPL activity is 
markedly reduced or completely absent in post-heparin plasma. Hepatic lipase activity levels are 
usually found to be normal. Parents often present with reduced post-heparin plasma LPL activity 
levels in keeping with the familial nature of the condition. VLDL may be normal to moderately 
elevated, but LDL and HDL levels may be markedly depressed. A low cholesterol/triglyceride ratio 
is often recorded, with a ratio of less than 0.2 being diagnostic. 
Table 4: Clinical Manifestations associated with the 
Chylomicronemia Syndrome and Type I 
Hyperlipoproteinemia. 
Clinical Manifestations 
Abdominal pain/Pancreatitis 
Eruptive Xanthomata 
Hepatosplenomegaly 
Lipemia Retinalis 
Objective Dyspnoea 
Recent Memory Loss( Dementia) 
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Obligate heterozygotes usually present with reduced post-heparin plasma LPL activities but 
sometimes may overlap with levels in normals (Kondo et. al., 1985; Barbirak et. al., 1989). Fasting 
triglyceride levels often are in the upper normal range, while VLDL-cholesterol levels can be raised 
in the presence of low LDL and HDL.i-cholesterol levels (Wilson et. al., 1990). Carriers have been 
shown to exhibit an abnormal lipoprotein pattern and pronounced lipemia in the post-prandial state. 
HDL.i were found to be enriched in triglyceride, VLDL and IDL were enriched in cholesterol esters, 
IDL levels were elevated and LDL was reduced in size (Miesenbock et. al., 1993). These findings 
are consistent with a defect in LPL function. Secondary hyperlipidemia (Table 5) may often 
complicate diagnoses with the underlying primary LPL deficiency only detected following treatment 
of the former condition. 
Table 5: Conditions associated with hypertriglyceridemia. 
Secondary Hypertriglyceridemias 
Common Rare 
Diabetes Mellitus Cushing's Syndrome 
Hypothyroidism Acromegaly 
Renal Failure (Uremia) Systemic Lupus Erythematosus 
Nephrotic Syndrome Dysglobulinemias 
Alcoholism Lipodystrophy 
Obesity Storage Diseases (Gaucher etc.) 
Pregnancy 
Post-transplantation 
1.4.2 Apolipoprotein C-II Deficiency. 
Apolipoprotein C-11 (apoC-11) deficiency is a rare autosomal recessive disorder characterised 
by the absence of the physiological activator of LPL, apoC-11, in the circulation. Molecular defects 
at this gene locus result in a clinical phenotype indistinguishable from familial LPL deficiency. It was 
originally described by Breckenridge et. al. (1978) in a 59 year old man with diabetes mellitus 
showing typical symptoms of LPL deficiency (Brunzell, 1989). A blood transfusion and substitution 
therapy with normal HDL caused a dramatic increase post-heparin plasma LPL activity, 
demonstrating that a deficiency in apoC-11 was the primary defect in this patient. Yamamura et. al. 
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(1979) established apoC-II deficiency as the basis for the Type I phenotype in two siblings. 
Consanguinity was demonstrated in both studies with all parents showing apoC-II levels at 50 % of 
normal, confirming a familial nature for this disease. 
1.4.2.1 Age of Onset. 
It usually has a later age of onset than classical LPL deficiency, ranging from 12 to 60 years 
of age with symptoms often traced back to childhood (Brunzell, 1989). 
1.4.2.2 Clinical Profile. 
A diagnosis is often confirmed when the absence of apoC-11 can be demonstrated on 
immunoblot or radioimmunoassay. Intravenous infusion of normal plasma usually results in a marked 
reduction in chylomicron, VLDL and triglyceride levels. Also the recovery of normal post-heparin 
plasma LPL activity in the presence of an exogenous source of apoC-11 again confirms the diagnosis. 
Symptoms are often less severe than that observed in familial LPL deficiency. Heterozygotes usually 
have 50% plasma apoC-11 levels compared to normal individuals. 
1.4.2.3 Genetics. 
ApoC-11 deficiency occurs at a frequency of less than 1 in 106 in the general population. The 
apoC-II gene was mapped to chromosome 9pter-q13 (Jean-Pierre et. al., 1984)(Hayden et. al., 
1986). The availability of the gene sequence greatly facilitated the characterization of this disorder 
in more than 11 kindreds to date (Brunzell, 1989). Evidence of a worldwide ethnic distribution 
including individuals of Canadian (Breckenridge, 1978; Huff et. al., 1990; Connelly et. al., 1987), 
Japanese (Yamamura et. al., 1979), English (Miller et. al. , 1981), American (Kashyap et. al., 1980; 
Sprecher et. al., 1988; Menzel et. al., 1986), Peurto Rican (Saku et. al. , 1984), Turkish (Fojo et. al. , 
1988), French (Parrot et. al. , 1992) and Italian (Hayden et. al., 1986)(Sprecher et. al., 1988)(Fojo 
et. al., 1989)(Baggio et. al., 1986) origin has been described. Consanguinity is a common feature 
in this disorder. To date fifteen different mutations with several sequence variants as well as base 
deletions, insertions and splice-junction defects have been described at this locus, underlying the 
genetic heterogeneity in this disorder (Table 6). 
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Table 6:Gene variants reported at the ApoC-11 gene locus upto 1993. 
Designation (Exon) Amino Acid Substitution/ Reference 
Mutation 
ApoC-llsLMlchacl (exon 4) Gin 70'-t Pro/ base insertion ca uses Connelly et. al., 1987 
frameshift with extension to Pro96• 
ApoC-IINUmegcn (exon 3) Val18'-tstop / G deletion causes Fojo et. al., 1988 
frameshift. 
ApoC-IIuamburg (exon 2) G'-tC substitution causes a donor Fojo et. al., 1988 
splice defect in intron 2. Beil et. al., 1992 
ApoC-IIToronto (exon 4) Leu75'-tstop / T deletion causes a Cox et. al., 1988 
frameshift. 
. 
ApoC-IIPadova (exon 3) Tyr37Ystop / CYA transversion. Fojo et. al., 1989 
ApoC-IIParlsl (exon 1) Met'22Y Val / AYG transition. Fojo et. al., 1989 
ApoC-IIuai1 (exon 3) Tyr37Ystop / CYG transversion. Crecchio et. al., 1990 
--------------
(exon 4) Phe67YSer / T'-tC transition. Fojo et. al., 1990 
--············ 
(exon 2) Lys19YThr / AYC transversion. Hegele et. al., 1991 
ApoC-IIJapan (5'-untranslated) -821:w / C deletion and Xiong et. al., 1991 
-28bp / TYG transversion Fojo and Brewer, 1992 
upstream of initiation codon. 
(exon 3) Gln2Ystop / C deletion . 
(polyadenylation site/exon 4) AT deletion. 
ApoC-Ilvenezuc1a (exon 3) Gln 2Ystop / C deletion. Xiong et. al., 1991 
(exon 3) Ser21YPro / TYC transition. Fojo and Brewer, 1992 
(exon 4) Gln70Ystop / CYT transition. 
(exon 4) Glu79Y Val / A'-tT transvers ion. 
(3' -untranslated) CYT transition. 
ApoC-IIParls2 
-
(exon 1) Arg·19'-tstop / CYT transition. Reina et. al., 1992 
Parrott et. al., 1992 
ApoC-Ilwakayama (exon 3) Trp26YArg / TYC transition. Inadera et. al., 1993 
A poC-1 lsan Francisco (exon 3) Glu38YLys / GYA transition. Pullinger et. al., 1993 
Variants (Polymorphisms) 
ApoC-llucthcsda Lower apparent MW, more basic pl. Sprecher et. al., 1988 
ApoC-112 (Black Africans) Lys55YGln. Menzel et. al., 1986 
ApoC-Ilv More acidic pl. Huff et. al., 1990 
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1.4.3 Site-specific and Transient Expression LPL variants. 
A 21 year old patient with no detectable LPL activity in post-heparin plasma was shown to 
process LPL normally in the endoplasmic recticulum but translocation to the golgi complex was 
impaired, indicative of a transport defect. Berger (1986) demonstrated disproportionate expression 
of LPL activity in five patients; four patients exhibited low levels of both adipose tissue LPL (1 % of 
normal) and muscle LPL (5 to 20% of normal) activity, while one had normal muscle LPL activity 
with a significantly depressed adipose tissue LPL activity. In another report, a 33 year old female of 
East Indian extraction had a markedly reduced post-heparin plasma LPL activity (10% of normal) and 
a normal AT-LPL activity. However, a peculiar finding was the return to normal post-heparin plasma 
LPL activity 4 hours after continuous heparin infusion (Burton and Nadler, 1977). 
1.4.4 Circulating LPL Inhibitors. 
Brunzell et. al. (1983) reported on two Caucasian subjects; a 47 year old mother and her 27 
year old son, presenting with chylomicronemia and low post-heparin plasma LPL activities due to the 
presence of a heat-stable, non-apolipoprotein inhibitor of LPL. Autoimmune chylomicronemia due 
to the presence of antibodies to LPL in patient plasma has also been described (Kihara et. al., 1989). 
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1.5 Aims of this Work. 
The general aims of this study were twofold (i) to establish the molecular basis for the LPL 
deficiency in the index patient, JJ(Kindred I) and (ii) to verify if LPL deficiency was the underlying 
condition that led to the death of the index patient, LB (Kindred II), by searching for gene mutations 
at the LPL gene locus. 
The specific aims were: 
i) To search for mutations at the LPL gene loci, through the application of: 
a) Direct DNA sequencing of individual LPL exons. 
b) RT-PCR technology. 
ii) To set up and apply mutation detection systems for screening of gene mutations, such as: 
a) Allele-Specific Oligonucleotide Hybridisation. 
b) "Amplification Refractory Mutation System" PCR. 
c) PCR Restriction analysis. 
d) PCR-SSCP analysis. 
1.6 The Layout of this work. 
The current knowledge on LPL structure-function relationships, molecular genetics, metabolic 
function and its role in the aetiology of Type I hyperlipoproteinaemia is reviewed in Chapter 1. The 
case report of index patient, JJ (Kindred I) is given in Chapter 2 which contains: 
i) a short Introduction 
ii) a Case History section, which describes clinical histories including findings from an 
earlier workup on this patient. 
iii) a Clinical and Biochemical Data section which describes the clinical and laboratory 
investigations performed on patient JJ and his available family members. 
iv) a Results section. 
v) a Discussion section, in which a detailed summary of the findings is presented and 
specific conclusions are proposed. 
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Chapter 3 contains the case report of index patient, LB (Kindred II) which comprises a: 
i) brief review (Introduction) of the role of LPL in pregnancy and some case reports 
published in the literature to highlight the association of pregnancy with hyperlipidaemia. 
ii) Case History and Laboratory Findings section presenting the patient clinical profile. 
iii) Results section 
iv) Discussion section, which summarises the major findings and conclusions. 
General Conclusions and Future Studies are discussed in Chapter 4. A detailed outline of the 
methodologies employed in these studies is described in Chapter 5. Appendix 1 describes the Primer 
Design and oligonucleotides utilised in the respective studies. A full list of references is given at the 
end. 
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CHAPTER 2 
KINDRED I ANALYSIS 
This section of the thesis describes the genetic workup of patient, JJ, who presents with familial 
LPL deficiency. He is shown to be a compound heterozygote for two missense mutations located 
in exons 5 and 9 of the LPL gene. These point mutations result in amino acid substitutions of 
Ile194-Thr (1194T) and Cys418-Tyr (C418Y), respectively. Earlier transfection studies in COS 
cells established that the 1194T substitution produces a catalytically defective protein. The absence 
of LPL activity in post-heparin plasma of JJ, is rather consistent with a primary LPL deficient status, 
in contrast to the earlier suggestion of a variable phenotype. 
Part of this workup was published as a journal article: 
Henderson H.E., Ma Y., Hassan M.F., Monsalve M.Y., Marais A.O., Winkler F., Gubernator K., 
Peterson J., Brunzell J.D. and Hayden M.R. (1991). Amino Acid Substitution (I1e194-Thr) in 
Exon 5 of the Lipoprotein Lipase Gene Causes Lipoprotein Lipase Deficiency in Three 
Unrelated Probands: Support for a Multicentric Origin. J. Clin. Invest., 87; 2005 - 2011. 
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2.1 Case History . 
The index patient, JJ, is a 26 year old South African male of mixed ancestry, being derived 
from the indigenous Khoisan peoples with admixture from early Dutch, German and French settlers 
(Kindred I, Fig. 14)(Berger et. al., 1987). JJ was first investigated at the age of 4, upon presentation 
of hepatosplenomegaly and complaints of pain in the right subcostal region. Although his triglyceride 
level was only moderately raised at 4.67mmol/1 (normal, 0.3-2.3), lipoprotein electrophoresis showed 
a chylomicron and an elevated pre-beta band. He was diagnosed as having Type I 
0v 
hyperlipoprotemkmia and placed on a strict low-fat diet. Although he remained symptomless on this 
regimen, fluctuating VLDL levels (normal to moderately elevated) led to an unstable lipoprotein 
pattern with a Type V or even a Type IV phenotype being recorded at times. The patient's father, 
WJ, had triglyceride levels in the upper normal range, from 1.91 to 2.41 mmol/l; his mother and his 
only sibling, W~J, were normolipif mic. A complete · family study revealed occasional 
hypercholestero~mia in paternal relatives. Consanguinity was ruled out in this kindred. 
Fig. 14: Family Pedigree of Kindred I. 
(Reprinted from Be1·ger, 1987) 
8 (:) - not investigated, 88- normolipideamic, ~/- proband, 
- W - hypercholesterolea~ic. 
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Patient JJ was hospitalised at the age of 11 years, essentially to determine his response to 
dietary fut reduction and to monitor his post-heparin lipolytic activity. The diet instituted had a high 
carbohydrate content (65% of total calories) with a moderate fat intake (25% of total calories). A 
significant decrease in plasma triglyceride levels was achieved, representing a reduction in 
chylomicron and VLDL fractions. Reducing the fat intake further to 5% of total calories caused a 
further drop in triglyceride levels with a concommitant disappearance of chylomicrons after 24 hours. 
Replacing this regimen with a normal western diet (fat content equivalent to 40% of total calories), 
caused a rapid rise in plasma triglyceride levels (75 mmol/1) after two days which was characterised 
by the presentation of severe chylomicronemia with near normal VLDL levels, typical of a Type I 
phenotype. Despite this acute respon5e to a fut bolus, JJ has remained relatively symptom-free. Post-
heparin plasma lipolytic activity measured before this dietary trial, by the protamine sulfate method 
(Berger et. al., 1982) revealed significant LPL activity, of the order of 38% of normal, while hepatic 
lipase (HL) activity was within normal range. However, later assays of his post-heparin plasma LPL 
activity using a different procedure revealed a complete absence of activity (Table 7). 
While, JJ, has not maintained a strict low-fat diet, he has remained symptom-free except for 
occasional bouts of acute pancreatitis. The working diagnosis at this stage was Type I 
hyperlipoproteinemia with a variant form of LPL deficiency (Berger et. al., 1987). 
2.2 Clinical and Biochemical Data. 
Following the cloning of the LPLcDNA and the publication of the gene sequence (Wion et. 
al., 1987) it was decided to reexamine JJ and identify the underlying gene mutations. Lipid profiles 
were again determined for JJ and all available family members which are given in Table?. 
Grossly lipemic fasting plasma was recorded for JJ with a triglyceride level of 43 mmol/1 
(normal, 0.3-2.3). Lipoprotein electrophoresis showed the presence of a large chylomicron peak 
( 46% of total) and a broad pre-Peta fraction ( 4 7% of total)(Table 7), rather indicative of a Type V 
phenotype (BrunzeU, 1989), corroborating the earlier findings of a variable lipoprotein phenotype for 
this patient. A markedly elevated cholesterol level of 15mmol/l (normal < 5.2) with a 
cholesteroVtriglyceride ratio of 0.3 (Type I <0.2)(Beaumont et. al., 1970) is in agreement with a Type 
V diagnosis, but this may not be defin itive, since overlap with the Type I phenotype has been 
documented (Nikkila, 1978). 
A. LIPID 
II 
Plasma Tri~lyct'riclt>* 2.0 1.4 41.K 
Total Chuleslt'rnl* 5.2 6.K 7.4 
Ll>Lc* J.5 4.6 
HDL.-* 0.K 1.6 cu 
ApnA-1** 106 134 
ApnB** 90 96 
1.1'1 . Al'livity # IJO 60 0 
IIL Al'livity # 2-l-l t<,K -l12 
LPL l\lass T = O' # # -15 2-l-l 27 
I.PL !\lass T = 10 '# # -lJ5 621 J5-l 
lmTl'lllt' lllal !\lass## -lJ5 J77 J27 
PROFILE 
2 
17.K K.1 26.6 
5.7 K.K 12.4 
7.2 
0.4 I.I 0.4 
114 520 
201 250 
1111 0 
12-l 2J7 
-IK -7 
-l2<, 2K6 
-l2<1 2K6 
1.2 
5.4 
4.0 
1.0 
113 
92 
92 
17K 
-5 
75 
75 
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B. LIPID ELECTROPHORESIS 
FRACTIONS 
ChMi (1) 
Prepeta (2) 
Alph (3) 
% 
46.4 
47.6 
6.0 
Ta hie 7: A. Lipid profiles ol' two kindreds with LPL deficiency due to a 1194T mutation. 
Control Kindred (1), Kindred I (2). Fasting plasma lipid levels, apolipoprotein A-1 
and B concentrations, LPL and IIL activities are shown. Conccntrntions are given 
as : * - mmol/ 1, **- µg/ml, # - nmol FF A/min/ml, # # - ng/ml. 
8. Lipid electrophoresis on index patient, JJ (.,.),are shown. Ch Mi - chylomkron, 
Prep eta - p VLDL, Alph - HDL. 
• • - homozygous, CJ () - heterozygous, o o - nonnolipideamic. 
Other findings were a low HDL-cholesternl (HDL-C) level (0.4mmol/ l; normal, 0.8-2). Both 
ApoA-1 (52mg/dl; nonrnil, I 00-170) ;111d apoB levels (25mg/dl ; normal, 60-120) were also depressed 
(Crepaldi et. al .. I 979; Brunzel I. I 989; Nikkil ;i, I <J78) consistent with inefficient conversion of 
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circulating triglyceride-rich lipoproteins into remnant particles. ApoC-11 deficiency was ruled out, 
since apoC-II activator activity in JJ plasma was normal. Post-heparin plasma LPL activity on this 
occasion was found to be zero (Table 7). However a different assay was used which incorporated 
the use of a LPL-specific monoclonal antibody, Ab5D2 (Methods). Repeat post-heparin plasma 
samples were assayed on several occasions with zero activities consistently being recorded. 
Further evidence in support of a familial defect was derived from post-heparin plasma results 
of JJ's father, WJ where a 50% reduction in LPL activity was found (110 nmol FFNmin/ml; normal 
- 214 - 244). His lipid profile was also consistent with a heterozygous state for LPL deficiency in 
association with a normal LPL immunoreactive mass (Table 7) and moderate lipemia. He presented 
with a plasma triglyceride level of 8.1 mmol/1, a low HDL-C level (1.lmmol/1; normal, 0.8-2) and a 
raised apoB level (201mg/dl; normal, 60-120). These are fairly common features in carriers over the 
age of 40 (Wilson et. al., 1990)(Miesenbock et. al., 1993; Fager et. al., 1990). Also note that the 
low incremental mass recorded for JJ's sibling is not unusual for normals. The patient's mother was 
unavailable for study. 
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2.3. Results (Mutation Analysis). 
The author must acknowledge that while he was not involved in the sequence analysis which 
led to the identification of the I194T mutation in patient JJ, he was responsible for carrying out and 
setting up most of the other methodologies used, such as, DNA isolation, plasmid preparation, probe 
labelling, southern blot hybridisation, haplotype analysis, DNA sequencing, PCR Restriction analysis, 
"ARMS" PCR, PCR-SSCP analysis, LPL activity assays. 
2.3.1 The I194T Mutation. 
2.3.1.1 Haplotype Analysis. 
An early indication of genetic heterogeneity in monogenic disorders is often obtained through 
haplotype analysis of mutant alleles as different mutations tend to manifest different haplotypes. This 
has been investigated in LPL deficiencies by constructing haplotypes at the LPL gene from three 
restriction fragment length polymorphisms (RFLP), namely, Hindlll, PvuII and BamHI (Heizmann 
et. al., 1987 and 1991; Fisher et. al., 1987; Chamberlain et. al., 1989; Oka et. al., 1989). These 
haplotypes were determined for nine South African Type I patients, comprising four of Indian 
extraction, three from the Afrikaner community, one of Malay origin and one of mixed ancestry (JJ) 
(Henderson et. al., 1990, 1991 and 1992). 
The use of three RFLP's gives a theoretical possibility of 8 [(2)3] different haplotypes. An 
assessment of the haplotype distribution in the Afrikaner community was determined by analysing 
DNA from 33 normolipidemic subjects. The haplotypes are listed in Table 8 and the distribution is 
similar to that reported for American Caucasians (Funke et. al., 1987; Fisher et. al., 1987). 
Haplotype 2 is the most common and accounts for 26 (39%) of 66 alleles examined in the South 
African control population; all the others are 12% or less. JJ (proband of kindred I) is homozygous 
for haplotype 1, which thus characterises the I194T mutation in this kindred. However this same 
mutation associates with a different haplotype, haplotype 4, in our I194T reference family . Neither 
of these two haplotypes are common in the Afrikaner population, each being less than 10%. 
Table 8: RFLP Haplotype Frequencies at the LPL gene locus for 33 normolipidemic 
South African Afrikaners. 
HAPLOTYPE Hind Ill BamHI Pvull Alleles % 
1 + - - 7 10 
2 + - + 26 39 
3 - + + 3 5 
4 - - + 8 12 
5 + + - 8 12 
6 - + - 8 12 
7 + + + 3 5 
8 - - - 3 5 
TOTAL 66 100 
Haplotype nomenclature is according to Monsalve et. al., 1990. 
2.3.1.2 Sequence Analysis. 
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The author was not involved in the sequence determination of the Il94T substitution which 
has previously been reported in Henderson et. al. (1991). Briefly, exons 1-10 of the LPL gene were 
individually amplified by PCR from genomic DNA. Single-stranded DNA (ss-DNA) was generated 
by assymetric PCR using one primer only and the product was subjected to direct sequencing using 
the dideoxy chain termination method using the alternate primer in the sequencing reaction 
(Methods). 
Fig. 15 shows a sequence ladder from exon 5 of the LPL gene of proband, JJ (Kindred I) and 
a normal control. A single T-C transition at position 836 in codon 194 of the published LPLcDNA 
sequence (Wion et. al., 1987) is clearly evident with the ATI codon of isoleucine being converted 
to the ACT of threonine. To verify that this transition was not a PCR error both the sense and 
anti-sense strands of exon 5 were sequenced from several independent PCR amplications. 
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LIPOPROTEIN LIPASE GENE 
EXONS 
3' 3' 
normal l} Ile Ile {l patient· 
__ / \ i} Gly Gly {i 
- -..... 
--.- ~ 
-
-
:: !} De -194- ~{~ 
-
I• 
-
-
--/ 
~} {t - Ser Ser --GA T TC 
g} Arg Arg {g 
5' 5' 
Fig. 15: Nucleotide sequence of the sense strand from exon 5 of patient, JJ, showing 
the T-+C transition at codon 194, resulting in the threonine to isoleucine 
substitution. Sequence analysis was performed using the Sequenase Version 
2.0 Kit (USB Biochemicals, Cpy, Ltd). Codon positions are taken from 
the published LPLcDNA sequence (Wion et. al., 1987). 
Heternzygnsity for this mutation was confirmed in JJ, since a consistent finding was the presence of 
both the T and C hands at position 836 in the sequence ladder. Inspection of the rest of exon 5 
revealed no additional base substitutions. Sequence analysis of the other exons was similarly 
determined and no evidence of a second 111ut:1tion was found. The I I 94T mutation neither created 
nor destn 1yed a restrict ion site. whid1 llL'L"t·ss i t:1 tl'd :111 :ti tern:, t ive technique to restriction analysis for 
detecting the presem·e of this mutation . 
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2.3.1.3 Detection. 
Several methods were developed to detect the I194T mutation. 
2.3.1.3.1 Allele-Specific Oligonucleotide(ASO) Hybridisation. 
ASO hybridisation has proven to be a reliable test for the detection of point mutations in 
genomic DNA and is amenable to rapid screening of a large number of subjects (Farr et. al., 1988). 
It is however, restricted to the detection of known mutations. The method employs two 
oligonucleotides usually 19-20 bases in length, whose sequence spans the point mutation and are 
either complemetary to the sequence of the normal or mutant allele. The specificity of the assay is 
based on the marked differences in melting temperature of DNA duplexes formed between the 
matched and mismatched oligonucleotides and the template DNA. 
Approximately 20ng of PCR product was transferred to Hybond N+ membrane filters 
(Amersham Corp., Arlington Heights,IL) and hybridised separately with a (y-32P]labelled ASO, 
complementary to the normal sequence (ASOI) or the mutant sequence (ASOII)(Primer Design), 
spanning the T~C transition. Following hybridisation, the membrane filters were washed and 
autoradiographed as descibed in (Methods). 
Fig. 16 represents a schematic diagram of an autoradiograph of hybridisation blots from LPL 
exon 5 DNA. Exon5 DNA of JJ was found to hybridise to both the normal probe, ASOI and the 
mutant probe, ASOII, consistent with the assignment of a heterozygous status for the 1194T 
mutation. Similar results was also noted for WJ, the father of JJ, which demonstrates a paternal 
inheritance for this mutant allele. Exon5 DNA from Wi!J hybridises to ASOI only, demonstrating a 
normal sequence for this sibling. The possibility that the 1194T substitution was a common 
polymorphism in the general population was discounted by the absence of this mutation in 50 
normolipidemic control subjects. 
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Fig. 16: Schematic diagram of an autoradiograph of exon 5 ASO hybridisation blots 
from a control kindred (1) and kindred I (2) . Blots were probed with 32P-
labelled allele-specific oligomers complimentary to the normal (ASOI) or mutant 
allele sequence (ASOII). 
2.3.1.3.2 "ARMS" PCR. 
The Amplification Refractory Mutation System (ARMS) is a simple PCR-based assay, 
designed to dis.criminate between mutant and normal alleles through the use of two sequence specific 
primers (Newton et. al., 1989; Sarkar et. al., 1990; Wenham et. al., 1991; Wittwer et. al., 1993). 
The success of the assay is dependent on the design of the PCR primers which are identical except, 
the nucleotide at 3'-terminal end is matched with the normal or mutant sequence. The thermostable 
Tag polymerase utilised in the PCR assay requires a non-refractory 3'-terminal end (matched) to 
facillitate amplification. Primer extension would thus only be achieved with the "normal" or "mutant" 
complemetary primer if the normal or mutant sequence were present. Several studies have shown 
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that the deliberate introduction of additional mismatches, close to the 3'-terminal end i.e. to within 
2-3 bp, enhances the specificity of the procedure significantly. This modification was introduced into 
the primer sets for the 1194T mutation. 
Genomic DNA from JJ and his family members were subjected to ARMS PCR utilising two 
internal primers, one non-refractory (194 mutant primer, 5'-GGGTCCCCTGGTCGAAGIAC-3', the 
other refractory (194 wild type primer, 5'-AACTGGTTTCTGGATTCJM-3') for the T--+C transition 
at position 836 of the LPLcDNA sequence in combination with two flanking LPL exon 5 primers 
(Primer Design, Methods). In spite of extensive optimisation procedures the results obtained with 
these primers were unsatisfactory and often unreproducible. 
2.3.1.3.3 PCR-SSCP Analysis. 
The conformation of small single-stranded DNA fragments in non-denaturing environments 
are infleunced by its primary sequence (Orita et. al., 1989; Suzuki et. al., 1991; Poduslo et. al., 1991; 
Sheffield et. al., 1993). Sequence alterations thus induce conformational changes which may be 
detected as altered banding patterns (mobility shifts) following non-denaturing gel electrophoresis and 
silver staining. Other factors which may infleunce conformer formation are, the gel temperature, the 
acrylamide concentration, buffer ionic strength and glycerol content. 
PCR-amplified LPL exon 5 DNA fragments from proband, JJ and his family members were 
subjected to SSCP analysis as described (Methods). The banding patterns obtained are shown in Fig. 
17. Proband, JJ (lane 3), and his father, WJ (lane 1), share a pattern which is identical to that 
observed for another 1194T heterozygote (lane 7; NIM) as well as bands B2 and BS with a normal 
individual (lane 8; N/N). These findings are consistent with heterozygosity for the 1194T mutation 
in JJ and WJ. Carrier status could be ruled out for the maternal uncle, FD (lane 4), maternal 
grandmother, JD (lane 5) and JJ's only sibling (lane 2; WilJ) as their banding patterns were identical 
to that of the normal individual (lane 8; WT). 
Fig. 17: 
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B6 
B7 
B8 
1194T 
CONTROLS 
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FD JD M/M N/M N/N .J .J 
SSCP analysis of PCR-amplitied LPL exon 5 products from kindred I. PCR 
amplification was performed using two LPL spedfic primers, LPL57 and 
LPL58 (See Primer Design, Methods). Electrophoresis was performed on 
0.25xHydrolink MOE polyacrylamide gels with approximately 5µ1 of PCR 
producl1; loaded per lane. Gel., were visualised hy silver staining. Bands are 
labelled, Bl • B8. Lanes 1 • 5 represent paticnt samples. 
e -homozygous (M/M) ,[l(t · heterozygous (N/M),~cleceasccl, 
DQ-nonnolipidemic (N/N), /. prohand. 
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2.4 Mutagenesis and Transfection Studies. 
To demonstrate the abolishment of catalytic activity by the I194T mutation, expression 
plasmids were constructed containing the normal LPLcDNA sequence as well as the I194T mutant 
sequence (Henderson et. al., 1991). Transfection studies were carried out in COS-1 cells and LPL 
activity and protein mass measurements were assessed in the medium. These experiments clearly 
showed that the I194T substitution produced a catalytically inactive LPL product (activity< 1 %), 
while mass levels were similar to that of the normal plasmid. Similar LPLmRNA levels were found 
in both the normal and 1194T mutant transfected cell cultures which likely indicates that the mutation 
did not influence transcriptional rates or the stability of the mRNA species. Secondly, the mass assay 
used, only detected the dimer form of LPL and as similar mass levels were recorded for the mutant 
lipase variant, it must be secreted as a stable dimer. 
Transfection studies clearly establish that the I194T allele of JJ generates a catalytically 
defective protein. The second mutation in this patient is therefore likely to produce a partially 
defective gene product which underlies the variable phenotype observed in JJ. 
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2.5 The Second Mutation. 
Direct sequencing of PCR-amplitied LPL exons had failed to reveal the second mutation in JJ, 
therefore it was decided tn try a new approach and utilise Reverse Transcriptase-PCR (RT-
PCR)(Gihbs et. al., 1989; Naylor et. al., 1991) on total RNA isolated from monocyte-derived 
macrophages which are known to synthesize LPL. The first objective was to demonstrate the 
expression of the alternate allele by cloning of LPLcDNA fragment<; and identifying clones with a 
normal sequence at codon 194. The second objective was to sequence cDNA from the alternate allele 
in search of the second mutation. 
2.5. l RT-PCR Analysis. 
RT-PCR has been widely used to genernte cDNA copies of mRNA from a variety of cell types; 
eit her total RNA or purified mRNA preparations have been used. Once transcibed, the cDNA 
preparation is amenable to any number of DNA manipulations in use today. An outline of the 
experimental prntocul followed in the workup of JJ is given in Fig. 18. 
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2.5. 1. l Monocyte-derived Macrnpha~e Preparations. 
The monocyte-derived macrophage is one of a variety of cell types synthesizing LPL and was 
used as a source of LPLmRNA. Monocytes (buffy coat layer) were isolated from 50ml blood 
samples on Ficnll-Histopa4ue gradients as described (Methods). Recoveries were of the order of 
20%. The isolated monocytes were either processed directly or cultured for 1-2 weeks under 
controlled conditions (Methods). 2-3 x 107 cells/dish were cultured, with approximately half (1-1.5 
x 107 cells) being recovered as adherent, differentiated macrophages. Total RNA was isolated using 
the acid-guanidium-phenol-chloroform (AGPC) method as described by Chomczynski and Sacchi 
(1987). Following quantitation, the quality of the RNA preparations were checked by electrophoretic 
separation on agarose/formaldehyde gels and visualised by ethidium bromide staining (Methods)(Fig. 
19). A good preparation was characterized by the appearance of clear 28S and 18S rRNA bands on 
a background of streaking. Intact, non-degraded RNA is required for the generation of full-length 
cDNA Spectrophotometric analyses were used to assess RNA concentrations. On average, the total 
RNA yield obtained from monocyte-derived macrophages of a 50ml blood specimen was lOOµg. 
Absorbance ratios (A26o/A280) of 1.5-1. 7 were generally recorded. 
Fig. 19: 
1 2 3 4 5 
28s 
18s 
Total RNA isolates from patient and control monocyte and cultured 
monocyte-macrophage cell preparations. RNA samples were electrophoresed 
on 1 % agarose/1.85% formaldehyde gels with visualisation by EtBr staining. 
Lane 1 - patient, JJ , monocyte cell prep., Lane 2 - patient, JJ, monocyte-
macrophage cell culture prep., Lane 3 - control monocyte cell prep., Lane 
4 - control monocyte-macrophage cell culture prep., Lane 5 - blank isolate. 
28S and 18S 1·RNA bands are indicated. 
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2.5.1.2 cDNA Synthesis. 
Total RNA was subjected to first strand synthesis using oligo dT and random hexamers as 
initiation primers (Methods)(Gibbs et. al., 1989). Oligo dT hybridises to the polyadenylate (poly-A) 
tail, common to all mRNA's and the random hexamers hybridise along the stretch of the RNA 
templates. RNasin, a ribonuclease inhibitor (Promega), was included in the reaction mix to preserve 
the integrity of the RNA template. 10 ug of total RNA yielded sufficient single-stranded cDNA 
product for the subsequent PCR amplication,cloning and sequence analysis. 
2.5.1.3 PCR Amplification of cDNA fra2ments. 
Two sets of PCR primers, LPLcDNAl and LPLcDNA8, and LPLcDNA6 and LPLcDNA7, 
were designed to produce two overlapping fragments (Fig. 18)(See Primer Design). A 1/50th of the 
cDNA preparation was used for each amplification generating fragments 1049 bp (5'-fragment) and 
1019 bp (3'-fragment) in length. These fragments spanned 1585 bp of sequence which included the 
entire coding region of the LPL gene. The amplified fragments were assumed to represent the 
products of both alleles with the 5'-fragment, spanning exons 2-6 and the 3'-fragment spanning exons 
5-9, in addition to portions of exons 1 and 10 of the LPL gene (Fig. 18). Each individual fragment 
was purified and quantitated (as described). For control purposes, the full-length LPLcDNA 
(pLPL35) was subjected to fragment amplification in a similar fashion. 
2.5.1.4 Cloning of cDNA fragments. 
Cloning of PCR-amplified cDNA fragments allowed for the selection of clones representative 
of both alleles. The T-tailed cloning vector, pT7BLUE T-vector (Novogen)(Methods) was used, 
which allows for blue-white screening of recombinants. Ligation to this vector exploits the template 
independent terminal transferase activity, inherent in most thermostable Tag (thermas aquaticus) 
polymerases, which generates a single-3' dA nucleotide overhang. Optimally, 1/lOth of the ligation 
mix was used to transform competent cells by the heat shock process in a standard transformation 
reaction (Methods). A vector:insert ratio of 1:3 was found to be optimal for ligation and 
transformation. After overnight culture at 37°C, recombinant clones (white) were picked onto a 
gridded library. Transformation efficiencies are shown in Table 9. 
Table 9: Transformation efficiencies of cloned LPL gene fragments from patient, 
JJ (Kindred I). 
Colonies screened Colony forming units per µg % Ligation 
(cfu/µg) 
Control plasmid 7.00 X 107 -
pT7 + control insert 2.50 X 104 -
pT7 + pLPL35(6-7) 2.20 X 104 60 
pT7 + JJl-8 1.86 X 104 58 
pT7 + JJ6-7 1.30 X 104 58 
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Transformed colonies were screened by using LPL-specific primers, LPLcDNAl, LPLcDNAS and LPLcDN6, 
LPLcDNA7 (see Primer Design)(Fig.18). The pT7 - vector was used for cloning, pLPL35(6-7) - 5'-fragment of 
the fuU-length LPLcDNA, JJl-8 - 3'-fragment of the LPLcDNA from JJ, JJ6-7 - 5'-fragment of the LPLcDNA 
fromJJ. 
Generally, the number of recombinant colonies obtained were similar to the number observed for the 
control insert. Recombinant colonies were screened for the presence of the insert DNA as described 
below. 
2.5.1.5 PCR Screening. 
Screening of clones by direct colony PCR (Methods) was carried out using a primer set 
comprising a vector-specific primer, U-20 (reverse) and a LPL-specific primer (See Primer Design). 
Positive identification of LPL DNA insert, was denoted by the presence of a distinct band of about 
± 1.1kb on agarose gel electrophoresis. Rapid PCR screening of the order of 100 white colonies, 
revealed a 58% fragment incorporation (Table 9) with the remainder of the recombinant clones most 
likely representing ligated vector. 
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2.5.1.6 1194T "ARMS" PCR Screening. 
Clones containing insert DNA were subjected to direct colony "ARMS" PCR utilising the 
primer sets as described earlier (Primer Design)(Methods). Representative agarose gels of direct 
colony ARMS PCR for fragments JJl-8 and JJ6-7, of patient, JJ, are shown in Fig. 20. Gel A shows 
six recombinant clones which contain the JJl-8 insert and which were screened for the 1194T 
mutation. Duplicate lanes represent a single colony screened for both the wild-type and mutant 
sequence. Four colonies contain the wild-type sequence (lanes 1-6) and two colonies (lanes 7-10), 
the mutant sequence, when compared to the "wild-type" control sample (lanes 11, 12). Gel B shows 
eight colonies which contain the JJ6-7 insert and which were screened for the 194 mutation. Again, 
duplicate lanes represent a single colony (see above). The mutant sequence is present in four colooies 
(lanes 5-10, 15 and 16). Wild-type and I194T mutant control samples are indicated, their sequences 
previously confirmed by sequence analysis. 
Gel A . 
Gel B 
Fig. 20: 
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Colony screening by "ARMS" PCR for the verification of insert DNA. 
Duplicate lanes represent single colonies screened with the normal and mutant 
primers (see Primer Design). GEL A : Colonies screened for the J Jl-8 insert. 
GELB: Colonies screened for the JJ6-7 insert. +: the normal insert is present, 
- : the mutant insert is present. MC • mutant control, NC. normal control. 
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Unfortunately, amplification of the normal clone (NC) was achieved with both the normal 
(wild-type) and mutant 194 primer, whereas the mutant 194 primer amplifies up the mutant clone 
(MC) only, as expected. In conclusion, the results are therefore not definitive, since optimal assay 
conditions for the discrimination of the wild-type sequence could not be established. However the 
assay did allow for distinction between clones containing the 1194T "mutant" and the "normal" 
(alternate) allele. 
2.5.1.7 Sequencing of the Alternate Allele. 
The colonies identified by ARMS PCR containing the LPL gene fragments (JJl-8, JJ6-7) of 
the alternate allele were picked and each individual overnight culture was subjected to bulk plasmid 
purification (Methods). A total of four colonies (2 - JJl-8; 2 - JJ6-7) were sequenced (Sequenase 
Version 2.0 kit, USB)(Methods). 6-8µg of purified plasmid DNA were generally used per 
sequencing reaction in combination with a cohort of sequencing primers (see Primer Design) spanning 
the entire LPL coding region (Methods). 
Sequence analysis of the four clones revealed a single G-+A transition at position 1508 of the 
LPL gene (Wion et. al., 1987)(Fig. 21 - see next page). This transition is located in exon 9, in the 
second position of codon 418, resulting in a codon change from TGT to TAT, substituting 
tyrosine(Y) for cysteine(C). No other sequence alteration was detected in the remainder of the 1585 
bp sequence of this allele. The possibility that the substitution was a PCR error was discounted by 
repeat PCR, cloning and sequencing which revealed the same base substitution. 
These findings clearly demonstrate compound heterozygosity for proband, JJ. As discussed 
above, in-vitro transfection studies have established that the protein product derived from the 1194T 
"mutant" allele is catalytically inactive. Similar studies are still to be carried out for the C418Y 
mutant cDNA, but it is expected that this mutation will only partly abolish catalytic activity which 
could possibly explain the hypervariable nature of the LPL deficiency in patient JJ (see Discussion). 
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Fig. 21: Nucleotide sequence of the sense strand of exon 9 of the LPL gene of index 
patient, JJ (Kindred I) and a normal control subject. The G-+A transition 
(-+) is hoxed. The amino add suhstitution and nucleotide position is 
indicated and the codon is numhered. 
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2.5.2 Detection of the C418Y mutation. 
Several mutation detection systems were employed to detect the C418Y mutation as the 
sequence alteration neither creates nor destroys a restriction site. These are presented below. 
2.5.2.1 C418Y "ARMS" PCR. 
Primer design was identical to that employed for the 1194T "ARMS" PCR assay. 
Amplification was accomplished using two internal primers, one, refractory (wild type; 5'-
CTTCCACAGGGTGATCTTATG-3') and one, non-refractory (mutant; 5'-
CTTCCACAGGGTGATCTTATA-3') for the Q--.A transition in combination with two intronic 
external primers (see Primer Design). To improve the specificity of the assay, each of the internally, 
matched and mismatched primers, had an additional mismatch base introduced two nucleotides from 
the 3'-terminus. 
Difficulty was again experienced with these ARMS primers as absolute discrimination between 
the normal and mutant allele could not be obtained. 
2.5.2.2 PCR Restriction Analysis. 
PCR restriction analysis is a simple mutation detection system, first described by Haliassos, et. 
al. (1989). The aim here was to introduce a sequence change in the amplified fragment by altering 
the primer sequence such that the combination of the primer sequence and the patient base transition 
creates a restriction palindrome. 
A 21bp primer, LPL23 (forward, 5'-TATTCACATCCATTTTCTTC-3') was designed to span 
the exon 9 intron-exonjunction with the 31 terminus adjacent to the C418Y mutation. Two deliberate 
mismatched bases were introduced, three and four bases upstream from the 31- terminus (see Primer 
Design). Substitution of AG for TT at the 3n1 and 4th base, respectively, creates a Pvull restriction 
enzyme site (5'- CAGCTG -3') in combination with the guanine nucleotide of the normal allele. 
Amplification of the mutant allele abolishes this Pvull site by altering the palindromic sequence to 
5'- CAGCTC-3'. These primers in combination with a 20bp LPL intronic primer (LPL24, reverse, 
5'-GTCAGCTTTAGCCCAGAATG-3') yields a 114 bp fragment. 
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Fig. 22: PCR Mismatch Analysis of LPL exon 9 for kindred I. 
Genomic DNA was subjected to PCR amplification utilizing two specific 
primers, a 5'-GTCAGCTTTAGCCCAGAAT-3' (reverse, 20mer) and a 
5'-TTTCTTCCACAGGGTGATCAGCT-3' (forwar·d, 23mer) designed to 
generate or destroy a Pvull restriction site in combination with the normal 
or mutant sequence, respectively. Individual samples are represented in 
duplicate lanes as undigested and digeskd samples, respectively. 
Fragment sizes are indicated. UNA standard size markers are shown in 
lanes l and 13. [I - 1194T heterozygote, I[] €1) - C4 l 8Y heterozygote, 
~ - compound heterozygote,Q· nonnolipidemic,&- deceased, 
E] - not investigated,/- index patient. 
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Genomic DNA from kindred I was amplified using these primers and subjected to digestion with 
Pvull. The resultant banding pattern observed on PAGE gels show clear discrimination between the 
"normal" and "mutant" alleles (Fig. 22). A 27 bp decrease in size of the PCR fragment following 
Pvull digestion is indicative of the normal allele. The presence of both the 114 and 87 bp fragments, 
for proband, JJ (lanes 6, 7) confirms heterozygosity for the C418Y mutation. As the proband's 
mother was recently deceased and therefore unavailable for study, his maternal uncle (FD) (lanes 8, 
9) and maternal grandmother (lanes 10, 11) were included in the study. Both these individuals were 
found to be carriers indicating a maternal origin for this mutation. The banding pattern observed for 
father, WJ (lane 2, 3) and sibling, WilJ (lane 4, 5) of JJ indicates homozygosity for the normal allele. 
The success of the PCR mismatch methodology renders it amenable to broad-based population 
screening procedures. It is a rapid test with no need for radioisotopic-labelling and it is not 
labour-intensive since it provides a direct method of analysis, without the need for blotting, probe 
labelling and hybridisation as required for other techniques. The test is applicable to prenatal testing, 
newborn screening and general carrier status detection. It is however limited to the detection of 
known mutations only. 
2.5.2.3 PCR-SSCP Analysis of exon 9 
A similar approach to that outlined for the 1194T mutation was adopted in detecting the 
C418Y mutation. Gels were visualised as described (Methods). 
Results from PCR-SSCP analysis are shown in Fig. 23 (see next page). Proband, JJ (lane 
3), his maternal uncle, FD (lane 4) and maternal grandmother, JD (lane 5) share a banding pattern 
distinct from the other family members. As expected father, WJ (lane 1) and sibling, WilJ (lane 2), 
show a banding pattern identical to that of the normal control subject (lane 6). B3, is a unique 
conformer and is presumed to contain the C418Y sequence alteration. The individual DNA bands 
were excised and subjected to DNA cycle sequence analysis using a PCR-based dideoxy chain 
termination protocol [fmollM DNA Sequencing System (Promega)](Methods). The results confirmed 
the G-+A transition at position 1508, as the only base change in exon 9 of the LPL gene sequence. 
Similar sequencing of the "normal" band, B4, confirmed the presence of the normal guanine base, at 
nucleotide position 1508. This technique clearly confirmed the carrier status for proband, JJ, and his 
maternal relatives, for the C418Y mutation. 
Fig. 23: 
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2.6 Discussion. 
The evidence presented in this report confirms LPL deficiency as the primary cause for the 
hyperchylomicronaemia syndrome in the index patient, JJ. In the initial report, Berger et. al. (1987) 
proposed an atypical and milder phenotype for this patient, but this was based on the residual LPL 
activity level (38% of normal) measured in JJ's post-heparin plasma when assayed by the protamine 
sulfate method. In our study, however, when utilising a more specific LPL assay, we consistently 
demonstrated a complete absense of LPL activity in his plasma. He also presented with a history of 
phenotypic sequelae (hepatosplenomegaly and abdominal pain) since the age of 4. Laboratory 
investigations revealed the following characteristic features, namely (i) a 4°C stored plasma test 
showed a typical dense chylomicron-rich band over a slightly turbid infranatant (ii) markedly elevated 
plasma triglyceride levels and (iii) a significantly depressed HDL-cholesterol level. Also, a fat 
tolerance test was consistent with a Type I phenotype. Despite these findings, JJ has been relatively 
symptom-free since puberty, except for occasional bouts of pancreatitis. 
The detection of two gene mutations at the LPL gene locus and the establishment of compound 
heterozygosity in JJ is consistent with the above findings. Only one of these mutations has however 
been shown by in vitro studies to yield a catalytically defective enzyme; the other is likely to be 
partially defective and may explain the variable levels of LPL activity recorded in post-heparin plasma 
in the prepubertal stage as opposed to during puberty. The first of these mutations comprises a T .... c 
transition at position 836 in codon 194 of exon 5, causing a substitution of a Thr for an Ile. The 
second mutation was detected through the application ofRT-PCR methodology on monocyte-derived 
macrophage mRNA which revealed a (}4A transition at position 1508 giving rise to substitution of 
a Tyr for a Cys, at codon 418. Confirmation of compound heterozygosity for JJ was obtained by 
using various mutation detection systems. 
The majority of missense mutations causing LPL deficiency occur in exons 4, 5 and 6 of the 
LPL gene (Peterson et. al., 1992; Hayden et. al., 1995). These exons, in particular exon 5, are 
located in an evolutionary conserved section showing strong homology to the other members of the 
LPL/HL/PL gene family. They code for residues making up the structural core of the N-terminal 
domain and active site residues. As reported earlier, the 1194T mutation is located in exon 5. 
Structural predictions for LPL and the effect the Il 94T mutation may have on the overall LPL 
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structure can be inferred from the molecular model of the homologous hPL molecule (Fig. 9)(van 
Tilbergh et. al., 1992; Derewenda and Cambillau, 1991). Residue 215 in PL, which corresponds to 
isoleucine 194 in LPL, is located in the loop linking P-strands 8 and 9 (Fig. 9), and packs against the 
fragment containing the His residue of the catalytic triad (Fig. 9)(Derewenda and Cambillau, 1991). 
This residue also makes Van der Waal's contact with Tyr114, A1a171 and Pro180, all three of which are 
conserved in LPL. The conservation of hydrophobicity around Ile194 in LPL is supported by the 
finding of a Val in the homologous position in hHL. This implies an important structural role for 
these amino acids. The introduction of a hydrophillic residue, such as, Thr, is likely therefore to 
disrupt the local hydrophobic enviroment essential for the maintenance of the .active site motifs. Only 
those motifs required to process long chain acyl esters are affected as the mutant has been shown to 
have normal activity towards soluble esters. The exact mechanism of this inactivation is unknown 
but it is possible that construction of the hydrophobic channel as well as repositioning of the active 
site lid is abnormal. The Il94T mutant protein has also been shown to form a stable dimer and has 
normal heparin binding properties as it manifests similar elution kinetics to that of normal LPL on 
heparin-sepharose chromatography. This implies that the heparin binding site of the mutant enzyme 
is intact and is separate from the catalytic site. 
The second mutation in patient, JJ, the C418Y mutation is located in the C-terminal domain 
of the LPL molecule, in a region which appears to play a role in lipid binding and has been implicated 
in heparin binding (Fig. 8). The substitution of a Cys in this position destroys the only disulphide 
bridge in this domain. While the functional effects of the loss of this cysteine have not been 
established, other workers have shown by in-vitro transfection studies on LPL deletion mutants that 
alterations in the C-terminal domain are usually associated with partial catalytic deficiencies. The 
M437~stop mutant, for example, which has lost the C-terminal decapeptide including the Cys438 
residue involved in the Cys418-Cys438 disulfide bridge, shows a 41 % decrease in LPL activity (Bruin 
et. al., 1994). Presumably this mutation disrupts the local structure, and hence interferes with lipid 
binding or dimer formation. In support of this proposal, several workers have demonstrated an 
absolute requirement for an intact LPL C-terminal domain for maximal activity against long-chain 
triacylglycerol emulsions (Wong et. al., 1991; Davis et. al., 1992). Furthermore, strong support for 
the presence of a secondary lipid binding site localised to the C-terminal domain, proximal to the 
disulfide bridge, Cys418-Cys438 have been derived from expression studies in COS-1 cells of C-terminal 
truncated mutants (Kozaki et. al., 1993). Residue C438 is juxtaposed to six highly conserved 
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hydrophobic residues, AP A VFV, while residue C41 8 has three such conserved residues in close 
proximity. Disulfide-bridge formation bring these two regions into close proximity, which could form 
a large, hydrophobic lipid binding domain. Disruption of this crucial disulfide bridge would clearly 
prevent the formation of this potential lipid binding domain and thereby affect funtional activity. The 
truncated LPL mutants, 435--+stop and 436--+stop, expressed lipase activities of 22% and 88%, 
respectively, compared to native LPL in keeping with the other data and demonstrating the 
importance of Val436 in enhancing the lipid substrate association with LPL. These data suggest that 
the C418Y mutant may exhibit partial activity. Evidence for the presence of a heparin binding region 
in the LPL C-terminal domain has been presented (Fig. 8)(Bengtsson-Olivecrona el. al., 1986; Wong 
et. al., 1991; Davis el. al., 1992). The presence of this mutation may therefore lead to the disruption 
of this region, thus altering the heparin binding properties and stability of the mutant protein. The 
only other mutation described in exon 9, a Ser44 7--+stop (Kobayashi el. al. 1992; Hata el. al., 1990), 
produces a truncated LPL molecule, two residues shorter than the native protein. The removal of 
this carboxy-terminal dipeptide (Ser - Gly) has no apparent effect on the catalytic activity of LPL. 
In fact, one study proposed an enhancement in LPL activity (Hata el. al., 1990). 
The initial proposal of an atypical and milder phenotype for the index patient, JJ (Berger el. 
al., 1987) which was based on residual LPL activity measured in post-heparin plasma, muscle and 
adipose tissue biopsies, needs to be reassessed in the light the of our findings of zero activity in post-
heparin plasma. We were unfortunately, unable to confirm the initial report of residual LPL activity 
as measured by the protamine sulfate assay. This difference is likely to be explained by differential 
processing and/or alterations in post-translational modifications which may occur at various stages 
of human development with a loss of LPL activity post puberty. The LPL dimer/protein mass levels 
are within the normal range in patient JJ and therefore it is likely that both the 1194T and C418Y 
mutant proteins are expressed normally and form stable dimers. In vitro expression studies have 
previously shown the 1194T/1194T dimer to be inactive towards triolein emulsions thereby implying 
that both the C418Y/C418Y dimer and the heterodimer species may also be inactive in vitro. 
Our laboratory reported earlier the association of haplotype 4 with the mutant 1194T allele in 
two unrelated kindreds of Dutch and French origin, including the control kindred in this study. While, 
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proband JJ is of mixed ancestry, the finding of a different haplotype (haplotype f) associating with the 
194 allele in kindred I was unexpected. Haplotype 1 and 4 differ at the Hindlll and Pvull restriction 
sites. Generally, single haplotypes segregate with single mutations in genetic disorders which is 
compatible with singular ancestral events (DiLella et. al., 1987; Wainscoat et. al., 1986). The 
association therefore of the mutation at codon 194 with two divergent RFLP haplotypes, more than 
likely indicates an identical ancestral mutation occurring separately on two different chromosomal 
backgrounds rather than these haplotype changes occurring on a common ancestral gene. These 
haplotype associations suggest a multicentric origin for the 1194T mutation in the South African 
population. 
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CHAPTER 3. 
3.1 INTRODUCTION. 
3.1.1 Pregnancy and Hyperlipidaemia. 
Mild hyperlipidaemia has long been recognised as a common feature in the third trimester of 
pregnancy with triglyceride levels increasing between two and four fold; increases in cholesterol and 
phospholipid being less common (Warth et. al., 1975). Earlier work on rats (Scow et. al, 1964), 
revealed that hyperlipidaemia was associated with pregnancy at late gestation in both the fed and 
fasted states. This hyperlipidaemia was aggravated by dietary fat, since pregnant animals fed on a fat-
free diet had significantly reduced lipid levels compared to rats fed on a normal diet. 
The changes in lipid metabolism during the pregnancy-lactation-involution period results from 
the down regulation of adipose tissue LPL activity and the significant increase in VLDL production 
in response to higher estrogen levels. As early as 1970, Hamosh et. al., described reciprocal changes 
in the adipose tissue and mammmary gland LPL activity during gestation in the rat. They also 
showed a marked increase in LPL activity (2 fold) in the parametrial adipose tissue during the second 
trimester which decreased significantly at parturition and remained low throughout lactation. In 
contrast, in the mammary glands of the rat, LPL activity increased very slowly throughout the first 
and second trimester with a dramatic rise being observed during the third trimester. This was 
followed by a transient decrease in LPL activity at parturition with levels increasing and remaining 
high throughout the lactation period. These tissue-specific reciprocal changes in LPL activity serve 
to divert plasma triglyceride from storage in adipose tissue to the mammary gland for milk-fat 
synthesis (Scow and Chernick, 1987). 
3.1.2 Pregnancy, Hyperlipidaemia and Pancreatitis. 
Several reviews and case reports have described the association of pancreatitis with pregnancy-
induced hyperlipidaemia, a condition which is estimated to have a mortality rate of 21 % for both 
mother and child. In the majority of these patients the underlying defect was gallstone formation and 
blockage of the bile duct (Montgomery and Miller, 1970). Hyperlipidaemia is rarely encountered 
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as a cause of pancreatitis but several patients have now been described with hypertriglyceridaemia-
induced pancreatitis and most of these patients have been shown to have a clearance defect as a result 
of LPL deficiency. Gleuck et. al. (1980) described three patients whom developed pancreatitis 
during their pregnancies. One of these patients had a known Type V hyperlipoproteinemia 
phenotype, and the increase in triglycerides during pregnancy was controlled by the introduction of 
a fat-free diet leading to an uncomplicated pregnancy and the delivery of a healthy infant. Watts et. 
al. (1992) reported two cases; a clinical profile of both patients, revealed a history of recurrent bouts 
of abdominal pain, raised triglycerides and chylomicronaemia. The diagnosis of LPL deficiency in 
these patients provided a suitable explanation for their clinical presentation. One of these patients 
miscarried her foetus as a result of a bout of acute pancreatitus. The second patient, after being 
placed on a strict lipid lowering diet, had an uneventful antenatal course despite hypertriglyceridaemia 
being recorded. Following the birth of a healthy infant, the patient's triglyceride levels decreased 
rapidly. Ma et. al. (1993, 1994) reported five patients, four of which were diagnosed with partial 
LPL deficiency after developing pancreatitis during pregnancy. In three of these patients, the apoE2 
isoform (associated with defective receptor binding) was elevated, which implies that remnant uptake 
was also impaired. The occurance of this mild hyperlipidaemia in these patients, is thus exacerbated 
during the third trimester of pregnancy. Gestational pancreatitis thus carries a significant risk of death 
for both mother and foetus and hence the early detection of any underlying lipid disorder is essential 
for the proper management of pregnant individuals. 
3.1.3 Kindred II. 
The marked hyperlipidaemia recorded in the index patient, LB, during her acute attack of 
pancreatitis was suggestive of a primary defect in LPL activity, hence we set out to search for the 
gene defect/s at the LPL loci. Due to the non-availability of suitable sample preparations from the 
deceased proband, LB, analysis was initially confined to the study of her parents, father, DR and 
mother, ER. RT-PCR, cDNA cloning, PCR amplification, PCR-SSCP and DNA sequencing were 
the techniques employed. During the course of our investigation, histological slide preparations of 
a spleen biopsy from the index patient, LB, and a genomic DNA specimen from her only female 
offspring, BB, became available. 
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3.2 Case History and Laboratory Findings. 
Patient, LB, ,1 24 ye,1r-old woman presented in 1987 with lower back pain and pyrexia during 
the 36th week of her pregnancy. She was admitted tn a nursing home for observation on the 
assumption of a urinary tract infection. It's important to note that she had no previous clinical history 
and her pregnancy had thus far been uneventful. Shortly after admission, she suffered spontaneous 
rapture of membranes and ,1 foul smelling liquor was noted. Signs of foetal distress necessitated an 
emergency caesar and a healthy female infant was cleliverecl. Inspection of the peritoneal cavity 
during surgery revealed a thin milky tluid which was thought to be pus but the source of the infection 
could not be determined. 
Her condition deteriorated and she was aclmittecl to the surgical ICU where an ultrasonar graft 
showed a diffusely enlarged pancreas, abdomi nal distention leading to a diagnosis of acute 
pancreatitis. In spite of aggressive therapy her condition deteriorated further and she developed all 
nine of Ransin"s Criteria nf fulminant acute pnncreatitis. She progressed into total organ failure and 
died, five days after admission. Post mortem examination confirmed the diagnosis of fulminant 
haemorrhagic pancreatitis. Blood samples taken a day after admission revealed a serum amylase level 
of 3290 mmol/1 and marked lipemia with a cholesterol of 21 mmol/1 (n = 3 - 7.3) and a triglyceride 
level of 87 mmol /1 (n = 3 - 2.3). 
The patient's, father, DR and mother, ER, 63 and 62 years old, respectively, were 
normolipidemic with no notable history of disease or illness. Following their informed consent, 
bloods were obtained for later genetic ,rnalysis. The mother, ER, who gave birth to two offspring, 
the proband, LB, and a male child had experienced no complications during either pregnancy. A 
family pedigree is shown in Fig. 24. 
I 
II 
III 
. Fig. 24: Family Pedigree of Kindred II. 0 \ deceased proband, [:J not investigated. 
3.3 Results (Mutation Analysis). 
3.3.1 RT-PCR Analysis. 
3.3.1.1 Total RNA Ac;;sessment: RNA was isolated from monocyte-macrophages from both 
parents, as described previously (Methods). 
3.3.1.2 cDNA Synthesis: cDNA was synthesised from total RNA preparations 
as described previosly (Methods). 
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3.3.1.3 PCR Amplification of LPLcDNA Fragments: The primer design and PCR conditions 
employed, were as described for kindred I (Chapter I). 
3.3.1.4 Cloning of Fragments. 
The PT7Blue T-vector (Novagen) was used as a vehicle for cloning the 5'- and 3'- of amplified 
fragments from LPLcDNA of subjects, DR and ER (Methods). Ligation was carried out at a 
vector:insert ratio of 1:3. Approximately 1/lOth of the ligation mix was used to transform 
"Novablue" competent cells. Transformation efficiencies are shown in Table 10. Based on the 
blue/white colony selection process,-several recombinant colonies (white phenotype) were identified 
and libraries of recombinants were prepared. 
Table 10: Transformation efficiencies of cloned LPL gene fragments from subjects, DR and ER. 
Colonies screened Colony forming units per µg % Ligation 
Control plasmid 7.0 X 104 
-
pT7 + control insert 2.5 X 104 -
pT7 + pLPL35(6-7) 2.2 X 104 60 
pT7 + DRI-8 0.2 X 104 25 
pT7 + DR6-7 1.3 X 104 20 
pT7 + ERI-8 0.4 X 104 0 
pT7 + ER6-7 0,4 X 104 0 
Transformed colonies were screened by PCR using LPL-specific primers, LPLcDNAJ, LPLcDNAS and 
LPLcDNA6, LPLcDNA 7(See Primer Design)(Fig. 18). The pT7 - vector was used for cloning, pLPL35 - S'-
fragment of the full length LPLcDNA; DRl-8 and ERl-8 - 3'- fragment of the LPLcDNA from subjects, DR 
and ER; DR6-7 and ER6-7 - S'-fragmentofthe LPLcDNA of subject, DR and ER. 
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3.3.1.5 PCR Screening. 
Direct colony PCR screening was carried out as described before (Kindred I)(Methods). The 
presence of a DNA fragment approximately 1.1 kb in length, following gel electrophoresis, indicates 
a clone positive for the insert DNA. Only 20-25% of colonies (white phenotype) representing the 
5'- and 3'- LPLcDNA fragments of subject, DR, contained insert DNA of the expected size. The 
greater proportion of the remainder of the clones contained DNA inserts of 200 to 600bp in length. 
However, enough clones containing the correct insert size were obtained for analysis of the entire 
LPL coding sequence of subject, DR. As for the mother, ER, despite screening over 30 recombinant 
clones containing the 5'-fragment, no 1.1kb DNA fragment was observed; instead a 200bp fragment 
was consistently amplified. A similar pattern was observed when screening recombinant clones 
containing the ER 3'-fragment. 
3.3.1.6 Sequence Analysis of Positve Colonies for DR. 
Insert DNA, from colonies containing DR 1-8 and DR6-7 LPLcDNA fragments were prepared 
for DNA sequence analysis as follows : Insert DNA from colonies positive for the 1.1kb fragment 
were subjected to PCR amplification, followed by gel electrophoresis on 0.7% agarose gels and the 
DNA fragments gel purified as described (Methods). The concentration of each DNA fragment was 
carefully assessed and subjected to direct PCR-based dideoxy chain termination DNA sequence 
analysis (Promega)(Methods). 50-100 ng of insert DNA was generally used per sequencing reaction. 
Due to the constraints imposed by the sequencing conditions only 300 bases could be sequenced per 
sequencing reaction. This prompted the use of a repertoire of LPL-specific sequencing primers (see 
Primer Design), spanning the entire LPLcDNA sequence. Successful sequence was only obtained 
for the region spanning exons 2 to 9. Further sequence analysis of several clones including the 5'-
untranslated region are in progress to verify the above results. 
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3.4 Genomic DNA Analysis of Kindred JI. 
The availability of genomic DNA from both parents allowed for an alternate approach to 
detecting mutations in the LPL gene in this kindred. The problems encountered during the 
investigation of the LPL gene locus for ER using RT-PCR methodology could be circumvented by 
amplifying and sequencing individual exons. Postmortem histological slide preparations from the 
index patient, LB was available for analysis. A protocol for the extraction of archival DNA from slide 
preparations, was developed, as was a PCR protocol for amplifying exonic DNA from these archival 
specimens. Genomic DNA was also obtained from the patient's daughter, BB. 
3.4.1 DNA Extraction of archival samples from LB. 
Histological tissue slide preparations obtained from the postmortem performed on LB, were 
the only samples available since all the wax blocks were destroyed by a fire in the mortuary. The 
DNA extraction protocol for Heamatoxylin/Eosin stained slides and wax blocks was developed by 
our laboratory staff as described (Methods). 
Patient spleen tissue DNA extracts were assessed for their degree of degradation by 
electrophoresis on a 1 % EtBr stained agarose gel. Fig. 25 represents DNA extracts from 
histopathological slides (lanes 7,8) compared to controls from paraffin wax blocks (lanes 6,7). Each 
extract represents material from a single slide preparation or wax block section. All postmortem 
tissues yielded highly degraded DNA consisting predominantly of low molecular weight DNA 
(200-300 bpr). Several reports, have suggested that the sample extraction process, the tissue 
scraping and/or vortexing steps (Provan et. al., 1992) as well as the fixation process (Rogers et. al., 
1990) may be the cause of mechanical shearing of high molecular weight DNA. Despite the problems 
encountered, the quality and yield of the DNA template recovered by this extraction protocol was 
good enough for PCR amplification of smaller LPL exons. 
Fig. 25: 
3.4.2 
1 K.b 
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0·5 
23 4 5 6 7 
Archival DNA extracts from tissue embedded in paraffin-wax and mounted 
on histopathological slides. Electrophresis was performed on 1 % agarose 
gels and stained with ethidium bromide. Lane 1 - DNA molecular weight 
marker, Lane 2 - Undegraded genomic DNA, Lane 3 - Degraded genomic 
DNA, Lanes 4,6 - DNA from wax blocks, Lanes 5,7 - DNA from 
histopathological slides. 
PCR Amplificritinn of LB Slide DNA. 
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Several groups hnve been successful in amplifying c1rchival DNA, extracted from either 
pc1rnffin-wc1x blocks nr histology slides (An and Fleming, J 9<J1; Prnvc1n et. al., 1992; Neubauer et. al., 
1992; Volkenanclt el. al., 1992; Gall et. al., 1993; Chen ancl Clejan, 1993). PCR amplification of 
archival DNA is usually successful with target sequences of 300 bp or less (Neubauer et. al., 1992). 
A problem sometimes encountered is the presence of PCR inhibitors in extracts (An and Fleming, 
1991). Also, formalin fixation c1ppears to induce crnsslinking of DNA thereby adversely affecting 
PCR amplification (Neubauer el. al., 1992). Mercury-h,1sed fixatives, such as B-5 and fixatives 
containing picric acid, such as Bouiins, are to be c1voided c1s they extensive ly degrade DNA, limiting 
PCR c1nc1lysis (Herbert el. al., 1989). 
The following protocol w,1s used in this study : (i) A series dilution of the extracted DNA (1/5 
to 1/100) was performed to dilute out any inhibitors. This proved to be an important step in 
determining the optimal concentrntion for successful amplification. (ii) The Tag polymerase enzyme 
wns cidded under den<lluring conditions (94°C), called a "lint start' ' . (iii) The PCR cycle number was 
increased to 40, generating ,1 stronger signal. Following nrnplification, DNA products were applied 
to 1 % c1gc1rose gels and visunlizecl by eth idium bromide st,1ining. 
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Fig. 2() shmvs ;1111plificatilln products llf eXllll 9 from kindred II. Primers, specific for exon 9, 
n;1mely, LPL 23 (reverse) :iml LPL 24 (tlirward) (Pri111er Design) were used, giving a DNA fragment 
of 159 hp. Lines I to 5 represent ;1 dilution series of amplified extract DNA from the prnhand, LB, 
clearly indicating a positive signal ;it a sample dilution nf I /25 (lane 3)(Methods). DR, ER and BB 
amplified DNA products (lanes(), 7, 8) are shown. These amplification products were subjected to 
SSCP analysis. 
Fig. 26: 
1 2 3 4 5 6 7 8 9 10 
.-..159hp 
PCR amplification of exon 9 from slide DNA of index patient, LB and 
genomic DNA of three kindred II subjects. Electrophoresis was performed 
on l % agarose gels and stained with EtBr. Lanes l to 4 · PCR products 
from 1/100, 1/50, 1/25, l/5 dilutions of LB slide DNA. Lane 5 · a PCR blank, 
Lane 6 · exon 9 PCR product from the father of LB, Lane 7 · exon 9 PCR 
product from mother of LB, Lane 8 · exon 9 PCR product from the 
daughter of LB, Lane 9 · PCR blank, Lane 10 · DNA molecular weight 
marker. 
Despite the successful arnplificatinn, the sensitivity :iml reliability of the assay remains a 
problem, since PCR product was 1wt ;ilways obtained. On a positive note, the results cnrrnbornte 
earlier reports. suggesting improved arnplificntilln following dilution of extrnct DNA since inhibitor 
concentrntions are presu111ably dilutnl (lllt (Volkt'11andt, ct. o/., I 1) 1)2) . Also, the "hot start" utilised 
is very effective in reducing pri111n loss through pri111er-di1ner f()rnwtion. 
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3.4.3 PCR-SSCP of Kindred II. 
The principles and strategy of this technique were outlined earlier. 
PCR-SSCP analysis was adopted in order to search for sequence alterations in the LPL gene 
as this methodology provides an efficient means for the detection of point mutations. This was 
effectively demonstrated for proband, JJ (Kindred I) in the previous chapter. Following 
electrophoresis of DNA fragments, SSCP gels were visualised by silver staining, as described in 
Methods. After excision of the abnormal bands from the stained gel, sequence variations were 
determined directly by PCR cycle sequencing from eluted DNA. 
Fig. 27 shows a SSCP gel of LPL exon 9 DNA for kindred II (see next page). Initially, 
SSCP analysis of exonic DNA was performed for DR and ER only. Band shift anomalies were only 
detected for exon 9 of ER (lane 2) while DR (lane 1) has a banding pattern identical to the normal 
LPL exon 9 control (lane 5). An interesting observation for ER, is the absence of a single 11 normal 11 
band, B8 as well as the presence of variant bands Bl, B3, B5, B6, B7 and B9 which suggested that 
she may be homozygous for a single sequence alteration or a compound heterozygote for two distinct 
base variations in exon 9. Individual bands were sequenced directly by a cycle sequencing protocol 
as described [fmol DNA sequencing system (Promega)] (Methods). Successful sequence was only 
obtained for the variant band, B9 of ER, which showed a single G-+A transition at position 1516 in 
the first positon of codon 421 in exon 9. This gave rise to a substitution of lysine (K)(AAG) for 
glutamic acid (E)(GAG) and was designated E421K (Fig. 28). Further investigation is necessary to 
determine the sequence the other ER SSCP bands. 
Fig. 27: 
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SSCP analysis of LPL exon 9 amplicons from kindred II subjects. PCR 
amplification was performed using two pdmers, LPL23 and LPL24 (See 
Primer Design). Electrophoresis was performed on 0.55xHydrolink MOE 
polyacrylamide gels with visualisation by silver staining. DNA bands are 
numbered Bl - B9. Lanes 1 - 4 are kindred II samples. Lane 5 is a normal 
control specimen. The normal control DNA gives three bands, B2, B4 and 
B8. Bands B 1 and B2 cannot he distinguished in lane 2 clue to overexposure 
to bring up hand, B7. 
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SSCP analysis nf exnn 9 was also carried nut for amplification product<; from the index patient 
(LB)(lane 3) and her only offspring (BB)(lane 4). The presence of the variant band, B9 in both 
subjects suggest that they had inherited the same maternal band. Sequence nnalysis of this band 
confirmed the inheritance of the E42 l K allele for both LB and BB. Therefore, the cluster of bands, 
B5, B6 and B7, probably represent "conformers" of the E421 K allele, since they were observed in 
Lys 
Fig. 28: 
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Nucleotide sequence of the sense strand of exon 9 of the LPL gene for ER, 
the mother of LB and a control subject. The G--+A base transition (-+) is 
boxed. The amino acid subsitution is indicated and the codon is numbered. 
the three subjects ER, LB and BB but not in DR. Bands 82, 84 and B8 present in DR, and normal 
cnntrnls a lsn occur in LB and BB suggesting that they also received a copy of the paternal allele 
which is most probably of normal exon 9 sequence. These band shifts were confirmed through 
severa l independent PCR-SSCP analyses. In a search for the paternal mutation, PCR-SSCP analysis 
of exons 2-9 from DR, spanning the entire coding region, including the exon-intron boundaries of the 
LPL gene locus, revealed no sequence variations, except for a G--+A transition in the third position 
of codon 108 in exon 3 (data not shown). DR proved to be heterozygous for this rare polymorphism 
(data not shown) and DNA analysi" is in progress to establish whether LB has inherited this allele or 
not. 
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3.5 Discussion. 
Familial LPL deficiency is known to exacerbate the hyperlipidaemia commonly associated with 
individuals in the third trimester of their antenatal course (Gleuck et. al., 1980; Watts et. al., 1992). 
The index patient, LB, despite having no history or clinical sequelae alluding to an underlying 
hyperlipidaemic condition, presented upon admission with acute pancreatitis. This condition 
progressed to fulminant haemorrhagic pancreatitis which eventually led to her death. The gross 
hypertriglyceridaemia (TG, 87rnmol/l) was considered the most likely cause in the absence of other 
precipitating factors such as, diabetes or alcohol abuse, which rendered her a strong candidate for a 
defect in LPL activity. 
A search for mutations in the LPL coding sequence in the parents of LB led to the discovery 
of a novel G-+A transition at position 1516 in exon 9 at codon 421 leading to a substitution of lysine 
for glutamic acid. This mutant allele was shown to be inherited by LB and was passed on to her 
offspring, BB. While completing the investigation on ER, a second mutation, a o-~G transversion 
(a known polymorphism) at position 1595 in exon 9 of the alternate allele, was identified by our 
research staff. This sequence change introduces a premature termination codon at Ser447 and gives 
rise to a truncated protein, lacking the C-terminal Ser-Gly dipeptide. Compound heterozygosity for 
the E421K mutation and the Ser447'4stop polymorphism clearly explains the abberant banding 
observed upon PCR-SSCP analysis in the mother of our patient. The fact that she has no history of 
hyperlipidemia and that both her pregnancies were uneventful would suggest that the expression of 
these two mutant LPL gene products does not manifest as a clearance defect. A search for the 
second mutation in LB by examining DNA from her father has thus far been unsuccessful. Her father 
was however shown to be heterozygous for a silent mutation in exon 3 at codon 108. This 
polymorphism can be detected by restriction analysis with Sau961. A possible defect in the LPL exon 
1 and the 5'-regulatory region of DR cannot be ruled out. Further analysis is also necessary to 
determine expression levels for both alleles. Complete sequencing of all the LPL exons of LB is now 
necessary as not all sequence alterations can be determined from SSCP band shifts. At present time 
we have shown that our patient, LB, is heterozygous for the E421K mutation, the "mutant" allele 
being of maternal origin, while the paternal allele has a "normal" sequence at this codon position. 
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LPL deficiency manifests a baseline carrier frequency of 1:500. While homozygotes present 
with marked hyperlipidaernia, establishing an autosomal recessive mode of inheritance, several reports 
have recently alluded to a possible role for the heterozygous LPL-deficient state in the genesis of 
hypertriglyceridaernia. This has been facillitated by the .ability to unequivocally identify carrier status 
by DNA screening techniques. Previous attempts to identify carriers had to rely on measurement of 
LPL activity levels in post-heparin plasma and adipose tissue. Obligate carriers have been reported 
with a 50% reduction in LPL activities in post-heparin plasma (Kondo et. al., 1985; Miesenbock et. 
al., 1993) and adipose tissue (Wilson et. al., 1990) compared to normal controls. On this basis mild 
and variable hyperlipaemia have earlier been shown to segregate with the carrier state (Babirak et. 
al., 1989) and was characterised by slightly elevated plasma triglyceride and VLDL-cholesterol levels 
with a reduced HDLi component (Wilson et. al. , 1990; Miesenbock et. al., 1993; Patsch et. al., 1983 
and 1987). In the post-prandial state, the carrier status manifests itself as reduced clearance of dietary 
triglyceride from plasma called "the syndrome of impaired TG tolerance". Earlier, Wilson et. al. 
(1990) confirmed that fasting hypertriglyceridaemia in carriers were strongly age-related with 
individuals older than 40 years showing increased plasma triglyceride levels suggesting a later age of 
onset for this condition. In addition, multiple secondary factors such as obesity, hyperinsulinaemia, 
hypertension and lipid-raising drugs ( contraceptives) are known to aggravate fasting 
hypertriglyceridaemia in heterozygous LPL-deficient individuals (Wilson et. al., 1990). Pregnancy 
must now also be recognised as one of the secondary factors that interact with the heterozygous 
LPL-deficient state. While a defect in LPL activity has not been adequately established it is clear that 
our patient manifested with a lipoprotein clearance defect. 
Female carriers of LPL-deficient alleles, however do not usually present with overt 
hypertriglyceridaernia during pregnancy. We therefore expected that our patient would manifest with 
two defective LPL allelic products generating a LPL-deficient state exacerbated by the 
pregnancy-induced lipaemia. One mutation, which may cause the production of a catalytically 
defective product has been found, while the other remains to be elucidated. 
The identification of two mutations in this kindred located to exon 9, brings to three the 
number of missense mutations identified in this exon of the LPL gene. Recently, five other groups 
have also reported the identical C--+G transversion at position 1595 (Ser447--+stop) in individuals of 
different nationalities. This mutation appears to have no effect on LPL function (Faustinella et. al., 
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1991) with most of the LPL activity being retained (Ma et. al. , 1992). Stocks et. al. (1992) reported 
no clear relationship between the presence of the mutation (Ser447--.stop), hypertriglyceridaemia and 
variable lipid levels as commonly associated with mutations causing LPL deficiency. This sequence 
variant may therefore be regarded as a common DNA polymorphism. Recently, a 30 year old East 
Indian woman presented for the first time at 33 weeks gestation, when she was diagnosed with 
pancreatitis precipitated by pregnancy (Ma et. al., 1993). She was confirmed to be homozygous for 
a 0-.G transversion at nucleotide position 770 in exon 5 resulting in a serine to cysteine substitution. 
In vitro expression studies of this mutant LPLcDNA, produced a partially active product with approx. 
6% LPL activity compared to the wild type. The concluding remarks in this case may be reported 
as, hyperlipidaemic pancreatitis as a result of partial LPL deficiency compounded by pregnancy. This 
case report appears to be identical to our index patient, LB, except our patient is heterozygous for 
the E421K mutation in exon 9 of the LPL gene. LPL-deficient carriers do not usually present with 
hyperlipidaemia in pregnancy. Hence, there is presumed to be a undetected second mutation or 
defective allele in our patient not usually associated with a defect in lipoprotein clearance. However, 
the E421K mutation may produce a partially active LPL protein product, which in combination with 
a second partially defective protein and a secondary factor such as pregnancy, may manifest as LPL 
deficiency. Another possibility, is the association of the "impaired triglyceride tolerance" syndrome 
with the LPL-deficient heterozygote in the post-prandial state, which in combination with all these 
genetic and enviromental triggers may have been the underlying cause for our index patient's 
condition, leading to the catastrophic events in 1987. 
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CHAPTER 4 
CONCLUSIONS AND FUTURE STUDIES 
The specific conclusions have been discussed at the end of each chapter. General conclusions 
relevant to the topic are presented in this chapter and a short summary on future studies is given at 
the end. 
4.1 General Conclusions. 
The findings in the two kindred studies corroborates the well described phenotypic and genetic 
heterogeneity that underlies Type I hyperlipoproteinemia. In kindred l , proband, JJ, has a milder 
phenotype and was shown to be a compound heterozygote for two mutations. Transfection studies 
showed the 1194T mutant to be catalytically inactive. In the absence of transfection studies, the 
preliminary evidence suggests that the C418Y mutant product is partially active. In the kindred II 
study (Chapter 3), the relatively benign clinical history and uneventful pregnancies of the mother, ER, 
implies that the E421K mutant product, more than likely is partially active. This mutation was also 
inherited by the kindred II proband and while it may have contributed to her condition, it is unlikely 
to have been the major determinant of the hyperlipidaemia which led to her death. This is in 
conformity with the findings of other workers, who propose that gene mutations located in the C-
terminal domain of LPL generate protein products that are partially active. It becomes evident that 
the number of mutations at this gene locus is underestimated since many of these sequence variants 
may only be detected in association with a secondary hyperlipidaemic state. It is therefore necessary 
to screen individuals with moderate hypertriglyceridemia in the presence of environmental stress 
factors commonly associated with hyperlipidaemia. 
In our hands RT-PCR has proved a reliable and powerful tool in the analysis of the coding 
sequence of genes and is now routinely applied to mutation analysis in a variety of genetic disorders 
presenting at this hospital. We have also applied several mutation detection techniques, which allow 
for broad-based screening programs for any known polymorphism or mutation prevalent in the 
general population. 
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4.2 Future Studies. 
In-vitro expression studies on the C418Y and E421K mutants and elucidation of the biochemical 
properties of the mutant proteins will clarify their functional properties and demonstrate any defect 
in intracellular processing. Furthermore, transfection experiments that allow for the expression of 
specific LPL dimers would facillitate the study of biochemical properties of the I194T/C418Y 
heterodimer. 
The 1194T and C418Y ARMS PCR system requires optimisation to facilitate screening for 
these mutations in the general population. 
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CHAPTER 5 
MATERIALS AND GENERAL METHODS 
This chapter contains a comprehensive list of all materials used in this work as well as the 
methods used. 
5.1 Materials, Reagents and Buffer Solutions 
All the water used in this work was deionized and doubly distilled in glass using a Quickfit 3 
DWS Double Distillation Water Still. The abbreviation, ddH20 will be used wherever water is used 
in procedures. The sources of all other reagents and solvents are shown in brackets. 
1) lM TRIS. HCl 
121.lg of Tris base (Boehringer Mannheim (BM) Pty, Cat. No.: 708976) was dissolved in 
800ml of ddH20. The pH was adjusted to the desired level by adding concentrated HCl. The 
final volume was adjusted to 1 liter with ddH20 and the solution was autoclaved. 
2) 0.5M EDTA (pH 8.0) 
186.lg of Disodium ethylene diamine tetraacetic acid.dihydrate (EDTA.2H20)(BDH Ltd., 
Cat. No.: 10093 5V) was dissolved in 800ml of ddH20 and the pH was adjusted to 8.0 with 
a lON NaOH (Merck, Cat. No.: 6498.0500) solution. This solution was autoclaved. 
3 ) lOxTE (Tris.EDTA) 
lOOmM TRIS.HCl (pH 7.4 - 8.0) 
lOmM EDTA (pH 8.0) 
4) 1M Dithiothreitol (DTI) 
3.09g of DTI (Cleland's Reagent)(Sigma, Cpy; Cat. No.: D5545) was dissolved in 20ml of 
0.01M sodium acetate (pH 5.2). The solution was filter sterilised and stored at -20°C. 
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5) 20xSSC 
175.3g of NaCl (Saarchem (Pty) Ltd., Cat. No.: 582 25 00) and 88.2g of trisodium citrate 
(Saarchem (Pty) Ltd., Cat. No.: 582 250) was dissolved in 800ml of ddH20. The pH of the 
solution was adjusted to 7.0 with lON NaOH and made up to 1 liter with ddH20 and 
autoclaved. 
6) 20xSSPE 
174g of NaCl, 27.6g ofNaH2P04.H20 (Merck, Cat. No.: 6346.0500) and 7.4g ofEDTA was 
dissolved in 800ml of ddH20. The pH was adjusted to 7.4 with a lON Na OH solution. The 
volume was adjusted to 1 liter and sterilised by autoclaving. 
7 ) 50xDenhardt's Solution 
5g ofFicoll (Merck, Cat. No.: 498.0250), 5g of Polyvinylpyrrolidone (Sigma Cpy., Cat. No.: 
PVP-40) and 5g of Bovine serum albumin (Fraction V) (Sigma Cpy., Cat. No.: A 7906) was 
dissolved in 500ml of ddH20. The solution was filter sterilised and stored at -20°C. 
8) 10% SDS 
100g of Sodium Dodecyl Sulfate (SDS)(Merck, Cat. No.: 13760) was dissolved in 900ml of 
ddH20. The solution was heated to 60°C to facilitate dissolution and the pH was adjusted 
to 7.2 with concentrated HCI. The volume was adjusted to 1 liter and the solution was stored 
at room temperature. 
9) Luria-Bertani Medium (LB Broth) 
10g of Bactotryptone (Oxoid, Unipath Ltd, Cat. No.: CM129), 5g of Bacto-yeast extract 
(Biolab Diagnostics (Pty) Ltd, Cat. No.: BX6) and 10g of NaCl was dissolved in 1 liter of 
ddH20. The pH was adjusted to 7.5 with lON NaOH and the solution was autoclaved. 
10) LB Agar 
15g of Bacto-agar (Oxoid Ltd, Cat. No.: L13) was added to 1 liter of LB broth and 
autoclaved. The solution was cooled to 55°C before adding the antibiotics. Approximately 
30 to 35 ml of LB agar was poured per 85mm petri dish. The top surface of the agar plate 
was flamed with a bunsen burner to sterilise and remove any surface bubbles. The agar was 
allowed to set and the plates were stored at 4°C until use. 
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11) 5xTBE 
54g ofTRIS.HCl (pH 7.4), 27.5g boric acid (Saarchem (Pty) Ltd, Cat. No.: 140 5200) and 
20ml 0.5M EDTA (pH8.0) were dissolved in ddH20 and made up to 1 liter . 
12) Taq DNA Polymerase (for PCR) (Concentration: 5 units/µl; Promega, Cat. No.: M1861) 
Tag DNA Polymerase Buffer (Promega, Cat. No.: M190A) 
lOOmMM TRIS.HCl (pH 9.0), SOOmM KC!, 1 % Triton X-100. 
Magnesium Chloride (25mM; Promega, Cat. No.: A351) 
Note: The above PCR reagents were used in all subsequent PCR reactions. 
13 ) Cell Lysis Buffer 
109.Sg of Sucrose (0.32M; BDH Ltd, Cat. No.: 10274), SmM MgC12, 10ml Triton X-100 
(1 %), and 10mM TRIS.HCl (pH 7.6) were mixed and made up to 1 liter with ddH20, 
autoclaved and stored at 4 °C. 
14) Saline-EDTA, pH 8.0 
Fifty milliters of a 100mM EDTA stock solution was mixed with 3. 75ml of a 4M NaCl stock 
solution and made up to 200ml with ddH20. The solution was autoclaved and stored at room 
temperature. 
15 ) Proteinase K 
The Proteinase K (Sigma Cpy, Cat. No.: P-0390) solution was prepared as a 10mg/ml stock 
with sterile ddH20. 1ml aliquotes were snap frozen and stored at -70°C. 
16 ) Sodium-perchlorate 
70.23g of NaC104.H20 (SM; Merck, Cat. No.: 6564.0100) was dissolved in 100ml of ddH20. 
The solution was autoclaved and stored at room temperature. 
17) Phenol/Chloroform (T.E. saturated) Mixture 
Redistilled Phenol (Merck, Cat. No.: 7632.0100) was saturated with a lxT.E. solution. An 
equal volume ofthis solution was mixed with an equal volume of Chloroform (BDH Ltd, Cat. 
No.: 10077). 
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18) Chloroform/Octanol Solution (24:1) 
480ml of Chloroform was mixed with 20ml of Octanol (Merck, Cat. No.: 991.1000) and 
stored in a dark bottle at room temperature. 
19) Ethidium Bromide (lOmg/ml) 
lg of Ethidium Bromide (EtBr; Sigma Cpy, Cat. No.: E 8751) was dissolved in 100ml of 
ddH20. 
20) Terrific Broth 
To 900ml of ddH20 was added 12g of Bactotryptone, 24g of Bacto-yeast extract and 4ml of 
glycerol. This solution was mixed and autoclaved for 20mins at 15 lbs. A solution 
containing 2.31g of KH2P04 and 12.54g of I). HPQ was prepared separately in 90ml of 
ddH20, made up to 100ml with ddH20 and autoclaved. Both solutions were allowed to cool 
to 60°C before combining the two solutions, which results in a final concentration of 0.17M 
for KH2P04 and 0.72M for K2HP04• 
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5.2 General Methods 
5.2.1 LPL Activity Assay 
5.2.1.1 Materials and Reagents 
1 ) 0.233M TRIS.HCI Buffer, pH 8.5 
29.289g of TRIS was dissolved in 1 liter of ddH20 and the pH adjusted to 8.5 with lON 
NaOH. 
2 ) L-a-Phosphatidylcholine (Type lx-E) from egg (lecithin), 50mg/ml: 
This phospholipid is supplied as a thick gel by Sigma Chemical Co. (Cat. No. P8640). The 
reagent was prepared as a 50mg/ml stock solution in chloroform and stored at 20°C. 
3 ) Salt Correction Solution (0. 78M NaCl in TRIS buffer) 
4 ) 
4.558g of NaCl was diluted in 100ml of 0.223M TRIS buffer, pH 8.5 and stored at 4°C until 
use. 
Krebs-Ringer Phosphate (KRP) buffer: 
NaCl ( 45 g/1) 100.0ml 
KCl ( 57.4 g/1) 5.0ml 
CaC12.2H20 (8.14 g/1) 1.5ml 
MgS04.7H20 (191 g/1) 1.0ml 
NaH2P04.H20 (13.8 g/1) 15.0ml 
Na2HP04.H20 (14.196 g/1) 85.0ml 
432ml dd8i0 was added to the above mixture and the pH was adjusted to 7.4 with HCl. The 
solution was stored at 4°C. 
4 ) Heparin (lmg/ml in TRIS or KRP buffer) 
Sodium heparin was obtained from Sigma Chemical Co. (Cat. No.: H3125) and dissolved in 
TRIS or KRP buffer at a final concentration of lmg/ml and stored at -20°C in 2ml aliquotes. 
5) Belfrage Extraction mixture (methanol:chloroform:heptane = 1.41:1.25:1) 
141 ml methanol 
125 ml chloroform 
100 ml heptane 
The solvent was prepared in a dark bottle and stored at 4 °C until use. 
6 ) 0.05M Carbonate-Borate buffer, pH 10.5 
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6.91g of Potassium Carbonate (Merck, Cat. No.: 4928.0500) and 3.092g of boric acid was 
dissolved in ddH20 and the pH was adjusted to 10.5 with SN potassium hydroxide. The 
solution was made up to 1 liter and stored at 4 °C. 
7 ) Bovine serum albumin (BSA) 
a ) Delipidation of BSA (Removal free fatty acids). 
Activated charcoal (5g; Merck, Cat. No.: 2186.0250) was layered on Whatman 
(No.1) filter paper in a buchner funnel and washed 3 to 4 times with ddH20. The 
fines floating on top of the suspension was syphoned off using a venturi pump. A 
BSA solution (10g BSA in 100ml ddH20) was prepared and mixed with the washed 
charcoal and while stirring, the pH was adjusted to 3 by the slow addition of 0.2M 
HCL The mixture was placed in an ice-bath and stirred for 1 hour. The charcoal was 
removed by centrifugation at 19500 rpm for 30 minutes. The supernatant was 
collected and the pH was adjusted to 7 with 0.2N NaOH. The delipidated BSA 
solution was dialysed against ddH20 for several hours or overnight. The dialysate 
was freeze-dried overnight and the dried, delipidated, BSA powder was stored in a 
brown bottle at 4 °C until use. 
b) The BSA, Fraction V (lyophilized and fatty acid free) obtained from Sigma (Cat. No. 
A7030) was used directly. 
8) Preparation of the Non-radioactive and Radioactive Triolein substrate (200 mg/ml). 
a) Reagents 
i) The Glycerol trioleote [C18:1, ( cis)-9] stock material was obtained from the Sigma 
Chemical Cpy. (Cat. No. T-7140) as a lg quantity. A stock solution of O.Smg/5µ1 
were aliquoted and stored at -20°C until use. 
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ii) Glycerol tri [l-14C] oleate (cone: 50µCi/0.5ml)(Spec.Act. 54.3mCi/mmol)(Amersham, 
Cat. No.: CFA 258). 5µ1 and 10µ1 were assayed. 
b) Protocol 
Non-radioactive triolein (O.lmg/µl) and radiolabelled triolein (Stock, 0.5- lµCi) were 
subjected to thin-layer chromatography (TLC), utilising precoated, TLC (KIESEL) 
Silica gel 60 plates (20x20; thickness 0.25mm)(Merck Cpy, Cat. No.: 5721.0001) and 
chromatographed for approximately 40 minutes in a Panglas TLC chromatank 
(Shandon, Ltd) containing 100ml of a petroleum ether: diethyl ether: glacial acetic 
acid (90:10:1) buffer solution. Foll~wing chromatography, the plates were air-dried 
for approximately 30 minutes and allowed to develop in the presence of iodine 
crystals. The stained spots were marked and allowed to destain by evaporation. The 
spots were scraped, pooled and the triolein extracted as follows: 
i) Triglycerides were liberated from silica gel by shaking vigorously in diethyl 
ether for 10 minutes. 
ii) The solution was centrifuged for 10 minutes at 3000 rpm to pellet the gel 
pieces. 
iii) The supernatant was transferred to a clean tube and the gel pellet extracted 
twice with 5ml of diethyl ether. 
iv) The supernatants were pooled and evaporated to dryness under N2 gas. 
v) The dried and purified samples were reconstituted in benzene. 
vi) The concentrations and recoveries of purified triolein were assessed as 
described below. The concentration of non-radioactive triolein was 
determined on a Technicon Random Access (RA) 1000 SYSTEM. The 
radioactive triolein concentration was assessed on a Beckman Scintillation 
Counter with O.lµCi being used per assay. 
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9 ) Preparation of non-radioactive and radioactive oleic acid ( cis-9-0ctadecenoic Acid) solution. 
a) Reagents 
i) Radioactive [l-14C]oleic acid (Spec. Act. 54.9mCi/mmol; Amersham Ltd; Cat. 
No.:CFA 243) was prepared as SOµCi aliquotes in toluene and evaporated to dryness 
under N2• 
ii) Non-radioactive oleic acid (Sigma, Cat. No.: 0 3879) was prepared in hexane as a 
SOµM solution (14.2mg/100ml). 
iii) The working stock solution was prepared as follows: SOµCi of radioactive oleic acid 
was diluted in 100 ml of a SOµM solution of non-radioactive oleic acid. This 
solution was stored at 20°C until use. 
10) Pre-heparin plasma (pEH) 
Approximately 20ml of blood was obtained from each subject and collected into heparinised 
tubes. The cell debris were removed by centrifugation at 3000 rpm at 4 °C; the plasma was 
collected and 1ml aliquotes were snap frozen and stored at -70°C. 
11) Post-heparin plasma (pOH) sample preparation 
After an overnight fast, subjects were administered a heparin bolus (50-100 units per kg of 
body weight) by intravenous injection. Infusion was usually carried out over a period of 1 
minute. This was followed by an intravenous saline wash (5ml). Following a 10 minute 
incubation period, bloods were drawn and collected into EDTA- or heparin-containing tubes 
(prevent clotting). The tubes were inverted several times and immediately placed on ice. 
Plasma was separated by centrifugation at 4°C and 1ml aliquotes were immediately snap 
frozen and stored at -70°C until use. 
12) Pooled Serum 
The bloods obtained were transferred to non-heparinised tubes and allowed to clot. After 
centrifugation the serum was collected, pooled and heat-inactivated at 56°C. 1ml aliquotes 
were snap frozen and stored at -70°C. 
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13) Bovine Skim Milk standard preparation 
Fresh unpasteurised bovine milk was obtained from the dairy distribution centre and the cream 
removed by centrifugation at 4 °C. Approximately 14. 7g of solid trisodium citrate dihydrate 
(O.lM) was mixed with 500ml of the skim milk supernatant and stirred for 30 minutes at 4°C. 
This solution was then dialysed against a 5mM sodium phosphate buffered-saline (0.15M) 
solution (pH7.4) for 18 hours with buffer changes at 6 hourly intervals. After dialysis, 
glycerol was added to 30% (V N) and 1ml skim milk aliquotes were snap frozen and stored 
at -70°C. 
14) Preparation of the Triglyceride Substrate Emulsion 
L-a-phosphatidylcholine (6mg/120µ1), triolein (SOmg/250µ1) and radioactive triolein 
(lµCi/100µ1) were aliquoted into a scintillation vial (2.2x7cm/flat-bottomed) and the contents 
were evaporated under a stream of nitrogen. To this mixture was added 4.95 ml of 0.233M 
Tris buffer (pH 8.5), 1ml of Salt Correction solution and 549.9mg of delipidated BSA was 
layered on top and allowed to dissolve. The mixture was cooled on ice and sonicated at 60 
Watts for 3 minutes and 20 seconds (10 repeated cycles of 10 sec bursts interrupted by 10sec 
pauses) using a Sonifier B12 sonicator (Brandon Sonic Power, Cpy). Each 6ml aliquote is 
enough for 10 assay incubations. 
15) Preparation of samples 
a) Post-heparin plasma (pOH) 
i) Just before analysis, aliquotes of pOH were rapidly thawed in cold water and 0.05ml 
of pOH was mixed with 0.2ml of pooled serum, 0.05ml heparin (lmg/ml) and 0.2 
KRP or TRIS buffer. 0.2ml of this preparation was assayed for lipase activity. 
ii) Antibody inhibition: Antibody 5D2 (A monoclonal antibody raised against bovine LPL 
in mice)(lmg/rnl) dilutions were prepared in KRP or TRIS buffer. The diluted pOH 
(1:10) was mixed in a 1:1 ratio with the diluted antibody preparations and incubated 
at 4°C for 2hrs prior to assay. A 0.2ml aliquote was assayed for lipase activity. 
b) Cell Cultures 
0.2ml of culture medium was assayed without further dilution. 
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c) Skim milk standard 
An aliquote of skim milk was rapidly thawed in cold water and diluted 1:10 or 1:20 
in KRP or TRIS buffer. 0.2ml of the diluted sample was assayed for lipase activity. 
5.2.1.2 Assay Conditions 
The complete assay mixture (pH 8.2 at 37°C and ionic strength 0.16) contained 0.178M TRIS-HCI 
buffer (ionic strength 0.05), 0.1 lM NaCl, 55mg/ml of albumin, 0.01 mg/ml of heparin, 5% of serum 
(V N), 5mg/ml of triolein and 0.05µCi/mg of C14-triolein emulsified with 0.6mg/ml of lecithin. 0.6ml 
of this mixture was aliquoted per assay tube. All tubes were kept in an ice-bath until the enzyme 
substrates were added. Blank assay incubations contains 0.6ml emulsified assay mixture, 0.2ml TRIS 
buffer and 0.2ml heparin in KRP solution. To each tube containing 0.6 ml emulsified assay mixture, 
0.2 ml of TRIS buffer was added. The enzyme solution (0.2ml)(i.e. pEH, pOH or skim milk 
standard) was added just before incubation is commenced. 
Specific radioactive oleic acid recovery: A known amount of the oleic acid stock mixture (0.2ml) was 
aliquoted into test tubes in triplicate and evaporated under a stream of N2 gas. 0.6ml assay mixture, 
0.2ml TRIS and 0.2ml pEH solution was added to these test tubes and incubated as above. Also 
0.2ml oleic acid stock mixture was aliquoted into two scintillation vials; scintillation fluid ( 4ml) was 
added and the radioactivity ( cpm) assessed. 
Specific radioactive triolein solution: 100µ1 of the assay mixture was added in triplicate to scintillation 
vials, dissolved in 4ml scintillation fluid and the radioactivity was counted. 
Incubation: After addition of the enzyme solution, the test tubes were covered, mixed and incubated 
with shaking at 37°C for 60 minutes. 
Incubations were terminated by the extraction of free fatty acids as follows: 
(i) 3.25ml of a methanol:chloroform:heptane solution was added to 13x100mm test tubes. 
(ii) A 0.2ml volume of the incubation mixture was transferred to the above tubes and vortexed. 
(iii) This was followed by the addition of 1.05ml of carbonate-borate buffer solution. 
(iv) The solution was again vortexed and centrifuged at 3000 rpm for 20 mins at room 
temperature to facillitate phase separation. 
(v) The upper phase (2ml) was pipetted into scintillation vials and 5ml scintillation fluid was 
added and each tube was counted for 10 mins in a scintillation counter. 
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5.3 DNA Isolation 
Anticoagulated blood (20ml) was collected in 50ml sterile evergreen tubes (heparinised or l.Smg/ml 
EDTA). The blood was mixed thoroughly and centifuged at 4°C (2700rpm/15min). The plasma 
supernatant was aspirated off, ensuring that the packed cell layer is not disturbed. Ice-cold lysis 
buffer was added to cell layer up to the 50ml mark and mixed by inverting 10 times and stood on ice 
for 30 min. This mixture was centrifuged at 4°C (2700rpm/15min) and the supernatant aspirated off 
up to the 10 ml mark. About 40ml of ice-cold lysis buffer was added and the mixture inverted several 
times. The nuclei was pelleted by centrifugation at 2700rpm for 15min at 4°C. The supernatant was 
carefully poured off: leaving behind the gelatinous white cell/nuclei pellet. The tube was inverted to 
allow for drainage of the excess supernatant. To the pellet was added 8ml of Saline-EDT A and 0.8ml 
of 10% SDS and the mixture gently vortexed. One hundred microliters of Proteinase K solution 
(lOmg/ml) was added to the mixture and incubated at 37°C for approximately 8 hours to overnight. 
To the mixture was added 0.5ml of 5M Na-perchlorate and 8ml phenol/chloroform (TE-saturated), 
which was gently stirred at 4°C for approximately 60 min, until the solution was homogenous. The 
solution was transferred to a sterile corex tube and centrifuged for 15min (10°C/8000rpm). The 
aqueous phase was carefully removed and transferred to a 50ml evergreen tube containing 10ml 
chloroform/octanol (24:1). This mixture was vigorously shaken for 30 min, transferred to a sterile 
corex tube and centrifuged for 15min (10°C/8000rpm). The aqueous phase was transferred to a 
sterile 50ml evegreen tube and 2 volumes of ice-cold absolute ethanol was added and mixed to 
precipitate the DNA. The DNA was recovered with a flamed-sealed glass pipette, dissolved in 1ml 
ddH20 and placed on a roller-mixer overnight at 4°C. A 1/100 dilution of the DNA sample was 
prepared and spectrophotometric analysis was performed at wavelengths of 260 and 280nm. Two 
micrograms of purified DNA were electrophoresed on 0. 7% agarose gels to assess the quality of the 
DNA preparation. The DNA was aliquoted, snap frozen and stored at -70°C until use. 
5.4 End Labelling of Allele-Specific Oligonucleotides 
5.4.1 Materials and Reagents 
1) 10 x Kinase Buffer 
121.lg of TRIS (lM)(BM Ltd, Cat. No.: 708 967) was dissolved in 800 ml of ddH20 and the 
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pH was adjusted to 8 with HCI. 15.43g of DTI (O.lM) and 20.33g of magnesium 
chloride-6-hydrate (O.lM) (MgC12.6Hp; BDH Ltd, Cat. No.: 10149) was dissolved in the 
above solution, which was made up to 1 liter with ddH20. 1ml aliquotes were stored at 
-20°C. 
2) T4 Polynucleotide Kinase (BM Ltd, Cat. No.: 709 557) 
5.4.2 Procedure 
5.4.2.1 Sample Preparation 
The following labelling mix was prepared: To a sterile, screw-capped 1.5ml eppendorf tube was 
added 20pmol of oligonucleotide, 2µ1 of lOxkinase buffer and 5µ1 of y 32P-ATP 
(lOµCi/µl)(Amersham, Cat. No.: PB 10168) and the solution was made up to 18µ1 with ddH20. The 
solution was vortexed and briefly centrifuged in a microfuge to collect the sample. T4 polynucleotide 
kinase (lOU/µl) was added and the solution incubated for 45 min at 37°C. This was followed by a 
10 min incubation at 65°C to inactivate the enzyme. 
To 19µ1 of end-labelling mix was added lµl loading dye (0.25% bromophenol blue; 30% glycerol in 
lxTE) and the mixture made up to 100 µI with ddH20. 
5.4.2.2 Purification (Spun Column Chromatography) 
A 1ml G-25 Sephadex spun column (Pharmacia Fine Chemicals: Cat. No.: 6139) was prepared as 
follows: The bottom of a 1ml syringe or pipette tip was plugged with a small amount of sterile, 
siliconised glass wool. The column was filled with the G-25 sephadex gel (equilibrated with TE, 
pH8.0). The column was placed inside a glass or polypropylene centrifuge tube and centrifuged at 
1000-1200 rpm for 2 mins to pack the gel and to remove excess fluid. Sephadex gel was added until 
the packed volume was approximately 0.9ml. The reproducibility of the packed column was 
monitored by loading approximately 100µ1 lxTE and the column was centrifuged as before. One 
hundred microliters of sample was loaded and centrifuged as before. The eluant was recentrifuged 
(to ensure that the excess dNTP's were completely removed) and transferred to an eppendorf tube. 
An aliquote (lµl) of the eluant was assayed to determine the recovery which is usually between 
30-40% of the total label used in the labelling reaction. 
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5.5 ASO Hybridisation 
5.5.1 Materials and Reagents 
1) Denaturation Solution: (0.4N NaOH/25mM EDTA): 
16g of NaOH was dissolved in 800ml of ddH20. To this solution was added 40ml 0.5M 
EDTA and the volume made up to 1 liter with ddH20. 
2) Hyperfilm MP (Amersham, Cat. No.: RPN 7) 
5.5.2 Sample Preparation 
1/200th of the PCR-amplified DNA product was adjusted to 0.4N NaOH/25mM EDTA in 
a 200µ1 volume. 
5.5.3 Procedure 
5.5.3.1 Blotting 
The wells of the Bio-Dot Spotting Apparatus (Bio-Rad) were overlayed with 3MM Whatman filter 
paper which had been soaked in ddH20. Hybond N+ filter paper (Amersham Ltd, Cat. No.: RPN 
1210B) was soaked in ddH20 and placed on top of the filter paper. The apparatus was clamped tight 
and a vacuum applied. Approximately 400µ1 0.4N NaOH/25mM EDTA was loaded into each well 
and the flow rate monitored. DNA samples (200µ1) were loaded into the wells and the DNA allowed 
to blot under vacuum. The sample blotting process was followed by an additional wash with 200µ1 
of denaturation solution. This was followed by a lOxSSE wash and the blotted filter was baked at 
80°C for 2 hours. 
5.5.3.2 Hybridisation 
Individual filters were pre-hybridised in a solution containing 5ml 5xSSPE, 5xDenhardt's, 0.5% SDS, 
and lOOµg/ml salmon sperm DNA (from salmon testes; Sigma Cpy, Cat. No.: D1626) for 2-4 hours 
at 55°C with shaking. Hybridisation chambers were preheated at 55°C. ASO probes were used at 
specific activities of 1 and 2xl06 cpm.pmor1 and boiled for 2-3 minutes just before use. The boiled 
probe was added to 5ml hybridisation buffer (pre-hybridisation buffer containing O.OlM EDTA) 
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(probe solution). The filters were placed in appropriately labelled chambers and overlayed with the 
probe solution. The chambers were clamped tight and incubated overnight at 55°C with vigorous 
shaking. The filters were removed and washed twice at room temperature for 30mins in 2xSSPE, 
0.1 % SDS. This was followed by a high stringency wash at 55°C for 10 mins. The filters were 
autoradiographed overnight at -80°C using a single intensifying screen. 
5.6 Southern Blot Analysis 
5.6.1 Sample Analysis 
5.6.1.1 Restriction Enzyme Digests 
Usually 5µg of sample DNA were mixed with lOx enzyme buffer (A, B. L, MOR H) and 40 units 
of restriction enzyme in a total volume of 20µ1. Samples were briefly mixed, centrifuged and 
incubated overnight at 37°C. 
5.6.1.2 Agarose Gel Electrophoresis 
1) Ordinary Electrophoresis 
For the purpose of RFLP analysis, gels were generally caste in 200ml lxTBE buffer. Gels usually 
contained 0.7 to 1.5% agarose (BM Ltd, Cat. No.: 1388 983); the powdered agarose were mixed 
with the buffer solution and the mixture was melted in a microwave oven for 5-6 mins. The solution 
was allowed to cool and the gel was caste and allowed to set at room temp. A few drops 20-50µ1 
of ethidium bromide (lOmg/ml, EtBr) may be added to the molten gel just before casting, to aid in 
visualization of the separated DNA fragments. Restriction enzyme digests were prepared as 
described, loaded into the wells and subjected to electrophoresis at room temperature overnight at 
a constant voltage of 55V. The gels may now be visualized under UV light. 
2) Pulsed-Field Gel Electrophoresis 
In order to separate large DNA fragments, 0.7% agarose gels were prepared as described. The 
restriction digests was mixed with loading dye and subjected to electrophoresis under a reverse pulse 
field (field-inversion) utilising a programmable switching/pulsing device (forward pulse setting ,.., 150 
milliseconds; reverse pulse setting,.., 50ms)(Hoeffer Instruments). The overall applied voltage for the 
48 hour run was a constant voltage of 100V. Since the power dissipation may cause the buffer 
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temperature to rise, gels were generally run at 15°C. The gel was stained with EtBr for visualisation 
after the electrophoretic run. 
5.6.2 Protocol 
5.6.2.1 Multiprime Labelling of Probe (Random-primer)(Amersham RPN. 160 Y[Z) 
DNA was diluted in ddH20 and denatured at 95-100°C for 2 min and immediately placed on ice. 10µ1 
of buffer solution (containing dATP, dGTP and dTTP in TRIS.HCl, pH7.8, MgC12 and 
P-mercaptoethanol), 5µ1 of random primer solution ( containing random hexanucleotides in BSA 
solution) and 5µ1 32P-dCTP (Spec. Act.: 15 - 30 Ci/mmol)(Amersham; Cat. No.: TRK 625) were 
mixed with the above DNA solution. Two units of DNA polymerase were mixed with the reaction 
mixture and the total volume was made up to 50µ1. The solution was mixed briefly, centrifuged and 
incubated at 37°C for 60mins or overnight at room temperature. The radiolabelled DNA was purified 
and quantitated as described (Spun Column chromatography). 
5.6.2.2 Blotting Procedure 
After electrophoresis of the DNA fragments on agarose gels, the DNA was denatured in situ and 
transferred from the gel to a solid membrane support (nitrocellulose paper or nylon filters) as follows: 
The gel was placed in a tray, overlayed with denaturation solution (0.5M Na0H/1.5M NaCl) and 
incubated at room temperature for 1 to 2 hours with gentle shaking. The denaturation solution was 
poured off and replaced with a renaturation solution (0.5M TRIS in 20xSSC) for a few mins. The 
excess gel was removed by trimming the edges with a clean blade and the gel was placed on a wick 
of 3MM Whatman filter paper that had been placed on a glass support over a tray; the wick extends 
over the glass support and into the 20xSSC buffer contained in the tray. The exposed areas 
surrounding the gel were covered in saran wrap to prevent any evaporation. A piece of membrane 
filter of appropriate size was cut, presoaked in 20xSSC buffer and placed on top of the gel matrix. 
Three to five pieces of 3MM Whatman filter paper were cut a few millimeters smaller than the gel, 
soaked in 20xSSC buffer and placed on top of the membrane. In turn, several layers of ordinary 
tissue paper were placed on top of the filter paper. A heavy weight placed on top of this pyramid 
completes the blotting sandwich. After the overnight DNA transfer, the blotted membrane filters 
were cut into appropriate sizes, placed between two sheets of 3MM Whatman filter paper and baked 
dry at 80°C for 2 hours. 
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5.6.2.3 Pre-hybridisation, Hybridisation, Post-hybridisation 
The filters were placed in a container or sealed bag, overlayed with 100ml of prehybridisation solution 
(3xSSC buffer) and incubated with shaking at 65°C for 30 mins. [Note: Filters are soaked 
individually into buffer solution to allow homogeneous wetting.] 
The filters were transferred to a preheated container containing 3xSSC, lOxDenhardt's solution and 
shaken for 30 mins at 65°C. In the meanwhile, 100ml of hybridisation solution 
(3xSSC/10xDenhardt's/0.1 % SDS) was preheated at 65°C and boiled salmon-sperm DNA (lµg/ml) 
was added. The filters were transferred to the above solution and incubated at 65°C for 60min. The 
filters were transferred to the hybridisation chambers such that the solution just cover the filters. The 
radiolabelled probe was denatured by heating at 95°C for 3 mins, added to the hybridisation solution 
and incubation was carried out overnight at 65°C with shaking. 
For the post-hybridisation step, the filters were transferred to a 3xSSC, 0.1 % SDS solution and 
incubated for 10 mins at 65°C. The filters were transferred to a lxSSC, 0.1 % SDS solution and the 
incubation was continued for 45min at 65°C. The filters were then transferred to a 0.2xSSC, 0.1 % 
SDS solution and incubated for a further 45min at 65°C. The excess probe was removed by washing 
the filters with 2xSSC and transferred to a plastic bag. The bag was sealed and the filters were set 
up for autoradiography as before. 
5.7 Large Scale Isolation of Plasmid DNA 
5.7.1 Materials and Reagents 
Sample: pLPL35 - contains full-length LPL gene copy cloned into the single ECORI site 
of the pUC19 plasmid vector. Stored in slope agar cultures. 
5.7.2 Preparation of LPL DNA Probe 
5.7.2.1 Isolation of Plasmid DNA 
A stock culture was plated out on agar plates and incubated at 37°C overnight. Single colonies were 
picked and two 1 liter LB broth cultures were inoculated and incubated at 37°C with gentle shaking. 
Ampicillin (final concentration.- 25µg/ml) was added to each culture and cell growth was monitored 
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by measuring the turbidity (OD600). At OD600 = 0.5, chloramphenicol (final cone - 170µglml) was 
added and incubation was continued overnight at 37°C with gentle shaking. The cells were pelleted 
by centrifugation at 8000 rpm ( 4 °C/10min) and the supernatant discarded. Ten milliters of solution 
I (25mM TRIS.HCI, pH 8.0; 50mM glucose; lOmM EDTA) was added to each 500ml cell pellet. 
The suspension was thoroughly mixed, followed by the addition of lysozyme (final cone.- 5mg/ml) 
and incubation at room tempemperature for 5 min. Twenty milliters of solution II (0.2N NaOH/1 % 
SDS) was added to each suspension and mixed until the solution became gelatinous and stood on ice 
for 10 min. Fifteen milliters of 5M potassium acetate was added to the above suspensions, mixed and 
stood on ice for 10 mins. The residue was pelleted by centrifugation at 10000 rpm for 10 mins at 
4°C. The supernatant was transferred to a fresh centrifuge tube and centrifuged at 20000 rpm for 20 
mins at 4°C. To each supernatant was added 0.6 volumes of isopropanol, which was thoroughly 
mixed and incubated at room temperature for 15 min. This solution was centrifuged at 10000 rpm 
for 30 min at room temperature. The supernatant was discarded and the white precipitate was 
washed with 70% ethanol by centrifugation for 10 mins at room temperature. The pellet was dried 
and resuspended in 8ml lxTE (pH8.0). 
5.7.2.2 Purification by Eqiulibrium-Cesium Chloride-Ethidium Bromide Centrifugation 
One gram of solid CsCl was added per ml of plasmid DNA. The mixture was allowed to dissolve, 
and 0.8ml ofEtBr (lOrng/ml) was added for every 10ml of the CsCl/DNA solution. The final density 
o f the solution was l.55g/ml and the concentration of EtBr was approximately 600µg/ml. The 
solution was centrifuged at 45000 rpm for 36 hours at 20°C (Beckman T-50 rotor, Beckman 
Ultracentrifuge). The rotor was carefully removed so as to ensure that the separated layers, 
consisting of linear DNA, nicked circular DNA (upper band) and the closed circular plasmid DNA 
(lower band), was not disturbed. A hypodermic needle was inserted just below the meniscus of the 
lower band and the closed circular plasmid DNA was collected. This solution was transferred to an 
eppendorf tube and an equal volume of isopropanol/CsCl solution (1:1) was added (EtBr dissolves 
in isopropanol). This solution was centrifuged at 3000 rpm for 3 min at room temperature to separate 
the isopropanol layer. This step was repeated 3 times or until the EtBr hue had disappeared. The 
aqueous phase was dialysed against several changes of lxTE to remove the CsCl. 
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5.7.2.3 Precipitation of Plasmid DNA 
The dialysate was transferred to a 25ml siliconised, polycarbonate, centrifuge tube. A 1/20th volume 
of 4M NaCl was added to the dialysate which was mixed with 2 volumes of ice-cold ethanol. The 
mixture was vortexed thoroughly, stoppered and incubated at -20°C for 2-3 hours. The mixture was 
then centrifuged at 7000rpm for 30 mins at 10°C. The supernatant was discarded and the white DNA 
pellet was reconstituted in approximately 0.5 to 1.0 ml ddH20. Again, a 1/20th volume of 4M NaCl 
and 2 volumes of ice-cold ethanol was added to the DNA suspension. This mixture was incubated 
overnight at -20°C and centrifuged at 12000 rpm for 15min. The supernatant was discarded and the 
pellet washed with 70% ethanol. The pellet was dried and reconstituted in 0.5ml ddH20. The 
concentration was assessed by spectrophotometric analysis at wavelengths of 260 and 280nm. Purity 
was assessed by electrophoresis on 0.7 to 1 % EtBr-stained agarose gels. 
5.7.2.4 Recovery and Electroelution of insert DNA (probe) 
Of the order of lOOµg of plasmid DNA was digested overnight at 37°C with 100 units of EcoRI 
enzyme (lOU/µl)(BM, Cat. No.: 703 737)(buffer H). Aliquotes of DNA restriction digests were 
electrophoresed on 0.7 to 1 % agarose gels at 80V for 30 to 60mins. The EtBr stained gel was 
visualised on a transilluminator box under UV light and blotted dry. Using a sterile scalpel blade, a 
trough (1-2mm wide) was cut in front of the band of interest. The gel was again set up for 
electrophoresis, ensuring that the electrophoresis buffer (lxTBE) was just below the gel surface. The 
trough was filled with lxTBE buffer and electrophoresis was continued and the progress of the DNA 
band of interest was monitored by visualisation under UV light. As the DNA band moved into the 
trough, the solution was collected and transferred to an eppendorf tube. The trough was refilled and 
the band collection continued until all of the DNA was recovered. The aliquotes were pooled and 
the DNA precipitated by adding 0.5 volumes of ice-cold 7.5M NH4Ac and 2.5 volumes of ice-cold 
ethanol. This mixture was incubated for 1 to 2 hours at -70°C and centrifuged at 12000rpm for 
10-15mins at room temperature. The supernatant was discarded and the pellet washed with 70% 
ethanol. The pellet was air-dried and reconstituted in lxTE buffer. Quantitation of DNA was 
accomplished by visual comparison against a known standard, BioMarker™ Low (Bio Ventures, Inc, 
Lot. No.: 021594) under equivalent electrophoretic conditions as described above. Insert DNA were 
prepared as 30ng/µI aliquotes and stored at -70°C. 
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5.8 SSCP Analysis 
5.8.1 Materials and Reagents 
1) Stock plate glue solution: Dilute 50µ1 of y-methacryloxypropyl trimethoxysilane (Sigma 
Cpy, Cat. No.: M6514) in 100ml absolute ethanol. 
2) Mutation Detection Enhancement gel (MDE™)(2 x Concentrate)(Hydrolink, AT Biochem 
Inc., Cat. No. 500-MDP). 
3) Sequencing Apparatus (BRL, Life Technologies Inc., Model S2; Cat. Series 1105) 
5.8.2 Protocol 
5.8.2.1 Preparation of Plates 
The surfaces of both glass plates were thoroughly washed with 70% ethanol. Three to five milliters 
of siliconising agent (dimethyl dichlorosilane solution; BDH, Cat No: L186291 426) were spread over 
the long plate with a tissue and allowed to dry. Three milliters of the diluted plate glue containing 
90µ110% acetic acid was applied to the short plate and rubbed vigorously with a tissue, covering the 
entire surface of the plate. The short plate was allowed to dry for a few mins, bathed in 100% ethanol 
and re-rubbed to remove the excess glue. 
5.8.2.2 Preparation of the SSCP gel 
A SSCP gel was prepared in a total volume of 60ml as follows: 
VOL 0.55x 0.5x 0.35x 0.25x 
MOE (2x) ml 16.5 15 10.5 7.5 
GLYCEROL ml 6 6 6 6 
5xTBE ml 6 6 6 6 
10%AMPS µl 0.24 0.24 0.24 0.24 
TEMED µl 24 24 24 24 
ddH20 ml 31.36 32.86 37.36 40.36 
The gel was poured and allowed to polymerise for 60mins. 
Note: A well-forming comb was used and clamped tightly in place until polymerisation was complete. 
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5.8.2.3 Sample preparation and analysis 
To each 100-200ng DNA sample was added lµl of loading dye (lOmM NaOH, 95% formamide, 
0.05% bromophenol blue, 0.05% xylene cyanol). The samples were heated at 80°C for 2-3mins and 
loaded directly into the wells. Electrophoresis was performed at 5 to lOV overnight at room 
temperature or at 4°C. 
5.8.2.4 Detection and Visualisation 
Silver staining was the method of choice: 
The plates were disassembled and the gel-bound plate was immersed in ddH20 and gently shaken for 
60min, with several changes (-5 times) of water. The water was discarded, replaced with the staining 
solution (ammoniacal solution; 0.1 % AgN03, 0.1 % NaOH, 0.4%(v/v) NH3) and the gel was soaked 
for 20 min without shaking. This solution was decanted and the gel was washed for 30sec with 
ddH20. The gel was now immersed in the developing solution (0.005% citric acid, 0.02% 
formaldehyde) and allowed to develop for approximately 5min or until the bands appeared. The 
reaction was stopped by washing with ddH20. 
5.8.2.5 Elution and PCR of DNA from SSCP Gels 
The bands of interest were excised by cutting with a sharp scalpel blade. The gel slice was transferred 
to a 1.5ml sterile, eppendorf tube containing 50µ1 lxTE buffer. The DNA was eluted by incubating 
with shaking for 1-2 hours at 37°C. The suspension was centrifuged at 12000g for 10 min to pellet 
the gel debris. The supernatant was collected and stored at -20°C until use. 
PCR-amplification was carried out as follows: 1/lOth of the eluted DNA (template) was heated at 
95°C for 5min in the presence of the two primer species. The mixture was immediately placed on ice 
to allow annealing to take place. The master reation mix contained; lOmM TRIS.HCI, pH 9, 50mM 
KCl, 0.1 % Triton X-100 (V/V); l.5mM MgC12, 0.2mM dNTP stock solution (contains 4 dNTP's). 
The annealing and master mixes were combined and the total volume was made up to 24µ1. The 
mixture was overlayed with mineral oil and heat denatured at 95°C. The Tag polymerase was added 
at 1 unit/reaction tube at 94°C, then the temperature cycling process was started; 94°C at 1 min, 50°C 
at 1 min, 72°C at 1 min. This program was repeated for 30 cycles, then the PCR samples was heat 
denatured at 94°C, a further 1 unit of Taq polymerase was added at 94°C and the above cycling 
program was repeated for a further 10 to 15 cycles. A final 5 min-extension step at 72°C completed 
the amplification procedure. PCR amplified products were visualised on 1 % EtBr-stained agarose 
gels. 
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5.9 PCR Amplification of Histopathological Slide Extract DNA 
A sample mix was prepared as follows: A dilution series of slide extract DNA were prepared such 
that the final concentrations were 1/100, 1/50, 1/25, 1/10 and neat. Primers, LPL23 (forward) and 
LPL24 (reverse)(see Primer Design) were mixed with the DNA sample at a concentration of 30pmol. 
The mixture was heated at 95°C for 5 min and then cooled on ice. 
A master reaction mix was prepared as follows: 5µ1 of lOxconcentrated Tag polymerase buffer, 
l.5mM MgC12 and 0.2mM dNTP solution (contains 4 dNTP's) were mixed. The sample mix and 
master reaction mix were combined and the volume was made up to 49µ1 with ddH20. The mixture 
was overlayed with mineral oil and the sample heated to 94°C. Two units of Tag polymerase were 
added and the temperature cycling program was started: 1 min at 94°C, 1 min at 50°C, 1 min at 72°C, 
for 30 cycles. The sample again heat denatured at 94°C and again 2 units of Tag polymerase were 
added and the above temperature cycling program was continued for a further 10 cycles. Aligoutes 
of products were analyzed on 1 % agarose gels and visualised by EtBr staining under UV light. 
5.10 PCR Restriction Analysis of the C418Y Mutation 
5.10.1 Enzymatic Amplification 
The sample mix was prepared as follows: To 0.5µg of sample DNA was added 30pmol of each 
primer, LPL24 (reverse) and 418MIS (forward)(see Primer Design). This solution was heat 
denatured at 94 °C for 5 mins and snap cooled on ice. 
A master reaction mix was prepared as follows: 5µ1 of lOxconcentrated Tag polymerase buffer, 
l.5mM MgC12, 0.2mM dNTP's solution (contains 4 dNTP's) and 2 units of Tag polymerase were 
mixed. The sample mix and master mix were combined and made up to 50µ1 with ddH20. The 
mixture was overlayed with mineral oil and the temperature cycling program was commenced: 1 min 
at 94°C, 1 min at 55°C, 1 min at 72°C, for 30 cycles. Amplification products were analysed on 1 % 
EtBr-stained agarose gels and visualised under UV light. 
5.10.2 
103 
PvuII Restriction Analysis 
Reagents: Restriction Buffer M (BM, Cat. No.: 1417 983) 
TRIS.HCl, 20mM; NaCl, lOOmM; EDTA, lmM; p-mercaptoethanol, lOmM; Triton 
X-100, 0.01 % (VN); glycerol, 50% (VN); pH 7.7. 
To 1/25th of the PCR product (- lOOng) was added lµl of lOxconcentrated buffer Mand 5 units of 
PvuII Restriction enzyme (BM, Cat. No.: 642 690) in a total volume of 10µ1. The solution was 
vortexed, briefly centrifuged and incubated for two hours at 37°C. The restriction digests were 
analysed on 10% polyacrylamide gels and detection was accomplished by a silver staining protocol 
as described. 
5.11 Ficoll-Histopaque Gradient Separation 
Twenty milliters of fresh whole blood were collected in EDTA tubes to prevent coagulation. The 
bloods were immediately centrifuged at 4°C for 20min at 1500 rpm. The mononuclear cell layer 
(buffy coat) was recovered by aspirating with a clean pasteur pipette and transferred to a clean tube. 
The cell suspension was diluted in an equal volume of Dullbecco's phosphate buffered saline solution 
(Highveld Biologicals, Pty, Ltd, Cat. No.: 1686-2) containing lmg/ml EDTA. Two milliters of 
Ficoll-Histopaque R-1077 (Sigma, Cpy., Cat. No.: 1077-1) solution were pipetted into a clean 
centrifuge tube. The cell/PBS/EDTA suspension was carefully layered on top of the Ficoll gradient 
solution and centrifuged at 2500 rpm for lOmin at room temperature. The mononuclear cells which 
bands as an opaque layer of cells at the interphase were recovered and mixed with an equal volume 
of PBS/EDTA solution. The Ficoll gradient separation was repeated until all traces of red blood 
cells were removed. The erythrocyte-free monoclear band was aspirated off, transferred to a clean 
centrifuge tube and pelleted at 2500 rpm for lOmin at room temperature. The supernatant was 
discarded and the pelleted cells are now ready for processing. Aliquotes of cells were taken for the 
assessment of cell number. 
Note: Lipemic plasma were treated as above, except where the buffy coat layer was not visible, 
approximately 1ml of plasma was left above the cell pellet following aspiration of the plasma, such 
that the cell layer is not disturbed. 
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5.12 Mononuclear Cell Culture 
5.12.1 Preparation of Autologous serum 
5.12.1.1 Lipemic serum: 
Fifty milliters of whole blood from the subject was collected into a 50ml evergreen tube and allowed 
to clot. The clotted serum was centrifuged at 20000 rpm for 60min at 4 °C using polycarbonate 
centrifuge tubes. The lipids band as a fat cake on top of a clear infranatant. The bottom of the tube 
was punctured with a hypodermic needle and the serum infranatant was collected and transferred to 
a clean tube. This serum was heat inactivated at 56°C for 30min and filter sterilised. 
5.12.1.2 Non-lipemic serum: 
A 50ml blood specimen was collected as a clotted specimen and centrifuged at 3000 rpm for 15-30 
min. The serum component was aspirated off, transferred to a fresh tube, heat inactivated and filter 
sterilised as above. 
5.12.2 Preparation of Growth Media 
To 90ml of Dulbecco's modified eagle medium (DMEM; Highveld Biological Ltd., Cat. No.: 1299-3) 
or 90ml RPMI1640 medium (+L- glutamine)(Highveld Biological Ltd., Cat. No.: L07) was added 
10ml of autologous serum (as prepared above), 50µ1 penicillin [lOOU/ml; Labethica (Ltd)] and 50µ1 
streptomycin [166.7mg/ml; Novo Nordisk (Ltd)]. This mixture may be stored at 4°C until use, but 
should be warmed to room temperature before use. 
5.12.3 Cell Cu 1 ture 
The freshly isolated mononuclear cell pellet was added to 10ml growth media and thoroughly mixed. 
The cells were plated out at 2-3x107 cells per dish (35mm petri dish, Falcon Ltd). An equal volume 
of fresh growth medium was added to the culture dish and incubated at 37°C (5% COz/95% 
humidity) for 30 min. This allowed for cells to adhere to the dish. Half of the culture medium was 
aspirated off and replaced with an equal volume of fresh growth medium. This would ensure that 
enough growth factors remain behind. The cell density was checked under a microscope. The cells 
were cultured for 8-10 days with growth media supplementation carried out every 2 days until 
harvesting. 
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5.12.4 Harvesting of Cells 
The growth medium was aspirated off and the monolayers washed three times (2ml) with ice-cold 
PBS. Approximately 200µ1 of ice-cold PBS were added to the monolayer of cells and placed on ice 
for a few mins to allow for diffusion of the solution. The cell sheet was scraped off using a rubber 
policeman. The cell suspension was collected with a wide-mouthed pipette and transferred to a clean, 
sterile eppendorf tube. A further 200µ1 of ice cold PBS were added to the plate and the procedure 
repeated until no cells were visible under the microscope. The cells were pelleted at 1500 rpm for 
5min at 4°C. The supernatant was aspirated off; the cells were snap frozen and stored at -70°C. 
OR 
The growth medium was aspirated off and the cell monolayer washed three times (2ml) with ice cold 
PBS. The excess PBS was aspirated off and the plates were stored at -70°C until use. 
5.13 Total RNA Isolation 
( Ref: Chomczynski and Sacchi; 1987) 
5.13.1 Materials and Reagents 
All solutions, where possible were prepared in 0.1 % DEPC-treated H20. Glassware and spatulas 
were baked overnight at 180°C . These treatments are designed to destroy any RNAases that may 
be present. 
5.13.2 Protocol 
Frozen cells were allowed to thaw on ice and 1ml solution D ( 4M guanidium thiocyanate; 25mM 
sodium citrate, pH 7.0; 0.5% sarcosyi O.lM P-mercaptoethanol) was added to the tissue culture dish. 
Using a rubber policeman the monolayer cells were scraped, dislodged and transfered to a fresh tube 
containing 4ml of solution D or freshly isolated mononuclear cells were mixed directly with 5ml of 
solution D. These suspensions were homogenised on ice in a glass-teflon homogeniser 
(approximately 10 strokes). The homogenate was poured into a polypropylene tube. Five milliters 
of phenol (TRIS-EDTA saturated), 1ml of chloroform: isoamyl alcohol ( 49:1) and 1ml 2M sodium 
acetate, pH 4.5 were added sequentially to the homogenate which was vigorously agitated for 60secs 
and incubated on ice for 15min. This suspension was centrifuged at 7000 rpm for 15min at 4 °c. The 
upper aqueous phase was transfered to a fresh polypropylene tube and re-extracted as above. Again 
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the suspension was centrifuged as before and the aqueous phase mixed with an equal volume of 
isopropanol and placed for 1 hour or overnight at -20°C. The mixture was centrifuged at 7000 rpm 
for 15mins at 4 °C, to pellet the RNA. The excess supernatant was drained off and the pellet was 
reconstituted in 0.3ml solution D (without P-mercaptoethanol) and transferred to an eppendorf tube. 
An equal volume of isopropanol was added and the mixture was placed at -20°C for 1 hour. The 
mixture was centrifuged at lOOOOrpm for lOmin at 4 °C; the pellet was washed with 70% ethanol and 
briefly dried under vacuum. The dried RNA pellet was dissolved in 20µ1 DEPC-treated H20. 
Aliquotes may now be subjected to spectrophotometric (OD260 and 280) and electrophoretic analysis 
to assess RNA concentration, purity and integrity. 
5.14 Electrophoretic Analysis of RNA 
5.14.1 Materials and Reagents 
1) lOx MOPS/EDTA, pH 7.0 
41.86g 3-(N-Morpholino) Propanesulfonic Acid (0.2M)(MOPS; Sigma Cpy, Cat. No.: M-8899), 
40mls 2M sodium acetate (50mM)(NaAc; Merck, Cat. No.: 6264.0500) and 3.72g EDTA (lOmM) 
were dissolved in 1 liter of DEPC-treated H20 and the pH was adjusted to 7.0 with approximately 
30ml lON NaOH. The solution was autoclaved at 15lbs/sq. inch for 30min. 
2) Deionized Formamide 
One hundred milliters of formamide solution (Merck, Cat. No.: 9684.1000) was mixed and stirred 
with 10g ofDOWEX TMD-8 mixed bed resin (Sigma Cpy, Cat. No.: M 8157) at room temperature 
for 60min. The solution was filtered twice through 3MM Whatman No.1 filter paper and stored 
as 1ml aliquotes under nitrogen at -70°C. 
3) Electrophoresis Sample Buffer 
The sample buffer was prepared as follows: 0.75ml of deionized formamide, 0.15ml 
lOxMOPS/EDTA buffer, 0.24ml formaldehyde, 0.1 % DEPC-ddH20, 0.1ml glycerol and 0.08ml 10% 
(WN) bromophenol blue was mixed and stored in 1ml aliquotes at -20°C. 
4) Electrophoresis buffer 
lxMOPS/EDTA buffer. 
5.14.2 Sample Preparation 
107 
Five micrograms of the total RNA preparation were added to 25µ1 electrophoresis sample buffer and 
the solution was made up to 30µ1 with DEPC-treated ddH20. The samples were heated at 65°C for 
15min; they were briefly centrifuged and 2µ1 of a lmg/ml EtBr solution were added. The samples 
were thoroughly mixed and immediately loaded onto the gel . 
5.14.3 Preparation of 1 % agarose/1.85% formaldehyde gel 
Two grams of agarose (Bio-rad Laboratories, Cat. No.: 162-0100)) were weighed and transferred 
to a RNAse-free flask. Twenty milliters lOxMOPS/EDTA buffer were added and the mixture was 
made up to 200ml with 0.1 % DEPC-treated ddH20. The agarose solution was melted and allowed 
to cool to approximately 50°C before adding 10ml of 37% formaldehyde (This is carried out in a 
fume-hood). The gel was poured and allowed to set for 60min at room temperature. 
Samples were electrophoresed at 25V for 18 hours at room temperature. The gel was visualised 
under UV. 
5.15 cDNA Synthesis 
5.15.1 Material and Methods 
1) SM dNTP stock 
A SM dNTP stock solution was prepared as follows: 
dNTP Source/Cat. No. mg/ml mM 
dATP BM/103 977 14.73 20.24 
dGTP BM/104 094 13.78 21.14 
dTTP BM/104 272 14.26 20.50 
dCTP BM/104 035 12.78 20.34 
Each dNTP solution was adjusted to pH 7. 250µ1 of each dNTP solution was mixed to give a final 
working stock of 5mM for each dNTP. 
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2) 5xRTbuffer 
The following solution was prepared: 250mM TRIS buffer, pH 8.2; 35mM MgC12; 200mM KCl; 
50mM DTT; 0.5mg/ml bovine serum albumin (BSA stock, 20mg/ml; BM, Cat. No.: 652 237) was 
prepared in DEPC-treated ddH20. 1ml quantities were aliquoted and stored at -20'C. 
5.15.2 Protocol 
First strand cDNA synthesis was accomplished by preparing a sample mixture containing lOµg of 
total RNA, 0.5µg oligo dT (BM, Cat. No: 814270), 0.5µg random hexamer primers (BM; Cat. No: 
1034731) and 1µ1 dimethyl sulfoxide (DMSO)(Burdick and Jackson Inc; Cat No. 081) in a total 
volume of 10µ1 with DEPC-treated ddH20. The mixture was vortexed, heated at 65°C for 3 min and 
immediately placed on ice, to allow for primer annealling. A reaction mixture was prepared by adding 
the following sequentially: 2xRT buffer; SmM dNTP stock (final cone. - O.SmM), 40 units rRNasin 
(RNase Inhibitor )(Promega Corp, Cat. No: N251/1-4), 1/20th DMSO, in a total volume of 40µ1 with 
DEPC-treated ddH20. The reaction and sample mixtures were combined and thoroughly mixed. 
Two hundred units of the Murine-Molony Leukemia Virus Reverse Transcriptase (M-MLUV 
RT)(Promega Corp; Cat. No.: M530/1,2) was added, followed by incubation at 37°C for 60 min to 
facilitate linear amplification. To improve the transcription efficiency, the transcribed product was 
denatured at 95°C for 3 mins, followed by the addition of a further 200 units M-MLUV RT enzyme 
and 40 units of RNasin; the mixture was thoroughly mixed and again incubated at 37°C for a further 
. 60mins. This procedure was repeated three times and the samples stored at -20°C until use. 
5.16 PCR Amplification of LPLcDNA Products 
5.16.1 PCR Protocol 
The polymerase chain reaction was carried out as follows: To 1/25th cDNA product was added 
30pmol of each LPL primer (LPL fragment 1-8; forward primer, LPLcDNA8; reverse primer, 
LPLcDNAl) or (LPL fragment 6-7; forward primer, LPLcDNA6; reverse primer, LPLcDNA7). This 
mixture was heat denatured at 95°C for 2-3min and snap cooled on ice to allow for primer-template 
annealing. A master mix was prepared containing 5µ1 of a 10 x concentrated Taq polymerase buffer 
(lOOmM TRIS buffer, pH 8.5, 500mM KCl, 0.1 % gelatin)(Promega; Cat No: PL M190A); 2mM 
MgCI2; 0.2mM dNTP stock ( containing 4 dNTP's) and 2 units of Taq Polymerase. The total volume 
was adjusted to 50µ1 with ddH20. The samples were overlayed with mineral oil. This was followed 
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by the temperature cycling process performed on a Hybaid thermal cycler with the following program: 
1 min at 94°C, 1 min at 56°C (LPL fragment 1-8) or 1 min at 60°C (LPL fragment 6-7) and 2 min 
at 72°C, over 30 cycles. The final cycle was followed by a 5 min extension step at 72°C. 
5.16.2 Product Analysis 
Aliquotes of PCR products were analysed directly by electrophoresis on 1 % agarose or 10% 
polyacrylamide gels and visualised by EtBr staining and photographed under UV light. 
5.16.3 Purification of PCR products 
The Qiaex DNA Gel Extraction Kit (Qiagen; Cat. No.: QXGE 4111) was used for the purification 
of the amplified PCR products as follows : 
Following agarose gel electrophoresis, a clean scalpel blade was used to excise the gel slice containing 
the DNA fragment of interest. The gel slice was transferred to an eppendorf tube and 0.3ml of the 
QXl buffer was added per 100mg of gel. The solubilisation process was allowed to go to 
completion, followed by the addition of 10µ1 of QIAEX beads. The suspension was thoroughly 
mixed by inverting the tube several times and incubated for lOmin at 50°C with intermittant mixing 
at 2min intervals. The sample was centrifuged for 30sec at 12000g in a bench top microcentrifuge. 
The supernatant was discarded and the pellet washed twice in 0.5ml QX2 buffer. This was followed 
by a second wash in 2 x 0.5ml QX3 buffer. After each wash the supernatant was discarded and the 
pellet retained. After the final wash the pellet was dried at room temperature. The DNA was 
generally eluted from the beads by reconstituting in 20µ1 of lxTE buffer. After incubating the beads 
for several minutes the suspension was centrifuged at 12000g for 30sec; the supernatant was 
recovered and stored at -20°C until use. To ensure that no beads were carried over, a second 
reconstitution and centrifugation step was carried out. The yield of DNA was assessed by 
electrophoresis on agarose gels against a known standard (Biomarker™ Low, Bioventures Inc. Lot 
No: 021594). 
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5.17 Cloning of LPLcDNA Fragments 
5.17.1 Materials and Reagents 
The pT7BLUE T-Vector Kit (Novagen Inc.; Cat. No.: 69836-1) was used for the cloning of the 
PCR- amplified LPL fragments. 
5.17.2 Ligation Reaction 
A standard ligation reaction was carried out as follows : A 50ng or 0.3pmol of pT7BLUE T-Vector 
aliquote was mixed with lOOng of PCR-amplified product (0.2pmol) in a total volume of 10µ1. This 
mixture was combined with the reaction mix which contained lOxLigase buffer (200mM TRIS.HCl 
pH 7.6, 50mM MgCli); 0.5µ1 lOOmM DTT and 0.5µ1 lOmM ATP. Two to three Weiss Units of T4 
DNA ligase was added to the aoove mixture. The total volume was made up to 10µ1 with ddH20 and 
the ligation reaction was allowed to proceed at l6°C overnight. 
5.17.3 Transformation 
The required number of Novablue competent cells was thawed on ice to ensure that the cells were 
evenly suspended. Twenty microliters of cells were pipetted into pre-chilled microfuge tubes on ice. 
One microliter of the ligation mix was added directly to the cells and gently stirred with the pipette 
tip. This mixture was incubated on ice for 30 mins. The tubes were heated at 42°C for 40 secs 
without shaking and immediately placed on ice for 2 mins. Eighty microliters of room temperature 
SOC medium was then added to each tube and vigorously shaken at 200-250 rpm for 60 mins at 
37°C. 
5.17.4 Preparation of Agar Plates and Colony Plating 
LB agar plates containing 75µg/ml ampicillin and 15µg/ml tetracycline were prepared. 
Approximately 100µ1 ofX-GAL (20mg/ml in dimethylformamide) and 40µ1 ofIPTG (lOOmM) were 
spread over the plate surface and allowed to soak in for 2 hours at room temperature. Approximately 
100µ1 of each transformation mix was plated out and the excess fluid allowed to evaporate, followed 
by overnight incubation of the plates at 37°C. 
5.17.5 PCR Screening of Colonies 
PCR amplification was the method of choice for screening large numbers of colonies for the presence 
of the insert DNA. 
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5.17.5.1 Bulk PCR Screening 
Individual colonies were picked with a sterile pipette tip or loop. The bacteria was then transfered 
either onto a master plate (grid library) and then into an eppendorf tube containing 50µ1 ddH20. The 
cells were vortexed and the tube was placed in a boiling water bath for 5 mins to lyse the cells and 
to denature DNAses. The tube was centrifuged at 12000g for 1 min to pellet the cell debris. 1/50th 
of the cell lysate (supernatant) was subjected to PCR amplification under the following reaction 
conditions. The cell lysate was mixed with 30pmol of each primer and the mixture heat denatured 
at 95°C for 5 min. The tube was immediately placed on ice to allow primer-template annealling to 
take place. A master reaction mix was prepared containing lxTRIS.HCl, pH 8.2; 2mM MgC12, 
0.2mM dNTP stock ( containing each of the four dNTP's) and 1 unit of Taq DNA polymerase. This 
mixture was added to the annealling mix and made up to 25µ1 with ddH20. The samples were 
overlayed with mineral oil and subjected to 30 cycles of: 94°C at 1 min, 56°C at 1 min; 72°C at 1 
min. The final cycle was followed by a 5 min-extension step at 72°C. Products were analysed on 1 % 
EtBr stained agarose gels and visualised and photographed under UV light. 
5.17.5.2 1194T ARMS PCR Screening 
The following sample mix was prepared : One tenth of the colony extract or 0.5µg of genomic DNA 
was mixed with 15pmol of each primer (LPLcDNAl - forward primer; 194MUT- reverse primer) 
or (LPLcDNA8 - reverse primer; 194WT - forward primer)(Primer Design). This mixture was heat 
denatured at 95°C for 5 min and snap cooled on ice to allow for primer-template annealling. 
A master reaction mix was prepared as follows : Mix 2.5µ1 lOxconcentrated Taq polymerase buffer, 
2mM MgC12, 0.2mM dNTP stock (contains 4 dNTP's) and 1 unit of Taq polymerase. The sample 
mix and reaction mix was combined and the total volume was adjusted to 25µ1 with ddH20. The 
solution was overlayed with a few drops of mineral oil. The temperature cycling program was 
performed in a Hybaid Thermal Cycler for 30 cycles of: 1 min at 94°C, 1 min at 62°C, 1 min at 72°C. 
The final cycle was followed by a 5 min extension step at 72°C. Aliquotes of PCR products were 
analysed directly by electrophoresis on 1 % agarose gels and visualised by EtBr staining under UV 
light. 
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5.18 Colony Selection and Plasmid Purification 
5.18.1 Protocol 1 
Colonies of interest were picked and inoculated into 25ml terrific broth media ( containing 75µg/ml 
ampicillin, 15µg!ml tetracycline). These cultures were incubated at 37°C for two days with shaking 
at 250rpm. The cells were pelleted by centrifugation at 3000 rpm for 10 to 15mins. The cell pellet 
was resuspended in 2.5ml cell lysis buffer (25mM TRIS.HCI, pH 8.0; lOmM EDTA, pH 8.0; 50mM 
glucose; containing 5mg/ml lysozyme), vortexed and incubated at room temperature for 5mins. Five 
milliters of 0.2N NaOH/1 % SDS was added, inverted 2 to 3 times and placed on ice for 5mins. 
3.75ml of 7.5M NH4Ac, pH 7.6 was added to the above mixture which was inverted several times 
( a white flocculent debris observed) and then placed on ice for 5mins. The suspension was 
centrifuged at 8000 rpm for 15min at 4°C. The white pellet was washed with 70% EtOH, then air 
dried and resuspended in 1ml lxTE buffer. RNase was added to a final concentration of lOOµg/ml 
and the solution was incubated at 37°C for 30 to 60mins. The DNA was precipitated by adding 0.5 
volumes of 7.5M NH4Ac, pH 7.6 and 2.5 volumes of 100% EtOH to this solution followed by 
incubation at -70°C for 30mins. The DNA was pelleted by centrifugation at 12000g for 10 to 15mins. 
The pellet was washed with 70% EtOH, air dried and resuspended in 100µ1 lxTE buffer. The 
concentration and purity of the plasmid DNA was assessed by spectrophotometric analysis and 
electrophoresis on 1 % EtBr stained agarose gels. 
5.18.2 
5.18.2.1 
1) 
2) 
3) 
Protocol 2 
Materials and Reagents 
Magic Minipreps™DNA Purification System (Promega Pty, Cat. No.: A7100). 
All solutions were as indicated in the protocols. 
Column Wash Solution: Dilute 1:1 in 50ml absolute ethanol. 
5.18.2.2 Plasmid Minipreps 
One to three ml of cells were pelleted by centrifugation. The cell pellet was resuspended in 0.2ml of 
Cell Resuspension Solution. This suspension was transferred to a microcentrifuge tube and 0.2ml of 
Cell Lysis Solution was added. The suspension was mixed by inverting the tube several times until 
the suspension cleared. 0.2ml of the Neutralization Solution was added and the suspension was 
centrifuged at 14000g for 5 min. The supernatant was transferred to a fresh eppendorf tube and 1ml 
of Magic Mini prep DNA purification resin was added and mixed by inverting the tube. A 3ml 
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disposable syringe barrel was attached to the luer-lok extension of each mini-column. The 
Resin/supernatant suspension was poured into the syringe barrel. The syringe plunger was inserted 
and the slurry was gently pushed through the mini-column. The column was washed with 2ml of 
Column Wash Solution. The column was transferred to an eppendorf tube and centrifuged for 20 
secs to dry the resin. The column was transferred to a fresh eppendorf tube and 50µ1 of preheated 
ddH20 or TE buffer (65-70°C) was applied to the column. The plasmid DNA was eluted by 
centrifugation of the column for 20 secs. The eluant was collected and store at -20°C. The yield and 
quality of the DNA preparations were assessed as before. 
5.19 DNA Sequence Analysis 
1) The Sequenase(R) Version 2.0 DNA Sequencing kit (United States Biochemical and 
Amersham, Cat. No.: 70770) was generally used. The protocols followed were as per 
instructions (see the accompanying step-by-step protocol booklet). 
2) The PCR-based Sequencing Kits. 
a) Sequenase™ PCR + Product Sequencing Kit (USB and Amersham, Product No: 
70170). See Step-by-Step protocols for instructions. 
b) fmol™ DNA Sequencing System (Promega; Cat No: Q4100). Instructions as per 
protocol booklet. 
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APPENDIX 1 
PRIMER DESIGN 
The oligonucleotides (primers) described below have been utilised at various stages in the 
experimental procedures. R - reverse primer, F - forward primer. The numbers in brackets denotes 
the primer length (number of bases). 
Al ) Primers for the amplification and sequencing of individual LPL exons. 
a) Exon2: LPL8 (F) 5'-CTCATATCCAA'I'ITITCCIT-3' 
LPL9 (R) 5'-CTCITCCCCAAAGAGCCTCC-3' 
(20mer) 
(20mer) 
b) Exon3: LPLlO (F) 5'-AAGCITGTGTCATCATCATCITC-3' (23mer) 
LPLll (R) 5'-ATAAGTCTCCCTTCTCCCAGT-3' 
c) Exon4: LPL12 (F) 5'-GCAGAACTGTAAGCACCTTC-3' 
LPL13 (R) 5'-GACAGTCTTTTCACCTCTTA-3' 
(20mer) 
(20mer) 
(20mer) 
d) Exon5: LPL57 (F) 5'-TACGGATCCCATGCGAATGTCATACGAATGG-3' (31mer 
e) Exon6: 
f) Exon7: 
LPL58 (R) 5'-AGTGAATTCGAAGCTACTGAGTAGGACATTGGG-3' (33mer) 
LPL16 (F) 
LPL17 (R) 
5'-TCTTGGTGTCTCITITITACC-3' 
5'-TTATTTACAACAGTCTCCAGC-3' 
(21mer) 
(21mer) 
LPL19 (F) 5'-ACAGGATCCATGTTCGAATTTCC-3' (23mer) 
LPL20 (R) 5'-GATGACCGCCCCCAGAGCTAC-3' (21mer) 
g) Exon8: LPL21 (F) 5'-CCAAATTTATTGCTITITTGT-3' (21mer) 
LPL22 (R) 5'-AAGGAAGAAAAATACATTTAATT-3' (23mer) 
h) Exon9: LPL23 (F) 5'-TATICACATCCATITTCITC-3' 
LPL24 (R) 5'-GTCAGCTITAGCCCAGAATG-3' 
A2) Primers used for amplification and sequencing of the LPLcDNA. 
a) LPLSP2 5'-AGAGAACCAGACTCCAA-3' (17mer) 
b) LPLSP3 5'-AGAGATITTATCGACATCG-3' (19mer) 
(21mer) 
(20mer) 
c) LPLcDNA3 5'-TGCAGATCTCAGATGCCCTACAAAGTCT-3' (28mer) 
d) LPLcDNA4 5'-GATCACCTITITCTGAGTICTCTCCT-3' (25mer) 
e) LPL62 5'-CATTIACCCGAATGGAG-3' (17mer) 
f) LPL65 5'-GTGGGACAGGATGTGGC-3' (17mer) 
g) LPL66 5'-CATIGCAGGAAGTCTGA-3' (17mer) 
h) PCR screening and sequencing primers for LPLcDNA (see Fig 18) 
i) Fragment LPLcDNAl-8 
LPLcDNAl: 5'-GCCGTACACITAAGACACITCIT-3' (23mer) 
LPLcDNA8: 5'-CTAGGATCCATCTCITGGGATACAGC-3' (27mer) 
ii) Fragment LPLcDNA6-7 
LPLcDNA6: 5'-TCAGTCGACITGCTCAGCGCCAAAC-3' (25mer) 
LPLcDNA7: 5'-TIGCTGCAGCGGTICTTICTACAA-3' (24mer) 
i) Vector-specific primer for PCR screening and sequencing 
U-20 5'-GGTITTCCCAGTCACGACGT-3' (20mer) 
A3) Allele-Specific Oligonuleotide (ASO) Primers for the detection of the 194 mutation. 
LPL59 (ASO I): 5'-TCGAAGCAifGGAATCC-3' (17mer) 
LPL60 (ASOII): 5'-TCGAAGCACTGGAATCC-3' (17mer) 
The T-C nucleotide change is double underlined. 
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A4) "ARMS" PCR Primers for the detection of the 1194T mutation. 
194 WT Primer: 
194 MUT Primer: 
5'-AACTGGTITCTGGATTCIAA-3' (20mer) 
5'-GGGTCCCCTGGTCGAAGJ:AC-3' (20mer) 
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The nucleotide complementary to the normal (WT) or 194 mutant (MUT) sequence is 
indicated in bold. The deliberate base incorporated two nucleotides upstream from the 3'-
terminal end of the primer is double underlined. Primers, 194 WT and 194 MUT were used 
in combination with primers, LPL57 and LPL58, respectively (see above). Nucleotide 
positions according to Wion et. al. (1987). See Fig 20 for the detection of the 194 mutant 
allele. 
a) 194 Wild-Type Primer 
818 860 
5'-GGTCCCCTGGTCGAAGCATTGGAATCCAGAAACCAGTTGGGCA-3' 
3'-AA CTTAGGTCTT TGGTCAA-5' 
\ I 
T 
818 860 
5'-GGTCCCCTGGTCGAAGCACTGGAATCCAGAAACCAGTTGGGCA-3' 
3'- A f'TTAGGTCT TTGGTCAA-5' 
I \ r A T 
b) 194 Mutant Primer 
TC 
I \ I 
5'-GGGTCCCC TGGTCGAAG A -3' 
3'-CACCAGACCCAGGGGACCAGCTTCGTAACCTT AGGTCTITGGT-5' 
810 852 
T 
I \ 
5'-GGGTCCCC TGGTCGAAG AC-3' 
3'-CACCAGACCCAGGGGACCAGCTTCGTGACCTTAGGTCTITGGT-5' 
810 852 
WT allele 
MUT allele 
WT allele 
MUT allele 
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AS) Primers for the detection of the C418Y mutation 
a) "ARMS" PCR Analysis 
i) 418 WT Primer : 5'-cttccacagGGTGATCITATG-3' (21mer) 
ii) 418 MUT Primer : 5'-cttccacagGGTGATCITATA-3' (21mer) 
iii) The nucleotide base complementary to the normal (WT) and 418 mutant (MUT) 
sequence is indicated in bold. The deliberate mismatch introduced is double 
underlined. These primers span the intron8-exon9 boundary, with the intronic 
sequence shown in small letters. These primers were used in combination with the 
reverse primer, LPL24 (see above). Nucleotide positions according to Wion et. al. 
(1987). 
iv) 418 Wild-Type Primer 
A 
I \ 
5'-c ttccacagGGTGATCTT TG-3' 
3'-gtaggtaaaagaaggtgtcCCACTAGAAGACAAGATCCCTCITTCACAGAGTA-5' WT allele 
1497 1530 
AG 
I \ I 
5'-cttccacagGGTGATCTT T -3' 
3'-gtaggtaaaagaaggtgtcCCACT AGAAGAT AAGATCCCTCTTTCACAGAGTA-5' MUTallele 
1497 1530 
v) 418 Mutant Primer 
A A 
I \ I 
5'-cttccacagGGTGATCTT T -3' 
3'-gtaggtaaaagaaggtgtcCCACTAGAAGACAAGATCCCTCITTCACGAGTA-5' WT allele 
1497 1530 
A 
I \ 
5'-cttccacagGGTGATCIT TA-3' 
3'-gtaggtaaaagaaggtgtcCCACT AGAAGAT AAGATCCCTCTTTCACGAGTA-5' MUT allele 
1497 1530 
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b) PCR Restriction Analysis 
i) 418 MIS Primer : 5'-tttcttccacagGGTGATCAGCT-3' (23mer) 
ii) 
The deliberate nucleotide bases introduced are double underlined. The nucleotide 
bases shown in bold completes the PvuII restriction site (-CAGCTG-) in the presence 
of the normal allele. The primer spans the intron8-exon9 boundary, with the intronic 
sequence shown in small letters. This primer is used in combination with LPL24 (see 
above). The sequence patterns shown below demonstrates how the PvuII restriction 
site is created or destroyed in the presence of the wild-type or mutant allele, 
respectively. 
Wild-Type Allele Mutant Allele 
AG GA 
5'-tttcttccacagGGTGATC CT-3' 3'-TC CTAGTGGgacaccttcttt-5' 
3'-gtaggtaaaagaaggtgtcCCACTAGAAGAC-5' 5'-TAGAAGATCACCctgtggaagaaaatggatg-3' 
! 
CAGCTG 
GTCGAC--
PvuII 
created 
PCR ! 
ATCGAC 
TAGCTG -----
PvuII 
destroyed 
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